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Abstract 
Media claims suggest that use of pharmacological cognitive enhancers (PCE) in UK 
universities is significant and is increasing, though academic research has come to less 
consistent conclusions. While there has been expansion of research in this area, the public 
health impact of long-term PCE use, including the potential for adverse effects to cognitive, 
neurological and physiological functioning remains unclear. Consequently, this thesis aimed 
to investigate the aetiology and long-term effects of PCE use in some UK universities. Study 
1 aimed to investigate CE use in four UK universities, including: which substances are 
commonly used, the reasons for use and which factors relate to consumption. Here, 
caffeinated products were the most popular, followed by modafinil. Furthermore, several 
sociodemographic and personality variables were part of a statistical model to predict CE 
use, although only gender, age and moral perceptions of modafinil use were found to be 
significant. Study 2 focussed on modafinil as the most popular PCE aiming to assess the 
long-term impact (> 3 months) of use on executive functioning by administering various 
cognitive performance measures.  Despite no behavioural differences on the 2-back 
(working memory) and the continuous performance task (sustained attention), modafinil 
users responded to both horizontal and vertical cues more quickly than nonusers on the 
cued go/no-go task (inhibitory control) without experiencing an accuracy trade-off or 
performance decrement. To investigate the neural substrates of any potential cognitive 
deficits, Study 3 assessed cognitive and neurophysiological processes by using functional 
near-infrared spectroscopy, electrocardiogram and a digital sphygmomanometer alongside 
cognitive performance measures designed to increase cognitive workload. It was found 
that there were no behavioural performance differences on easy and difficult variants of 
the multitasking framework (stressor) or 3-back (working memory) between groups, but 
users experienced significantly lower systolic blood pressure across the tasks and greater 
haemodynamic change during the 3-back. Blood pressure indicated that users appeared 
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less physiologically aroused during performance measures, but increased haemodynamic 
response compared with controls revealed possible underlying cognitive deficits. Taken as 
a whole, modafinil appears to be the most popular PCE in the UK for university students, 
and long-term use unexpectedly revealed enhanced inhibitory control but possible deficits 
to working memory performance. This research consolidates previous claims about 
modafinil as the most popular PCE among UK university students. Furthermore, this is the 
first study to investigate long-term modafinil use and establish behavioural and 
neurophysiological differences with nonusers.  
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Chapter 1: An Overview of Substances used for Cognitive Enhancement. 
 
1.1 Chapter Overview 
 
Cognitive enhancement (CE) strategies (also termed neuroenhancement strategies) are 
techniques used with the intention of enhancing cognitive performance or mood. 
Numerous CE techniques exist, including use of food supplements, pharmaceutical 
products and illegal drugs. This chapter explores the different substances which are most 
regularly purported to enhance cognition and investigates their pharmacology, mechanism 
of action and estimated level of use. Moreover, for the remainder of the thesis, the term 
‘cognitive enhancement’ refers to the user’s intention to enhance performance more so 
than the efficacy of the substance itself, which will be further explored in Chapter 2 when 
the pharmacological cognitive enhancement (PCE) modafinil is examined (Maier, Haug, & 
Schaub, 2016; Maier & Schaub, 2015).  
1.2 What are Cognitive Enhancement Drugs? 
 
The most popular CE drugs can be divided into two groups: soft enhancers and PCE. Soft 
enhancers are popular, legally available substances which include food products, herbals 
substances and tonics and products containing caffeine. On the other hand, PCE use is 
often prohibited, and includes synthetic pharmaceutical substances and some illegal drugs 
(Maier, Ferring & Winstock, 2018). Both CE groups differ in the magnitude of their effect on 
cognitive performance and in mechanism of action, although variations also exist within 
each group. Differences between the various CE substances are discussed below, including 
the primary differences which are apparent between soft enhancers and PCE.  
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1.2.1 Soft Enhancement 
 
Some soft enhancers are commonplace in society, particularly those products containing 
caffeine, which is the most widely consumed psychoactive substance in the world (Zhang, 
Jiang, Liu, & He, 2017). Further to this point, caffeinated beverages are among the most 
popular caffeine-based products because they act as a minor stimulant and promote 
feelings of alertness and wakefulness which often become integrated into a person’s daily 
routine. Consequently, it has been suggested that use of caffeine for CE is less explicit than 
other soft enhancers or PCE (Rosen & Weil, 2004). For example, nutraceuticals (herbal pills 
and tonics) are more explicitly marketed as CE drugs but are considerably less popular, 
owing to the fact that these drugs each have medicinal properties that are purported to act 
differently on cognitive performance and mood with some more successful than others 
(Rai, Bhatia, Sen, & Palit, 2003; Tsai, Lin, Simon Pickard, Tsai, & Mahady, 2012). Moreover, 
these substances are less widely obtainable and are often only available at speciality 
retailers, which suggests that users who seek them do so with a specific intention in mind, 
one of which could be CE purposes. Of course, nutraceutical drugs are not just marketed as 
CE substances, they are also lauded for their various physical health benefits (Ward et al., 
2019), meaning the reasons for their consumption are not always clear.  
Caffeine, a psychostimulant, acts on the autonomic nervous system and shifts dominance 
from the sympathetic (SNS) to the parasympathetic nervous system (PNS). Unlike PCE, its 
effects are non-selective as it acts through blocking adenosine receptors (A1 and A2) in the 
prefrontal cortex which in turn promotes monoamine release. As such, the 
neurotransmitters dopamine, serotonin and noradrenaline are released, which facilitate 
feelings of wakefulness and alertness (Fredholm, Yang, & Wang, 2017). Therefore, caffeine 
shares more similarities with pharmaceuticals used for PCE than nutraceuticals which 
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operate through enzyme synthesis (Ahmed et al., 2016), although effects are less 
pronounced and the substance has a shorter half-life than PCE (Franke et al., 2017). 
Notable soft enhancers which contain caffeine include; coffee, energy drinks, caffeine pills 
and guarana (Maier, Liakoni, Schildmann, Schaub, & Liechti, 2015). 
Of the nutraceutical substances, ginseng is perhaps the most popular and has been used in 
Eastern medicine for thousands of years (Geng et al., 2010). This drug comes from the root 
of the ginseng plant and can be brewed in tonics and formulated as a tablet, and is popular 
in alternative medicine because of a variety of medicinal properties, including: lowering 
fatigue, acting as a powerful antioxidant and boosting the immune system (Scholey et al., 
2010). There are two variants of the substance; Panax (Asian) and American ginseng which 
share many properties but have subtle variations (Scholey et al., 2010). Research has 
revealed that effects on cognitive performance appear to be linked to constituent saponins 
called ginsenosides, which are divided into two main groups: protopanaxadiol and 
protopanaxatriol which vary in concentration between Panax and American ginseng. 
However, studies suggest that the enhancing effects of the two types are similar, as each 
has been shown to improve working memory, memory retention and neural plasticity to 
some degree (Vogler, Pittler, & Ernst, 1999). Furthermore, long-term use may also be 
neuroprotective as ginseng proliferates antioxidants which are known to prevent cognitive 
impairment by eliminating free-radical compounds (Ramesh et al., 2012). 
Similar to ginseng, ginkgo biloba (ginkgo) is a nutraceutical plant extract which has 
garnered popularity for its medicinal properties (Major, 1967). This substance can be taken 
as a dietary supplement and can also be brewed in tonics and made into a tablet. Unlike 
ginseng, there is little knowledge about the precise mechanism of action of ginkgo, but 
some evidence suggests that it acts on adrenergic receptors which in turn promote 
wakefulness and vigilance (Blecharz-Klin, Piechal, Joniec, Pyrzanowska, & Widy-Tyszkiewicz, 
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2009; van Beek & Montoro, 2009). Moreover, bilobalide is the active saponin identified in 
the substance which is linked to acute increases in cognitive functioning. Similar to 
ginsenosides, bilobalide is an antioxidant and free-radical scavenger which increases 
adenosine triphosphate production which appears to reduce memory impairments and 
other reductions in cognitive functioning found as a result of mild cognitive impairment 
(MCI) (Duverger, DeFeudis, & Drieu, 1995). As such, ginkgo has been marketed as a useful 
drug to combat and slow the memory loss symptoms associated with dementia and 
Alzheimer’s disease which has been supported in a recent systematic review (Yuan, Wang, 
Shi, & Lin, 2017), although the authors state that benefits are only apparent when the drug 
is consumed daily for 22 weeks or longer. Furthermore, there is some evidence to suggest 
that ginkgo does not possess CE properties at all, despite marketing which promotes the 
drug for this purpose (Canter & Ernst, 2007). Overall, evidence for ginkgo as a CE is not 
definitive, despite the substance’s popularity. 
Bacopa monnieri (bacopa) is less popular than ginseng or ginkgo but is purported to have 
several CE effects. The cognitive effects of the drug resemble ginseng, with improvements 
observed in various executive functions such as attention and working memory (Stough et 
al., 2008). Some improvements are also apparent in attentional speed, but these findings 
are not consistently reported (Kongkeaw, Dilokthornsakul, Thanarangsarit, Limpeanchob, & 
Norman Scholfield, 2014). Bacosides, the constituent saponins thought to govern the CE 
effects of bacopa, are similar to ginsenosides as they act as antioxidants and may be 
neuroprotective with continued use (Calabrese et al., 2008). However, there is limited 
understanding of bacopa as a CE substance compared to ginseng and ginkgo, as such the 
effectiveness of the drug cannot be properly determined without further research. 
1.2.2 Pharmacological Cognitive Enhancement 
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Distinct from soft enhancers, PCE are typically synthetic pharmaceutical substances and 
illegal drugs, whose use is controlled or prohibited by law. Most studies on PCE effects 
focus on amphetamines, particularly dextroamphetamine (d-amphetamine) which is sold 
under the popular trade name ‘Adderall’, and racetams like piracetam. However, evidence 
in support of these drugs as effective PCE is limited, with the studies that exist identifying 
only modest enhancements with single periods of use. Effects are often also outweighed by 
high expectations, suggesting that the efficacy of these drugs does not often exceed user 
perceptions (Bagot and Kaminer, 2014; Battelday and Brem, 2015; Linssen, Sambeth, and 
Riedel, 2014). Some research has also looked at use of illegal drugs in the UK such as 
psychedelics (Elsey, 2017) and cannabis (Franke, Roser, Lieb, Vollmann, & Schildmann, 
2016), but as these techniques appear to be rare they will not be discussed further in this 
Chapter. Instead, the focus will be on substances which are most commonly self-reported 
by users for PCE, namely, d-amphetamine, methylphenidate (MPH) and modafinil. 
Amphetamine is a central nervous system (CNS) stimulant which is used as a treatment for 
attention deficit hyperactivity disorder (ADHD). D-amphetamine in particular has been 
identified to have modulatory effects on neurotransmitter networks, predominantly; 
dopamine, serotonin and noradrenaline (Darracq, Blanc, Glowinski, & Tassin, 1998). 
Alterations to monoamine neurotransmission are linked to feelings of increased 
wakefulness and alertness in humans, which has also made the substance useful for the 
treatment of narcolepsy syndrome in the past (Parkes & Fenton, 1973). Furthermore, in 
adolescents with ADHD, studies show improved learning outcomes during schooling, owing 
to a long half-life which extends the overall effect of the drug throughout the day (Pelham 
et al., 1999). Moreover, dopaminergic drugs like Adderall are shown to positively impact 
mood, which evidence suggests can increase creative thought processes (Farah, Haimm, 
Sankoorikal, Smith, & Chatterjee, 2009). Equally, benefits to cognition in healthy people do 
not appear to be as extensive as with other PCE, although findings are comparatively 
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limited (Bagot & Kaminer, 2014; Ilieva, Boland, & Farah, 2013). However, users regularly 
self-report pleasurable experiences with the drug which may contribute to the perception 
of enhanced cognition (Vargo & Petróczi, 2016; Vrecko, 2013). 
Similar to Adderall, MPH is prescribed for ADHD, and to a lesser extent, narcolepsy. 
Moreover, the pharmacology of both substances is similar, as MPH also modulates 
noradrenaline and dopamine in the prefrontal cortex which is linked to a reduction of 
symptoms associated with ADHD, as well as selective improvements in cognitive 
functioning (Linssen, Sambeth, Vuurman, & Riedel, 2014). In particular, MPH has been 
shown to be beneficial to cognition in adolescents and adults with ADHD, who exhibit 
improved reaction time, attention and executive and non-executive memory (Coghill et al., 
2014; Storebø et al., 2015). Emerging evidence has also suggested that MPH can ameliorate 
working memory deficits found in stimulant users, although more research must be 
conducted in the area to verify these findings (Moeller et al., 2014). With healthy people, 
studies using MPH to improve cognitive functioning show fewer compelling results. 
Although, some research indicates that the drug is beneficial to certain cognitive functions, 
including processing speed, inhibitory control, working memory and memory consolidation 
(Linssen et al., 2014; Spencer, Devilbiss & Berridge, 2015). While ADHD adolescents gain 
the most benefits from MPH, self-administration by healthy adults has risen, possibly in an 
attempt to medicate undiagnosed symptoms of ADHD or to achieve CE, although reasons 
behind use need to be more comprehensively explored (White, Becker-Blease, & Grace-
Bishop, 2006). Nevertheless, this kind of use appears to be relatively safe, as the potential 
for harm with MPH is seen to be low when taken in clinically safe doses, with the most 
extreme and commonly reported side effects being appetite suppression and disturbed 
sleep, which are symptoms frequently associated with stimulant use (Becker, Froehlich, & 
Epstein, 2016; Jeffers & Benotsch, 2016). 
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Less popular than MPH or Adderall, modafinil is a novel psychostimulant which is primarily 
used to treat narcolepsy but is also used for shift work sleep disorder. The mechanism of 
action of the drug was unknown until recently, where it was found to be a dopamine and 
noradrenaline reuptake inhibitor, as well as having modulatory effects on histamine in the 
prefrontal cortex (d-Angelo, Savulinch, & Sahakian, 2007). Despite similarities with MPH 
and Adderall, modafinil has the longest half-life of the PCE’s, lasting approximately 10 – 15 
hours, which is considerably longer than Adderall at 3.5 hours (Robertson & Hellriegel, 
2003). Modafinil is a prescription drug in the UK and is listed as a controlled substance in 
the US, restricting its possession by healthy people. However, because it is shown to 
increase feelings of alertness and wakefulness, research has revealed that is has gained 
popularity as a CE drug. Moreover, healthy people also exhibit benefits to attentional 
processes, learning and memory (Sahakian et al., 2015; Turner et al., 2003) and self-report 
feelings of increased energy and alertness (Stoops, Lile, Fillmore, Glaser, & Rush, 2005). 
Similar to MPH, it appears to have low potential to cause harm when taken in clinical 
quantities, however; evidence of doses in excess of clinical guidelines is limited, and thus 
potential adverse events cannot properly be evaluated (Battleday & Brem, 2015; Rush, 
Kelly, Hays, Baker & Wooten, 2002).   
1.3 Prevalence estimates  
 
Recently, there have been media reports estimating the prevalence of CE substance use. In 
the UK, an article by a Cambridge University student newspaper reported that of 1,000 
University of Cambridge students surveyed, 10% reported use of modafinil, MPH or 
Adderall for CE. Moreover, one third of the sample were allegedly considering PCE use if 
the opportunity presented itself (Lennard, 2009). A later article by the popular student 
website The Student Room (2016) suggested a similar trend on a national scale, with 1 in 
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10 students self-reporting use of study drugs at least once in their lifetime on an open 
survey. This anecdotal evidence is corroborated by scientific studies indicating that use of 
CE substances is increasing in both the US (Advokat & Scheithauer, 2013; Emanuel et al., 
2013) and Europe (Maier, Liechti, Herzig & Schaub, 2013). However, robust and 
comparable estimates of use are difficult to obtain due to the nature in which data is 
collected. Primarily, survey questions which investigate use lack standardisation, and drugs 
are not uniformly assessed between studies. Interpreting use is also a challenge, as many 
prevalence figures do not reveal the reasons behind use (e.g. CE or recreation), which can 
be further conflated by cultural differences in what constitutes CE drugs. There is also a 
lack of racial diversity in sample characteristics making generalisability of results 
challenging, and the limited follow-up studies make it difficult to perform trend analyses.  
Limitations notwithstanding, it is clear that use of soft enhancers, particularly coffee and 
other caffeinated products, is considerably greater than PCE (Maier et al., 2013; Singh, Bard 
& Jackson, 2014; Wolff, Brand, Baumgarten, Losel, & Ziegler, 2017). Furthermore, lifetime 
use of PCE among university students in the USA varies from 5 – 55% (McCabe, West, Teter, 
& Boyd, 2014; Smith & Farah, 2011), but other factors besides CE strategies underlie these 
estimates. In Europe, prevalence studies have a similarly wide spread of results ranging 
from 5 – 46%, but interpretation remains challenging, especially given the small number of 
studies (Schelle et al., 2015). A study in Switzerland found that 14% of respondents 
reported nonmedical use of PCE substances across their lifetime, however; use in the 
previous year and month was considerably reduced (Maier et al., 2013). Also considering 
that most respondents reported that PCE use did not match expectations, it is a reasonable 
assumption that recent use was limited because CE strategies were not thought to be 
efficacious. German students exhibit comparatively lower lifetime PCE prevalence rates, 
which range from < 1 – 20% (Dietz et al., 2013), and in the UK, research has suggested that 
use is similar, at 5% or below (Holloway & Bennett, 2012; Singh, Bard, & Jackson, 2014a). 
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However, a recent study and the biggest exploration of international CE use to date, found 
that between 2015 and 2017, self-reported use of PCEs increased from 1.7% to 5.1%. 
Further still, use of modafinil in the UK was highest among the 15 countries surveyed, and 
saw a substantial increase of 3.2% in 2015 to 10% in 2017 which is consistent with previous 
claims in the media (Maier, Ferris & Winstock, 2018). Prevalence estimates are, however, 
still limited in the UK, and if media reports are to be believed, more peer reviewed research 
is necessary to establish an accurate picture of use.  
1.4 Chapter Summary 
 
In summary, cognitive enhancement drugs belong to two groups: soft enhancers and PCE. 
Substances in each group have been discussed separately, in terms of their mechanism of 
action and pharmacology, with the efficacy of each substance also being briefly touched 
upon. Experimental studies with nutraceuticals and PCE have, however, shown modest 
results, but PCE do appear to exhibit acute benefits to some aspects of executive 
functioning such as working memory and attention. Furthermore, based on prevalence 
estimates in the UK, modafinil appears to be the most popular PCE, with recent data even 
showing a considerable increase in use. As such, the efficacy of modafinil will be discussed 
further in Chapter 2 by examining clinical studies, dose dependent effects and the potential 
harms of this drug, to further understand the implications on the user. Nonetheless, 
despite reports by the media which suggest an increase in the use of CE strategies, little 
robust peer reviewed data exists which supports these claims. Problems with methodology 
and sample diversity also raises the issue of generalisability, and intentions behind off-label 
use are rarely investigated making it difficult to interpret prevalence data. As such, a gap in 
knowledge exists concerning intentions and levels of use of CE drugs in the UK, which was 
addressed with a cross-sectional national survey which forms the first study of this thesis.  
21 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22 | P a g e  
 
Chapter 2: A Review of Modafinil use in Healthy and Clinical Populations 
 
2.1 Chapter Overview 
 
In the previous chapter, a comprehensive examination of substances used for CE was 
conducted. Through a combined exploration of anecdotal studies by the media and peer-
reviewed scientific research, it was established that pharmaceutical substances, termed 
PCEs, were appearing to grow in prevalence worldwide. This chapter takes a closer look at 
the drug modafinil, a PCE which appears to be most prevalent in the UK, and examines 
research which assesses acute use in healthy and clinical populations in terms of the effects 
the drug has on cognition and health.  
2.2 An Overview of Modafinil  
 
First marketed in France in the 1990’s, modafinil was identified as a wakefulness agent 
promoted for tackling excessive drowsiness (somnolence) in narcolepsy syndrome 
(Minzenberg & Carter, 2008). A recognised neurological disorder, narcolepsy is 
characterised by uncontrollable periods of sleep which can be highly disruptive to a 
person’s life, and despite being a rare condition, it affects upward of 30,000 people in the 
UK (NHS, 2019). Modafinil counteracts the symptoms of this disorder through a unique 
method of action which targets various neurotransmitter networks resulting in a prolonged 
wakeful state. By inhibiting the reuptake of dopamine and noradrenaline, modafinil 
counteracts deficits in orexin found in those diagnosed with the disorder, and prevents 
inappropriate periods of excessive sleep from occurring (d’Angelo et al., 2017). In light of 
the drug’s success, modafinil has garnered international attention and has been approved 
in the USA as a schedule IV drug and is also sanctioned to treat sleep apnoea and shift work 
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sleep disorder which leads to over 1,000,000 prescriptions a year (Minzenberg & Carter, 
2008). It is also prescribed for use in the US military, and is given to combat pilots and used 
by medical doctors completing long shifts (Francis, Wishart, Williamson, & Iverach, 2019; 
Ooi, Wong, & See, 2019). In the UK, modafinil can only be obtained through prescription 
and is only sanctioned for narcolepsy treatment, but recent research indicates that off-
prescription use is rising (Maier, Ferris & Winstock, 2018). As already explored, reasons 
surrounding unregulated use are numerous, but the potential health and cognitive 
consequences of use are not well understood. Consequently, the different populations who 
use modafinil off-prescription will be further discussed below, including any potential acute 
benefits or side effects to cognitive performance conferred from use.  
2.3 Modafinil effects in Healthy Non-Sleep Deprived Adults 
 
Studies assessing acute use of modafinil in healthy, non-sleep deprived people show mixed 
results. In some cognitive domains, acute modafinil use benefits cognition. For instance, 
studies examining working memory performance reveal improved capacity when compared 
with controls. Müller, Steffenhagen, Regenthal and Bublak (2004) found that on a delayed 
digit span task, 100 and 200mg doses improved working memory performance and delayed 
recall compared with a control group who did not receive modafinil. Furthermore, there 
was no difference in error rate between the groups, suggesting that modafinil improved 
working memory without a speed/accuracy trade-off. Similar findings have been reported 
on the backward digit span task, as both Randall et al. (2005) and Turner et al. (2003) found 
that 100mg and 200mg of modafinil improved working memory performance when 
compared with placebo. Furthermore, when examining IQ, Randall and Shneerson (2005)  
found that 100mg and 200mg of modafinil reduced errors on the digit span task in those 
with lower IQ scores, bringing performance in line with higher performers. These findings 
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support Müller et al. (2004), who found that on a digit span task and a numeric 
manipulation working memory task, modafinil (200mg) reduced errors in lower performers 
without a speed/accuracy trade-off. A later study by the same authors used the same dose 
of modafinil or a placebo and participants completed an IQ test and spatial working 
memory task (Müller et al., 2013). Working memory improvements were most pronounced 
in those with lower IQ, and during the higher difficulty levels of the tasks, implying that 
modafinil confers most benefits to under-performers and has modest benefits to working 
memory in already average or high performers. Nevertheless, some studies reveal limited 
to no benefits on working memory performance. For instance, 2 studies with the backward 
digit span failed to show an effect with 100mg (Pringle, Browning, Parsons, Cowen, & 
Harmer, 2013) and 300mg (Winder-Rhodes et al., 2010) doses. Moreover, on tests of verbal 
working memory, 300mg was shown to not only have no effect on performance, but 
participants self-reported overconfidence in cognitive ability (Baranski, Pigeau, Dinich, & 
Jacobs, 2004). The same was found in a 2-week follow-up study which combined 200mg 
daily administration of modafinil with cognitive training. Despite improvements to new 
language learning with English neologisms paired with visual stimuli, verbal working 
memory was not improved, suggesting that modafinil may only improve selective aspects 
of working memory in rested people (Gilleen et al., 2014).  
Studies examining attention and inhibitory control show less consistent findings. On an 
anti-saccade stop signal task, Rycroft et al. (2007) found that modafinil (200mg) improved 
response inhibition compared with placebo by reducing response latency. However, 
response errors were not reduced, suggesting that modafinil did not improve accuracy. 
Turner et al. (2003) also found reduced latency on a stop signal task and identified a dose-
dependent effect with 200mg conferring faster response times than 100mg. Conversely, 
Theunissen, de la Asuncion Elvira, van den Bergh, and Ramaekers (2009) compared 
modafinil (200mg) with MPH (20mg) and placebo on a stop signal task, and found that both 
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drugs in fact slowed response time, thus appearing to reduce inhibitory control, although 
the effect was non-significant. On tests of simple selective attention, healthy people appear 
to show limited gain from modafinil. Müller et al. (2004) reported that on a letter 
cancellation and trail making task, modafinil (200mg) did not improve attention above 
placebo. Furthermore, on the Cambridge Neuropsychological Test Automated Battery 
(CANTAB), R andall, Shneerson, Plaha, and File (2003) reported that 100mg and 200mg 
of modafinil did not improve selective attention compared with placebo, and even 
increased self-reported anxiety during the task. Additionally, a follow-up study by Randall, 
Shneerson and File (2005) confirmed these findings, but on a rapid visual information 
processing task (RVIP), both doses significantly increased sustained attention compared 
with placebo. Such improvements have also been reported by Turner et al. (2003), who 
found that modafinil (100mg and 200mg) improved performance on the RVIP and a set 
shifting task relative to placebo. Furthermore, on a visual and auditory attention shifting 
task, Marchant et al. (2009) found that modafinil (200mg) improved sustained attention, 
alertness and attentional speed compared with a placebo condition. Modafinil therefore 
appears to have some benefits for healthy people in inhibitory control, sustained attention 
and attentional speed, but not selective attention.  
Research assessing creativity and cognitive flexibility appears to show equivocal results. A 
construct which underlies creativity is problem solving capability, and modafinil does not 
appear to positively impact this function. Mohamed (2016) administered the Group 
Embedded Figures Task and the Remote Associates Task (RAT), and Modafinil (200mg) was 
found not to improve problem solving ability above a matched placebo. Moreover, 
participants in the experimental condition exhibited a marginal reduction on the 
Abbreviated Torrance Test for Adults (ATTA) relative to the placebo condition, signifying 
that modafinil reduced creativity. However, if participants were found to have low 
creativity at baseline, modafinil increased scores in-line with higher performers. 
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Nevertheless, on the Hayling Sentence completion test (HSCT), Mohamed and Lewis (2014) 
found that modafinil (200mg) increased response latency without increasing response 
accuracy relative to a placebo, indicating that creative thought was slowed. Moreover, 
Müller et al. (2013) showed that on the ATTA and a line drawing task, a modafinil (200mg) 
administration group exhibited decreased creativity scores compared with the placebo 
group, although differences were non-significant. Cognitive flexibility appears to decrease 
with modafinil, as Randall, Fleck, Shneerson, and File (2004) demonstrated that 200mg 
significantly increased errors on a set shifting task relative to placebo. As such, in healthy 
people, modafinil might, in fact, reduce creative thought and cognitive flexibility, which 
suggests that in order to produce benefits in certain cognitive domains, a trade-off exists in 
other aspects of performance.  
In summary, healthy people show benefits to various cognitive domains with acute 
modafinil use. Research appears to support increases to working memory performance 
often without a trade-off to speed or accuracy with moderate doses (200mg) of the drug. 
Some improvements are also reported in inhibitory control and sustained attention, 
although research is not as consistent as with studies examining working memory. 
Moreover, despite these improvements, studies assessing creativity and cognitive flexibility 
do not only seem to show null results, but moderate doses of the drug appear to decrease 
these functions. This suggests the existence of a cognitive trade-off, as certain cognitive 
domains are increased at the cost of others. Furthermore, most benefits seem to be 
recorded with 200mg doses, with 100mg and 300mg sometimes showing no benefits. This 
implies that there is an inverted ‘U’ shape effect with the drug, and that there is an 
optimum dose (200mg) where healthy people gain the most benefits.  
2.4 Modafinil effects in Healthy Sleep Deprived Adults  
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Modafinil’s effects on cognitive performance in sleep-deprived populations are promising, 
as it has been shown to reduce sleepiness. As with rested people, the drug benefits 
working memory processes, although there is less available research. For example, an early 
study by Pigeau et al. (1995) compared modafinil (300mg) with d-amphetamine (20mg) and 
placebo on 3 different occasions during 64 hours of sleeplessness in military personnel. 
Modafinil and d-ampetamine improved performance on a digit span task relative to 
placebo, although working memory was still impaired when compared with performance 
when rested. A follow-up study by the authors compared the same doses of modafinil and 
d-amphetamine to a group that was allowed intermittent naps (Friedl, 2000). Drug 
administration improved performance on a digit span task, in line with non-sleep deprived 
scores, although the duration of improvement was superior in the drug groups compared 
to performance following a nap. This indicates that modafinil may restore cognition more 
effectively than short periods of rest. Furthermore, on the n-back task, Thomas and Kwong 
(2006) found that modafinil (200mg) improved working memory performance after a single 
night of sleep deprivation. Performance was improved on the 1, 2 and 3-back compared 
with placebo, but improvements were most pronounced in the 2-back condition. Of course, 
it is unsurprising that both groups performed well on the 1-back due to the relative ease of 
the task, but differences on the 2-back suggest the existence of an inverted ‘U’ shape effect 
of the drug with sleep deprived people on working memory performance, in that most 
benefits appear on the moderate difficulty task. Similarly, Sauvet et al. (2019) found that 
modafinil (200mg), administered 3 times over 18 hours, improved performance on the 2-
back relative to a placebo after 40 hours sleep deprivation. Moreover, a compound of 
modafinil (100mg) and flecainide (9mg), TN102, which modulates the effects of modafinil 
by reducing cardiovascular activity, was shown to improve wakefulness and working 
memory performance more than modafinil alone.  
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Modafinil appears to be most beneficial to attentional processes, reaction time and 
memory recall in sleep deprivation studies. A body of research by the Institut de Medicine 
Aerspatiale in France found various benefits to sustaining performance on a large task 
battery. In the first study, male air force pilots received either 6 treatments of modafinil 
(200mg) or placebo over 60 hours of wakefulness (Lagarde & Batejat, 1995; Lagarde, 
Batejat, Van Beers, Sarafian, & Pradella, 1995). On the second study, the effectiveness of 
modafinil (200mg) and sleep versus a matched placebo and sleep was investigated on the 
same test battery (Batejat & Lagarde, 1999). Both studies found that modafinil significantly 
improved attention, reaction time, mathematical reasoning, grammatical reasoning and 
spatial processing when compared with placebo. Moreover, in the first study, statistical 
differences were most pronounced after 48 hours of sleep deprivation, which indicates that 
modafinil is most effective after a significant period of wakefulness. Wesensten et al. 
(2002) compared modafinil (100mg, 200mg and 400mg) with caffeine (600mg) during 54 
hours of wakefulness. Five groups were administered the computerised Performance 
Assessment Battery (PAB), twice hourly, with 200 and 400mg of modafinil increasing 
response time and mathematical ability significantly more than placebo and equal to 
caffeine. Findings suggest that 100mg may not be sufficient to restore cognitive 
performance in unrested people, but medium and high doses produce similar performance 
outcomes to a high dose of caffeine. Modafinil (300mg) has also been shown to improve 
reaction time, memory recall and reasoning in military recruits compared with placebo 
after 64 hours of shift work (Buguet, Montmayeur, Pigeau, & Naitoh, 1995). Moreover, 
with doctors in the emergency department, modafinil (200mg) improved sustained 
attention on the CPT and improved accuracy without a speed trade-off after an overnight 
shift (Gill, Haerich, Westcott, Godenick, & Tucker, 2006). Moreover, Hart et al. (2006)  
found that during 3 days of simulated night shifts that 200 and 400mg of modafinil 
significantly improved divided attention and immediate recall compared with a placebo 
29 | P a g e  
 
when participants completed a battery of tests in day and night cycles. There were no 
dose-dependent differences in performance, signifying that attention and memory both 
benefit from moderate and high doses of modafinil when sleep deprived. Interestingly, 
both doses exerted strongest effects during night-time consumption, which may indicate 
that this is the optimal time to take the drug.  
On measures of inhibitory control and cognitive flexibility, different doses of modafinil 
shows strong results, although research is limited. Wesensten, Killgore, and Balkin (2005)  
found that after 85 hours of sleeplessness, a single dose of modafinil (400mg) significantly 
improved performance and flexibility on the Wisconsin Card Sort Test (WCST) and 
inhibitory control on the Stroop comparable with caffeine (600mg) and above d-
amphetamine (20mg). Furthermore, a study with a medium dose of modafinil (200mg) 
found reduced errors on the WCST and greater cognitive flexibility and control on the 
sentence completion test, compared with a matched placebo (Walsh, Randazzo, Stone, & 
Schweitzer, 2004).  
In sum, acute use of modafinil shows promising results across various cognitive domains in 
otherwise healthy but sleep deprived people. Unrested people appear to be receptive to 
different doses of modafinil, with moderate (200mg) and high doses (300 – 400mg) 
exhibiting strong restorative effects across various cognitive functions. Similar to healthy 
people, working memory performance is also improved, although some evidence indicates 
that this effect is only apparent in tasks of moderate difficulty and performance is still 
below when rested. Attentional processes, inhibitory control, reaction time, memory recall, 
spatial processes numerical and grammatical reasoning are also restored with medium and 
high doses of the drug, but 100mg doses do not appear to be effective. Moreover, unlike 
rested people who appear to experience decrements in cognitive flexibility, a moderate 
dose of modafinil is shown to improve this function is unrested people. Finally, different 
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doses of the drug even appear to be effective in excessive sleeplessness (54 and 64 hours 
respectively), suggesting that modafinil is most effective when counteracting sleep 
deprivation.  
2.5 Modafinil effects in Adults with Clinical Conditions  
 
The effects of modafinil on cognition in clinical populations has also been studied. For 
instance, research appears to show the reversal of working memory deficits commonly 
reported in patients with chronic schizophrenia. In a double-blind, placebo matched study, 
modafinil (200mg) administered alongside antipsychotic medication significantly improved 
performance on the digit span and backward digit span tasks (Turner, Clark, Pomarol-
Clotet, et al., 2004). Delayed visual recognition memory was also improved on the CANAB 
and the modafinil group showed improved attentional set shifting on the Tower of London 
task. People with Schizophrenia have also exhibited improvements on the n-back with 
modafinil (100mg) relative to placebo, which fMRI revealed was linked to increased 
activation of the dorsal anterior cingulate cortex (Spence, Green, Wilkinson, & Hunter, 
2005). Moreover, working memory improvements have also been reported on a letter-
number sequencing task, when schizophrenic patients received a continuous, 28 day dose 
(days 1- 14 100mg, days 15 – 28 200mg) (Rosenthal & Bryant, 2004). Additionally, modafinil 
led to mood enhancement and a significant reduction in fatigue during baseline 
measurements, but no differences were reported between 100 or 200mg treatments. 
Furthermore, Minzenberg et al. (2009) found that modafinil (200mg) improved inhibitory 
control relative to placebo on a stop signal task, which was linked to greater activation of  
the PFC. Modafinil has also been found to reduce some negative symptoms of 
schizophrenia as outlined by the DSM-IV, although findings are mixed. A longitudinal study 
from 2002 to 2006 found that in people with schizophrenia and schizoaffective disorder, 8 
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weeks of once-daily modafinil (200mg) significantly reduced symptoms of sleep irregularity, 
and improved sustained attention on a degraded performance-continuous performance 
test and verbal recall on the Californian Verbal Learning Test, all deficits commonly 
reported in the disorder (Pierre, Peloian, Wirshing, Wirshing, & Marder, 2007). 
Furthermore, modafinil did not improve psychosis reported on the Scale for the 
Assessment of Negative Symptoms (SANS) or the Brief Psychiatric Rating Scale (BPRS), but 
nor did it negatively impact symptoms, suggesting that the drug has effective but limited 
treatment utility for schizophrenia, and is not reported to degrade the condition. However, 
a systematic review by Saavedra-Velez, Yusim, Anbarasan, and Lindenmayer (2009) found 
that other studies reported no reduction in negative symptoms at all with different doses 
of the drug. Although, in these studies improvements to various aspects of cognition were 
reported, including sustained attention, attention shifting and short-term memory. 
However, not all studies show benefits to cognitive processes in patients with 
schizophrenia. An fMRI study with schizophrenic patients with prominent negative 
symptoms revealed that modafinil (100mg) did not improve Cognitive control on a motor 
activity task (Hunter, Ganesan, Wilkinson, & Spence, 2006). Furthermore, an 8 week follow-
up study showed no improvements to attention or working memory with once-daily 
modafinil (200mg) compared with placebo (Sevy et al., 2005). Nevertheless, studies 
indicate that modafinil at different doses can improve cognitive performance, and some 
associated symptoms, of schizophrenia.  
In people with depressive disorders, a small number of studies reveal that modafinil has 
some effectiveness, particularly for mood enhancement. For example, modafinil (400mg) 
taken once daily for 3 days, improved subjective ratings on the Positive and Negative Affect 
Schedule and a generalised mood scale in depressed but otherwise healthy people relative 
to placebo (Taneja, Haman, Shelton, & Robertson, 2007). Although, negative affect was 
also seen to significantly increase, as participants reported greater feelings of anxiety. 
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However, with patients from an out-patient clinic experiencing major depression, Price and 
Taylor (2005) demonstrated that subjective feelings of anxiety and depression were 
reduced with one daily treatment of modafinil (50 – 450mg doses) after 2 weeks and 3 
months of treatment as reported on the Beck Depression Inventory, Zung Self-Rating Scale 
and Hamilton Depression and Anxiety Rating Scale. Similarly, in patients with bipolar 
depression, Ballenger (2009) found that daily modafinil (average dose 177mg) significantly 
improved symptoms of depression relative to a placebo on subjective responses to the 
Inventory of Depressive Symptoms. Although, modafinil did not reduce incidences of mania 
or hypermania. In addition, on cognitive performance, evidence for improvements with 
modafinil is very limited. On the Stroop, modafinil (100 - 400mg) has been shown to 
improve inhibitory control and reduce interference compared with placebo (DeBattista, 
Lembke, Solvason, Ghebremichael, & Poirier, 2004). Finally, on the CANAB, which examines 
working memory, episodic memory, sustained attention and planning, modafinil (200mg) 
significantly improved performance on working memory and episodic memory, relative to 
placebo in people with remitted depression, but not on other measures (Kaser et al., 2017). 
Modafinil, therefore, appears to have positive outcomes in alleviating low mood and 
feelings of depression and anxiety in people with clinical conditions, but more research is 
required which inspects cognitive performance.  
In people with ADHD, the drug has been shown to significantly decrease attention deficits 
associated with the disorder. In children with the condition, Rugino and Copley (2001) 
found that daily modafinil (200mg) for an average of 4.6 weeks significantly decreased 
ADHD score on the ADHD Rating Scale-IV. Furthermore, Rugino and Samsock (2003) 
showed that children receiving a lesser dose of the drug (100mg), after 6 weeks of daily 
treatment, exhibited a significant decrease in symptoms as rated on the Conners Rating 
Scale. Moreover, in children who were assessed daily at school and home, modafinil (170 – 
425mg) was found to decrease symptoms of the disorder on the ADHD Rating Scale-IV in 
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both environments, although decreased appetite, weight loss, insomnia and headaches 
were reported as side effects (Greenhill et al., 2006). In another study, modafinil (170 – 
425mg) decreased scores on the ADHD Rating Scale-IV and Conners Rating Scale and 
appeared to be particularly effective at significantly reducing inattentiveness and hyper-
active impulse in the children compared with placebo. Finally, research investigating 
cognitive performance in the lab is rare, but one study with adults with ADHD found that 
modafinil (200mg) was associated with improvements in spatial planning, visual recognition 
memory and working memory on a battery of cognitive tasks, compared with a placebo 
group (Turner, Clark, Dowson, Robbins, & Sahakian, 2004). As such, modafinil appears 
effective at reducing disruptive symptoms of ADHD in children, but studies assessing 
cognitive performance are lacking.   
To summarise, in adults with clinical conditions modafinil is shown to be effective at 
improving cognitive functions impacted by various psychiatric disorders. Many of the 
studies use daily dosing regimens, which make comparisons with healthy and sleep 
deprived populations difficult, as most research with those samples are acute 
administration studies. Nevertheless, like the other populations discussed, working 
memory performance appears to be improved in people with chronic schizophrenia with 
200mg repeat doses of modafinil, as does attention shifting and inhibitory control to some 
extent. Furthermore, alongside antipsychotic medication, modafinil appears to have some 
effectiveness at reducing the negative symptoms of schizophrenia, although 100mg doses 
appear to be ineffective. In adults with depression, modafinil is mainly effective as a mood 
enhancer and is shown to alleviate low mood and anxiety. Finally, with ADHD children and 
adults, low and high doses of the drug appear to reduce attention deficits and other 
associated symptoms of the disorder, and in adults 200mg has also been seen to improve 
working memory, visual recognition memory and spatial planning.  
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2.6 Side Effects and Potential Harms 
 
In the populations discussed above, modafinil appears to be well tolerated and facilitates 
some aspects of cognitive performance while reducing several symptoms of various clinical 
conditions. Nevertheless, in periods of acute use, certain side effects are reported. In small 
to moderate doses (100 – 200mg), studies do not describe adverse reactions; however, 
with larger doses (300mg and above) some common side effects have been observed. The 
most frequently reported side effects are headaches, nausea and sleep disturbances, which 
have been found in rested (Saletu et al., 1989; Saletu, Grünberger, Linzmayer, & Stöhr, 
1986) and sleep deprived people (Caldwell, Caldwell, Smyth, & Hall, 2000). Anxiety, 
nervousness and racing heart rate are less observed, but have been recorded in 2 studies 
(Caldwell, Smith, & Brown, 2004; Wesensten et al., 2005). In a single case, hallucinations 
have been reported with a large dose of 900mg, although they were also later reported 
with placebo (Chapotot, Pigeau, Canini, Bourdon, & Buguet, 2003), suggesting that an 
expectancy effect may have been responsible. Consequently, no severe side effects have 
been reported in research, and at the time of writing, there have been no reports of serious 
adverse reactions or death from use of the drug. Nevertheless, Provigil, the official licence 
holder of modafinil in the USA, has published several guidelines surrounding safe use (FDA, 
2007). Moreover, the US Food and Drug Administration point out that research on the 
long-term health impact of the drug (above 3 months) has not been conducted, but short-
term clinical trials show no negative impact on cardiovascular or cognitive health. Of 
course, the absence of evidence does not equate to the absence of harm, and caution 
should be taken when repeatedly using any psychoactive substance over a significant 
period. It is also worth considering that modafinil is a psychostimulant which shares 
similarities with amphetamine and other neurotoxic substances, and despite not having an 
identical method of action, drugs known to modulate dopamine and noradrenaline are 
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proven to lead to physiological and psychological distress, and can result in addiction 
(Gawin & Ellinwood, 1988). If then, the prevalence reports discussed in the previous 
chapter about the rise in nonmedical modafinil use in the UK are true, then users 
potentially find themselves at an elevated risk. Further research is therefore required to 
assess the impact of long-term use (longer than 3 months), and to evaluate whether 
modafinil is harmful.  
2.7 Chapter Summary  
 
As a cognition enhancing substance, modafinil appears to have some benefits for improving 
cognitive functions in healthy people with or without sleep deprivation, and in people with 
various clinical conditions. Evidence is perhaps most persuasive in people who are 
unrested, as modafinil appears to reverse cognitive deficits associated with sleeplessness 
to baseline levels or just below. However, in healthy people, evidence for the drug’s 
effectiveness at improving cognitive function is not conclusive. Research supports working 
memory improvements in a laboratory setting, but effects of modafinil on inhibitory 
control and attentional processes are less consistent. In addition, creativity and cognitive 
flexibility show impairments with modafinil use, suggesting that there may be a cognitive 
‘trade-off’ when healthy people use the drug. In terms of dose-dependent effects, 200mg 
appears to be the optimal dose for conferring cognitive benefits, with doses below and 
above this amount showing some null results, suggesting an inverted ‘U’ shape effect. 
Adverse side effects also appear to be rare but are reported with larger doses of the drug 
(300mg and above), suggesting that a moderate dose is also the safest. Finally, the long-
term impact of modafinil on health and cognition has not been addressed in previous 
research, despite short-term use (3 months and below) indicating that the drug is well 
tolerated. Nevertheless, if the prevalence estimates explored in the previous chapter are to 
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be believed, then there is a recent and substantial increase in modafinil use. Such a rise 
could come with hidden implications for health and long-term cognitive functioning, 
particularly if users do not follow medical guidelines for safe use. Therefore, studies 2 and 3 
of this thesis further investigate people who report long-term use of modafinil, and they 
assess cognition, physiological and neurological functioning during completion of various 
cognitive performance measures. Furthermore, the following Chapter will examine the use 
of various methods for measuring cognitive workload, an umbrella term for examining 
different aspects of cognitive performance in response to task difficulty (e.g., working 
memory, multi-tasking and problem-solving), to determine which methods are most 
appropriate for capturing potential differences that might be apparent between long-term 
modafinil users and nonusers.  
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Chapter 3: Subjective, Cognitive and Neurophysiological indicators of Cognitive 
Workload: Examining the different methodologies.  
 
3.1 Chapter Overview 
 
This chapter explores the psychophysiological and neurophysiological correlates of 
cognitive workload, including a variety of neuroimaging and physiological techniques 
designed to measure cognitive effort. Additionally, highly demanding cognitive 
performance measures which increase effort investment are discussed here, including 
research in different types of substance users, to examine whether or not these measures 
are effective at detecting differences in performance in these groups. This Chapter 
therefore scrutinises the most effective methods for use in Study 2 and 3 of the thesis for 
examining potential differences in cognitive workload with long-term modafinil users.  
3.2 Defining Cognitive Workload 
 
Cognitive workload can be understood as the level of cognitive effort invested in a task in 
an attempt to successfully complete it (Cain, 2007). The level of workload required is 
therefore set by the individual and is not preset by the task. To further clarify, a task does 
not inherently possess a prerequisite level of workload in order for it to be completed;  this 
is determined by the individual and may vary as a function of who is attempting the task 
(Vidulich & Tsang, 2012). As such, there is a point in which a person reaches peak effort 
investment, which represents their maximum cognitive workload. Anything above this level 
of effort exceeds a person’s ability to attend to and process the requirements of the task, 
and this point has been termed cognitive overload (Kirsh, 2000). Furthermore, the point in 
which cognitive overload occurs has been shown to vary with different populations, such as 
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substance users, a point which will later be returned to (Cain, 2007). In the following 
sections of this Chapter, the various methods of measuring cognitive workload are 
evaluated.  
3.3 Subjective and Behavioural Measures of Cognitive Workload 
 
A popular subjective measure of cognitive workload is the NASA Task Load Index (NASA-
TLX), which assesses perceived workload across 6 domains (Hart & Staveland, 1988). This 
measure was developed by NASA to determine workload during complex aviation trials, but 
has seen growing use in healthcare settings and cognitive research (Tubbs-Cooley, Mara, 
Carle, & Gurses, 2018). Visual analogue scales investigate self-reported mental, physical 
and temporal demand, as well as maximum effort, perceived performance and frustration 
(See Chapter 7 for full description). A review of 550 studies over 20 years found that almost 
all studies assessed measures of cognitive performance, with 31% focusing on workload 
with computer-based cognitive performance measures (Hart et al., 2006). Moreover, 6% of 
studies also assessed other measures of cognitive workload against the NASA-TLX, including 
neurophysiological measures like cardiovascular reactivity, brain activity and skin 
conductance. As such, the NASA-TLX is treated as the benchmark with which other 
cognitive workload measures are compared (Hitt, Kring, Daskarolis, Morris, & Mouloua, 
1999). However, like other self-report measures, common criticisms of the NASA-TLX 
include issues with report bias, honesty and introspective ability. Consequently, cognitive 
workload is best measured alongside other methods, such as cognitive tasks and 
neurophysiological measures of effort investment.  
Working memory tasks are another effective measure of cognitive workload (Engle, Kane, 
& Tuholski, 1999). Characterised as the ability to maintain attention and remember specific 
stimuli in the presence of distracting information, working memory performance is strongly 
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associated with cognitive workload (Baddeley, 1992). Furthermore, n-back tasks are 
especially effective at capturing effort investment and working memory load because 
conditions can be altered to systematically increase workload, which can reveal the point in 
which a person experiences cognitive overload (Jaeggi, Buschkuehl, Perrig, & Meier, 2010). 
The n-back requires constant updating of working memory to recall the position of a 
stimulus (e.g. a spatial location or letter/number in a sequence) and whether the 
information currently displayed is a match or non-match (see Figure 3.1.). A recent meta-
analysis found that the n-back is often used in conjunction with neuroimaging techniques 
to capture neurophysiological correlates of cognitive workload (Redick & Lindsey, 2013). 
Nonetheless, this test appears to be an effective working memory task at increasing 
working memory load, and has been used to demonstrate differences in cognitive workload 
with clinical populations and chronic substance users (Martin et al., 2018; Sanvicente-
Vieira, Kommers-Molina, De Nardi, Francke, & Grassi-Oliveira, 2016). The previous chapter 
also highlighted that the n-back and other tests of working memory have demonstrated 
performance differences with acute modafinil use relative to placebo. As such, the task 
may also be sufficient to identify differences in working memory load with long-term 
modafinil users.   
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Figure 3.1. – Different conditions of a computerised letter-based n-back working memory task. 
Participants are required to click each time the current stimulus matches the letter ‘n’ back in the 
sequence. As the target becomes more distant, memory interference and the presence of distracting 
information makes the task demand greater which leads to greater cognitive workload.  
 
 
Inhibitory control tasks can also be manipulated to increase cognitive workload 
(Chmielewski, Mückschel, Stock, & Beste, 2015). These tasks require a response to certain 
stimuli, while simultaneously inhibiting/withholding responses to others. A popular 
inhibition task is the Go/No-go task, which presents ‘go’ signals, which require a response, 
and ‘no-go’ signals which require withholding a response (see Chapter 4 for full 
methodology). Differences in inhibitory control are observed by variations in response time 
between ‘go’ signals and ‘no-go’ signals, and in errors in inhibition where participants 
accidentally respond during ‘no-go’ trials. Increased response latency during sustained 
inhibition could indicate mental fatigue in response to increased workload (Kato, Endo, & 
Kizuka, 2009). Impairments in the ability to inhibit responses are common characteristics in 
psychopathology and substance abuse. A combined meta-analysis and systematic review of 
Go/No-Go tasks assessed 318 studies investigating 11 different psychiatric disorders, 
including substance use disorders, and found that when compared with healthy controls, 
the task exposed significantly more errors and slower response times in psychiatric samples 
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(Wright, Lipszyc, Dupuis, Thaypararajah, & Schachar, 2014). Moreover, research specific to 
substance users shows that chronic methamphetamine users demonstrate impaired 
latency to ‘no-go’ targets (Monterosso, Aron, Cordova, Xu, & London, 2005), as do heavy 
social drinkers when compared with light drinkers (Ahmadi et al., 2013), and cocaine users 
during harder task difficulties (Kaufman, Ross, Stein, & Garavan, 2003). As such, substance 
users, particularly chronic stimulant users, demonstrate deficits to inhibitory control on the 
Go/No-go task, which could yet be seen in other substance using populations such as 
modafinil users. A frequent criticism of the Go/No-go task, however, is that it is more a 
measure of sustained attention than response inhibition (Wright, Lipszyc, Dupuis, 
Thaypararajah, & Schachar, 2014) and that errors are attributed to plateaus in attention 
processes rather than deficits in inhibitory control.   
Figure 3.2. – A variant of the Cued Go/No-go task. In this version, participants are required to 
respond only to green rectangles which appear in either horizontal or vertical orientation. Horizontal 
rectangles appear primarily green, while vertical rectangles are mostly blue. Cognitive workload is 
created by determining which rectangles to respond to and which to ignore (Fillmore, 2003).  
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Nonetheless, tests measuring sustained attention have different characteristics to those 
measuring inhibitory control. These tasks are based on the simple premise of focusing 
attention over a duration of time to identify specific stimuli, such as letter sequences or 
number pairs (Shalev, Ben-Simon, Mevorach, Cohen, & Tsal, 2011). Such tests increase 
cognitive workload by causing the participant to invest sustained effort and vigilance for a 
long period of time, which leads to mental fatigue and can result in cognitive overload 
(Szalma, 2009). A popular test of sustained attention is the CPT, which requires participants 
to attend to strings of letters or numbers and to identify specific patterns (e.g., odd and 
even numbers), while simultaneously ignoring distracting information (see Chapter 6 for 
full methodology). This test was designed to measure deficits in sustained attention in 
patients with traumatic brain injury and psychiatric populations (Rosvold, Mirsky, Sarason, 
Bransome Jr, & Beck, 1956), with the earliest example presenting letter sequences and 
requiring patients to respond when ‘X’ or ‘AX’ was displayed. CPTs have been used 
alongside neuroimaging techniques to localise regions of the brain implicated in attentional 
processes, and to measure psychophysiological indicators of cognitive workload (Adler et 
al., 2001; Thermenos et al., 2005). The CPT also shows sensitivity to attention deficits found 
in adults with ADHD (Riccio & Reynolds, 2001), although a recent meta-analysis showed 
that the task is not sensitive to differences in attentional load between genders (Hasson & 
Fine, 2012). Research with chronic substance use has also been conducted, and focuses on 
attention deficits in children who experienced prenatal substance abuse, including alcohol 
(Dolan, Stone, & Briggs, 2009), heroin and cocaine use (Ackerman et al., 2008; Bandstra, 
Morrow, Anthony, Accornero, & Fried, 2001), although only prenatal heroin and cocaine 
use demonstrate impairments to attentional load. Furthermore, the previous chapter 
showed that acute administration of modafinil improved performance on a CPT in sleep 
deprived adults, although this task has not been used to demonstrate differences in 
attentional load with long-term use.  
43 | P a g e  
 
Figure 3.3. – An early variant of a CPT where participants respond only when ‘A’ and ‘X’ appear 
sequentially. Workload demand is heightened by gradually increasing the frequency with which X 
follows A, resulting in a state of heightened sustained attention (Lesh et al., 2015).  
 
 
Multitasking paradigms are another effective way of increasing cognitive workload, as 
these tests require high effort investment and the use of multiple, simultaneous cognitive 
processes (Manhart, 2004). These tasks are also effective stress inducers, as participants 
often must attend to multiple highly demanding tasks at once, and errors are often 
punished by loss of incentives or decreasing scores. However, multitasking cognitive tests 
lack standardisation, and as such vary in what aspects of cognitive performance they assess 
and the ease with which they are completed. Nevertheless, the emphasis with these tasks 
is not on what aspects of cognitive function are being examined, but that the executive is 
being loaded/overloaded by a series of high demands (Wetherell & Carter, 2014). A 
substantial body of research exists which demonstrates that multitasking in different forms 
is an effective means of increasing cognitive workload by challenging a person’s ability to 
44 | P a g e  
 
attend to the requirements of several tasks at once (Puma, Matton, Paubel, Raufaste, & El-
Yagoubi, 2018; Sanjram, 2013; Wilson & Eggemeier, 1991; Xie & Salvendy, 2000). However, 
at the time of writing, there is a lack of review data which compares multitasking cognitive 
performance measures in effectiveness for increasing cognitive workload, although a task 
has recently emerged which has been shown to increase workload and some associated 
psychobiological markers. The Multitasking Framework (MTF) (Wetherell & Carter, 2014), is 
a versatile multitasking model, which enables the simultaneous completion of up to 4 
different cognitive performance measures (see Chapter 7 for full methodology). Difficulty 
can also be altered by changing task parameters (e.g. increasing the length of sums on a 
mental arithmetic task or increasing speed on a visual monitoring task), and altering the 
timeframe that participants must complete the tasks. A numerical score is also kept in the 
centre of the window which updates in real-time and can enter negative values if 
participants falters across any of the tasks, a method shown to increase cognitive stress 
and workload by increasing the urgency to perform well (Wetherell & Carter, 2014). As the 
MTF is relatively new, research with the task is still growing, but some evidence suggests 
that it is an effective tool for increasing perceived workload and biomarkers of stress (Kelly-
Hughes, Wetherell, & Smith, 2014; Wetherell & Carter, 2014; Wetherell, Craw, Smith, & 
Smith, 2017). Furthermore, in substance using samples, the MTF has been shown to 
increase perceived workload in ecstasy users compared with controls (Wetherell, Atherton, 
Grainger, Brosnan, & Scholey, 2012) and increase haemodynamic response, a biomarker of 
increased cognitive workload, in ecstasy polydrug users relative to a control group (see 
below for more on the MTF and haemodynamic response with fNIRS) (Roberts, Wetherell, 
Fisk, & Montgomery, 2015). As such, multitasking methods appear to be an effective means 
of increasing cognitive workload by increasing effort investment and cognitive stress and 
reveal differences in cognitive performance between substance using samples, which could 
be a useful method when examining modafinil users.  
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3.3 Neurological Indicators of Cognitive Effort 
 
Neuroimaging technologies are useful tools for elucidating neurological correlates of 
cognitive deficits and increased cognitive workload (Ranchet, Morgan, Akinwuntan, & 
Devos, 2017; Unni et al., 2015). The technology for which there is most evidence is 
electroencephalogram (EEG), which demonstrates an increase in theta band and a decrease 
in alpha band power when cognitive workload is increased (Puma et al., 2018). This method 
has proven very effective when measuring attention (Borghini, Astolfi, Vecchiato, Mattia, & 
Babiloni, 2014; Kamzanova, Kustubayeva, & Matthews, 2014; Zhao, Zhao, Liu, & Zheng, 
2012) and working memory load (Başar, Başar-Eroglu, Karakaş, & Schürmann, 2001; 
Kahana, 2001; Klimesch, 1999), and is considered the most widely researched indicator of 
cognitive workload (Ke et al., 2014). Nevertheless, novel techniques could confer additional 
benefits when investigating cognitive workload.  
Functional near-infrared spectroscopy (fNIRS) is a neuroimaging technique which measures 
haemodynamic response to neuronal activation via a process termed neurovascular 
coupling (See Chapter 4 for full methodology). Moreover, studies reveal that fNIRS is 
sensitive when localising cognitive impairments in working memory and executive function 
(Ehlis, Bähne, Jacob, Herrmann, & Fallgatter, 2008; Izzetoglu, Bunce, Onaral, Pourrezaei, & 
Chance, 2004). The area of the cortex thought to govern these functions is the dorsolateral 
prefrontal cortex (DLPFC), which is deeply innerved with dopamine transporters which are 
related to cognitive performance (Collins, 2008). Therefore, there is a theoretical basis for 
use of fNIRS to measure changes in haemodynamic response, specifically oxygenated (oxy-
Hb) and deoxygenated haemoglobin (deoxy-Hb), localised to the DLPFC. Moreover, changes 
in haemodynamic activity can index increases in effort and cognitive workload and can 
provide a neuronal link of cognitive impairments. Furthermore, tasks which typically 
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require greater cognitive workload are often sensitive to the presence of cognitive deficits 
which are linked to substance use (Ranchet et al., 2017). Therefore, by exposing substance 
users to tasks of differing workload, specific cognitive impairments can be studied, and 
fNIRS can be used to measure these deficits.  
Studies using fNIRS to index cognitive deficits and workload in ecstasy and ecstasy polydrug 
users have revealed compelling results. Roberts and Montgomery (2015a) examined 
ecstasy users’ executive access on an oral variant of the Chicago World Fluency Test and 
found increased oxy-Hb change on the left DLPFC and right medial PFC in users relative to 
nonusers. No behavioural differences were apparent which suggests that users exhibited 
increased effort investment and activity in the PFC as a compensatory mechanism for 
ecstasy induced cognitive deficits. Another study by the same authors had similar findings 
on a random letter generation inhibitory control task (Roberts & Montgomery, 2015b). 
Ecstasy users showed increased oxy-Hb change on the left and right DLPFC and right medial 
PFC, despite no behavioural differences. Moreover, recency of ecstasy use significantly 
predicted increased oxy-Hb change across 2 channels on the right PFC, suggesting that 
recent substance use is most associated with the presence of cognitive deficits. 
Montgomery, Fisk, and Roberts (2017) also showed a difference in oxy and deoxy-Hb 
change on a verbal and spatial working memory updating task. Again, the left and right 
DLPFC showed increased oxy-Hb change in users, despite no differences on the behavioural 
measures. Total use and recency of use were also linked to most haemodynamic changes, 
suggesting again that recent and chronic ecstasy use was most detrimental to cognition. 
Conversely, Roberts et al. (2015) found that on an intermediate difficulty condition of the 
MTF, which used mental arithmetic, stroop, visual tracking and visual warning subtasks, 
ecstasy polydrug users exhibited decreased oxy-Hb change when compared with controls 
on the left and right DLPFC, and with non-ecstasy polydrug users on the right DLFPC. There 
were no differences in perceived workload on the NASA-TLX or in performance on the 
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subtasks of the MTF, suggesting that on an acute multitasking stressor, ecstasy users 
required less cognitive effort than the other groups to achieve equivalent results. These 
findings may diverge from other studies as cognitive multitasking is linked to bilateral 
cortical activation more so than completing single tasks (Deprez et al., 2013), and it may be 
that users need to invest less effort to access both hemispheres than nonusers, but use 
more for single cortex activation. This also supports a notion that substance users 
experience changes in patterns of neural activation which may come as a result of 
unresolved cognitive deficits. Taken as a whole, studies with ecstasy users show that 
through changes in haemodynamic response, fNIRS can detect cognitive workload 
differences in substance users across a range of cognitive performance measures and can 
even identify deficits linked to chronic and recent drug use. Therefore, despite the current 
lack of research, fNIRS appears to be an appropriate technology to study potential 
differences in workload with modafinil users. 
Although fNIRS studies have not explored modafinil use, or nonmedical prescription 
stimulant use in general, a small number have looked at populations with deficits to 
working memory and executive function, such as adolescents with ADHD. For instance, 
Moser, Cutini, Weber, and Schroeter (2009) found increased oxy-Hb change in the right 
DLPFC during a Stroop task with MPH abstinent ADHD adults compared with healthy 
controls despite a lack of performance differences on the task. Interestingly, Ehlis et al. 
(2008) observed reduced activation of the ventrolateral prefrontal cortex (VLPFC) in ADHD 
adults compared with healthy controls on a working memory n-back task, with controls 
also outperforming ADHD adults on the task. They also found the same oxy-Hb reductions 
and behavioral differences during a verbal fluency task, suggesting that deficits in executive 
function are coupled with decreased haemodynamic response in the VLPFC.  Furthermore, 
Monden et al. (2012) observed haemodynamic differences in ADHD adolescents pre and 
post MPH administration on a go/no-go task. MPH led to a general increase in oxy-Hb in 
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the right PFC which was not apparent before administration. Increased activation in the 
right PFC was also associated with improved task performance, providing strong support 
for a link between oxy-Hb change in the region and improvements in executive function. As 
such, fNIRS shows adequate sensitivity to differences in cognitive workload with ecstasy 
polydrug users and ADHD adults. Nevertheless, it remains to be seen whether fNIRS can 
capture differences in neurovascular coupling with nonmedical modafinil users.  
3.4 Physiological Indicators of Cognitive Effort 
 
Physiological measures of effort investment are also linked to changes in cognitive 
workload. These methods vary but tend to focus on the heart’s reactivity to cognitive 
performance measures. Moreover, a recent systematic review of physiological measures 
used to index cognitive workload reported that no single method stood out as the primary 
means of measuring working memory, but rather a combination of techniques was most 
effective (Charles & Nixon, 2019). Popular physiological measurements for capturing 
changes in cognitive workload are heart rate and heart rate variability (HRV), with some 
studies also assessing blood pressure (Ranchet et al., 2017). An increase in cardiovascular 
activity is associated with an increase in cognitive effort, and the use of stress-inducing 
multitasking tests show the strongest outcomes (Wetherell et al., 2017). For example, 
Wetherell and Carter (2014) administered 3 difficulty conditions of the MTF (low, medium 
and high) to 20 healthy people, and found that alongside subjective reports of increasing 
workload on the NASA-TLX, heart rate, systolic and diastolic blood pressure showed 
significant increases as the task difficulty increased. Furthermore, Wetherell et al. (2017) 
demonstrated that the added stress of performance evaluation during the MTF increased 
cardiovascular reactivity. At specific intervals during the task, participants were informed 
that they were under-performing compared to average and had to quickly improve their 
49 | P a g e  
 
score. This resulted in significant increases in perceived workload, heart rate and systolic 
and diastolic blood pressure when compared to the regular MTF condition. Similarly, Kelly-
Hughes et al. (2014) found that multitasking under higher difficulty caused significant 
increases in beat to beat blood pressure than low difficulty multitasking. Moreover, 
increased working memory load is an effective stressor and cause of cognitive overload, 
with high heart rate and blood pressure linked to increased working memory demand 
(Martens et al., 2019; Mehler, Reimer, & Coughlin, 2012). HRV is also affected by cognitive 
stressors, which has been demonstrated on a flight simulator, with reduced high-frequency 
HRV as the task increased in difficulty (Durantin, Gagnon, Tremblay, & Dehais, 2014), and 
on various working memory tasks, including the n-back, where harder paradigms also show 
decreased HRV (Backs & Seljos, 1994; Hansen, Johnsen, & Thayer, 2003; Mulder & Mulder, 
1981). Finally, some evidence indicates that tasks of inhibitory control, such as the Stroop, 
reduce HRV (Egner & Hirsch, 2005; Mathewson et al., 2010), although it has also been 
shown that this link may be attributed purely to attentional processes (Fairclough & 
Houston, 2004). 
Despite physiological measures of cognitive workload showing some compelling findings, at 
the time of writing, studies appear to have not looked at differences among substance user 
samples. Nevertheless, long-term use of illicit drugs are linked with cardiovascular 
reactivity and toxicity, and may result in episodes of cardiac tachycardia, dysrhythmia, 
hypertension and even myocardial infarction (Richards et al., 2016). Moreover, stimulants 
in particular activate the SNS through norepinephrine and adrenergic receptors which 
increase myocardial oxygen demand and are observed to raise heart rate and systolic blood 
pressure (Stankowski, Kloner, & Rezkalla, 2015). Studies assessing the effects of stimulant 
use on HRV in healthy adult users are rare and those that exist primarily focus on chronic 
prenatal use without assessing differences in workload, as such it is difficult to draw 
relevant conclusions from this research (Koenig, Menke, Hillecke, Thayer, and Jarczok, 
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2015). Still, as a prescription stimulant, it is feasible that long-term modafinil use may take 
a similar toll on cardiac functioning as illegal stimulants, particularly since the drug 
activates the SNS for prolonged periods (McClellan & Spencer, 1998). Research is therefore 
required to clarify the effects of modafinil on physiological processes, and to determine 
whether popular measurements of cardiovascular reactivity, heart rate, HRV and blood 
pressure are sufficiently sensitive to record drug-specific differences in cognitive workload.  
3.5 Chapter Summary  
 
In the previous chapters, CE drug use was comprehensively explored and the effects of 
acute modafinil use on cognitive functioning was evaluated. This chapter sought to build on 
the investigation into modafinil use started in the previous chapter by determining the 
most effective ways to measure cognitive performance in long-term users of the drug. By 
examining which methods effectively increase cognitive workload and which can detect 
differences between substance users and controls, it appears that a mixture of subjective, 
behavioural and neurophysiological measures is most effective. The NASA-TLX is the most 
established technique for measuring workload but is the most flawed, due to issues 
inherent to self-report measures, although findings are promising when it is used alongside 
other methods. With cognitive performance measures, tests of; working memory, 
inhibitory control, sustained attention and multitasking paradigms are also shown to 
effectively increase cognitive workload, with promising results seen with the n-back, go/no-
go task, CPT and MTF, respectively. While EEG appears to be the neuroimaging technique 
with the most evidence for recording increases in effort and workload, fNIRS is a 
significantly newer technology which has shown compelling results when examining DLPFC 
activity in substance using samples. No single physiological method stands out when 
measuring cognitive workload, but changes in HRV and blood pressure are linked to 
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increasing cognitive workload, although as of the time of writing, little research exists with 
substance users despite chronic stimulant use appearing to negatively impact these 
functions. The following chapter will link the methods evaluated here to the wider aims and 
methodology of the thesis, and the apparatus used in each empirical study will be 
discussed in detail.  
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Chapter 4: Research Aims and Methodology 
 
4.1 Chapter Overview 
 
The previous chapter evaluated the best methods for measuring cognitive performance 
and cognitive workload in substance using samples. Building on this assessment, this 
chapter describes the individual neurophysiological methods, along with their theoretical 
concepts, chosen to investigate cognitive function in long-term modafinil users and the 
usefulness of survey data for collecting reliable information of substance use behaviour. 
Furthermore, the aims of the thesis are outlined here, as are the empirical studies designed 
to address them.  
4.2 Research Aims  
 
The principal aim of this thesis is to investigate the use of cognitive enhancement drugs. To 
accomplish this, several additional aims must first be outlined which address different 
aspects of CE drug use. From the literature reviewed in this thesis, four overall research 
questions emerge, which must be addressed in order to explore CE use broadly. These four 
aims form the foundation for 3 research studies, and are as follows:  
(1) To investigate aetiology of CE use among UK university students, in terms of which 
substances are being used, the reasons for use, as well as other factors potentially 
associated with consumption. This question is explored in study 1 of the thesis, via 
a multi-site cross-sectional survey in 4 UK universities (see Chapter 5).  
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(2) To assess the effects of long-term modafinil use on executive functioning. Study 2 
of the thesis addresses this question with use of cognitive performance tests to 
measure executive function (see Chapter 6).  
 
(3) To explore the effects of long-term modafinil use on neurophysiological processes 
in the DLPFC, heart rate variability and blood pressure during cognitive testing. In 
study 3, fNIRS, ECG and a digital sphygmomanometer are used to measure these 
neurophysiological processes and address this aim (see Chapter 7).  
 
(4) To examine the relationship between changes in cognitive performance and 
neurophysiological reactivity, and to determine if cognitive performance can be 
used as a proxy for neurovascular activation. Study 3 addresses this question by 
using cognitive performance and neurophysiological measures concurrently (see 
Chapter 7).  
 
To address the aims detailed above, several hypotheses have been formulated. As CE use is 
a complex and wide-ranging topic, hypotheses have been generated to be study specific. 
Furthermore, where there is an absence of direct evidence for a hypothesis, specifically in 
the case of predictions relating to modafinil use, hypotheses have been derived from 
substances which are chemically similar, such as studies which examine illicit stimulant use. 
Chapter 1 defined different categories of CE drug and explored their levels of use in the UK 
and internationally, including factors relating to consumption. In Chapter 2, acute 
administration studies with modafinil in different populations were discussed. Although 
research indicated that acute modafinil use was not harmful with medically recommended 
doses, there was limited evidence on prolonged use. Therefore, predictions about the 
effects of long-term modafinil use on cognitive functioning were derived from those studies 
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which focused on better understood stimulants, such as cocaine and amphetamine. 
Chapter 3 discussed how cognitive performance was related to neurophysiology and 
cognitive workload. Studies investigating the effects of modafinil on cognitive performance 
and neurophysiology are limited, but stimulant users’ exhibit impairments in 
neurocognitive function and complications to the cardiovascular system which are not 
present in healthy controls. As such, similar findings were anticipated with long-term 
modafinil users on measures of fNIRS, ECG and blood pressure. All hypotheses are outlined 
in the respective empirical chapters. 
4.3 Introduction to Methods 
 
This thesis is primarily concerned with the effects of CE substances on behaviour, cognitive 
and neurophysiological performance. In the lab, it was investigated how modafinil users 
compare to non-users with respect to: cognitive performance, cortical haemodynamic 
response and cardiovascular physiology. To assess different aspects of cognitive 
performance a wide range of measures were used which are fully detailed in their 
respective chapters (see Chapter 6 and Chapter 7), each loading on different facets of 
attention and executive function. The neurophysiological methods were primarily chosen 
as a proxy for recording cognitive workload (see Chapter 3), and as an index of cognitive 
effort. For instance, fNIRS is capable of taking readings of haemodynamic changes in the 
DLPFC, and via neurovascular coupling, capturing changes in mental effort (Tachtsidis & 
Scholkmann, 2016). ECG provides a measure of heart rate and autonomic reactivity, in 
addition to heart rate variability as an index of parasympathetic control (Electrophysiology, 
1996). Furthermore, taken together, these recordings allow cognitive workload to be 
measured in a multidimensional way using neurophysiological and psychophysiological 
means.  
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4.4 Survey Method 
 
Survey methods can provide a wealth of data on subjective attitudes, intentions and 
behaviours and can provide in-depth demographic information about respondents. These 
methods are particularly useful when investigating phenomena that cannot easily be 
recorded in a lab, such as controversial topics like sexual behaviour and patterns of 
substance use. However, several limitations exist with self-report measures, which raise 
questions of validity and reliability, such as social desirability/ demand characteristics when 
subject matter is stigmatised and poor response rates. Nevertheless, this type of design 
enables research that would otherwise be difficult to conduct, and is very accessible to 
researchers (Fan et al., 2006). There are various ethical implications when research 
investigates sensitive topics or recruits vulnerable samples which makes questionnaire-
based studies a useful tool. For instance, in terms of investigating illicit substance use, it is 
not possible for the researcher to conduct lab-based studies where drug handling and 
administration are a feature, due to the legal status of many substances. Obtaining a 
license to acquire and administer a controlled substance such as modafinil is also very 
difficult, and is not often feasible as part of a time-constrained research project such as a 
PhD, due to issues that might arise in obtaining ethical clearance from university based or 
NHS ethics committees. Expense is also an issue, as drug synthesis is costly and not 
accessible as part of a PhD programme. Vulnerable and prohibited substance using samples 
are also difficult to recruit because of stigmas and issues of anonymity in the laboratory. It 
is therefore easier to use questionnaire-based methods that can be distributed online or 
via mailing lists which enable anonymous responses. Laboratory based research is also 
limited in terms of its ecological validity, as it does not represent naturalistic behaviour, 
particularly in terms of environments and situations that users would usually administer 
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substances. On the other hand, questionnaires provide an alternative for respondents to 
self-report in-depth information about patterns and frequency of drug use.  
There are numerous examples of substance use studies which use survey methods to 
identify specific user samples, such as the Global Drug Survey which is the biggest survey of 
its kind in the world (L. d'Angelo, Camilla, Savulich, & Sahakian, 2017; L. J. Maier, J. A. 
Ferris, & A. R. Winstock, 2018a; Maier, Liakoni, et al., 2015; Maier, Wunderli, et al., 2015). 
While others combine survey and experimental methods to examine user groups’ 
behavioural and cognitive performance (Montgomery, Fisk, Newcombe, & Murphy, 2005; 
Carl Roberts & Catharine Montgomery, 2015). The current research uses a similar 
methodology, first by administering a cross-sectional online survey to investigate general 
CE use patterns (see Chapter 5), and then by using a battery of questionnaires during a lab-
based study to identify user groups and to index drug use behaviour (see Chapter 6 and 7).  
4.5 Neurophysiological Apparatus  
 
4.5.1 Functional Near-Infrared Spectroscopy (fNIRS) 
 
fNIRS is a technique designed to measure changes in oxy-Hb and deoxy-Hb associated with 
neuronal firing, a process referred to as neurovascular coupling (Tachtsidis & Scholkmann, 
2016). This is measured by beaming near-infrared light (NIR) through transmitters which 
are spaced out across the scalp and forehead and make direct contact with skin. Light 
penetrates up to 6 cm from the surface of the head, and can access 3 mm of cortical tissue 
density, passing through the scalp, skull and cerebrospinal fluid (CSF), enabling a superficial 
reading of cerebral activity via a banana-shaped path from transmitter to sensory receiver 
(Firbank, Okada, & Delpy, 1998). fNIRS is therefore capable of capturing neurovascular 
activation in the upper regions of the cerebral cortex, such as the DLPFC (Scholkmann & 
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Wolf, 2012). NIR light must pass through divergent tissue matter before reaching the 
superficial brain layer, which causes light to scatter. However, due to the unique optical 
properties of NIR light, changes in oxy-Hb and deoxy-Hb levels can be calculated. Oxy and 
deoxy-Hb have unique wavelength signatures under NIR light because of their varying 
concentrations of chromophores. Thus, light absorption is altered based on changes in 
haemodynamic activity and return signals experience unique attenuation if regions under 
observation show changes in oxy-Hb and deoxy-Hb, which provides an index of 
neurovascular activation (See Figure 4.2). The optimum wavelength for measuring 
haemodynamic change is in the 650 – 950 nanometer (nm) range (Scholkmann et al., 
2014). Both oxy-Hb and deoxy-Hb share an absorption co-efficient of 800nm (the isosbestic 
point), which represents the point at which chromophores attenuate light equally (Zijlstra, 
Buursma, & van Assendelft, 2000). Therefore, oxy-Hb change is calculated in wavelengths 
below this co-efficient, and deoxy-Hb in wavelengths above. Preferred wavelengths may 
differ based on hardware and theoretical differences between researchers, although 
ranges fall in the NIR window (oxy-Hb 650 – 800; deoxy-Hb 800 – 950 nm). Wavelengths 
below the optimum range are too easily absorbed by haemoglobin, and the same is true of 
water when the range is exceeded (Scholkmann et al., 2014). Therefore, reliable 
measurements are contingent on the appropriate wavelength selection (see Figure 4.1).  
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Figure 4.1 – Wavelength frequencies of light in nanometers. The optimum NIR spectrum is 
highlighted in blue (650 – 950 nm) although the standard nominal wavelengths are 765 (oxy-Hb) and 
855 nm (deoxy-Hb).  
 
Figure 4.2 – Continuous wave NIR light path length through the head. Light travels via a banana-
shaped curve from transmitter to receiver, passing through several tissue layers of the head and 
returning information about cortical haemoglobin levels in specific areas of interest (denoted as the 
pink area) across the cortex (Hoshi & Michael, 2005).  
 
 
4.5.1.1 Modified Beer-Lambert Law 
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The modified Beer-Lambert Law (MBLL) is a calculation used to measure changes in 
chromophore concentrations, specifically oxy-Hb and deoxy-Hb (Kocsis, Herman, & Eke, 
2006). The MBLL stipulates that changes in light density are constant with changes in 
chromophore concentrations. However, this calculation has been revised from the original 
form (The Beer-Lambert Law) to consider light scattering properties in divergent tissues, 
such as the human head, which is comprised of differing tissue layers of varying density 
(i.e., scalp, skull and CSF). This method accounts for divergent tissues by calculating the 
photon mean pathlength through scattering tissues as an estimate for actual photon 
pathlength (Baker et al., 2014). The statistical formula is as follows:  
 
In this equation, light attenuation (A) is calculated by dividing light intensity (I0 ) by 
detectable light intensity (I1). This equals the differential path length factor (αlc DPF) plus 
what is accounted for in light-scattering loss (G) (Matthews, Pearlmutter, Wards, Soraghan, 
& Markham, 2008). However, it should be considered that although differing tissue layers 
are accounted for in the equation, the MBLL is not a perfect model for determining 
absolute haemodynamic response, as changes are only compared against a baseline 
measure. As such, fNIRS is considered a relative and not absolute measure (Scholkmann et 
al., 2014).  
4.5.1.2 Current configuration  
 
Due to the importance of the DLPFC in mediating higher cognitive processes, particularly in 
aspects of executive function and working memory (Carpenter, Just, & Reichle, 2000), and 
because of the relevance that this forebrain region has to the current research, a 12 
channel fNIRS configuration was selected that was placed across the forehead (see Figure 
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4.3). The configuration used a black fNIRS cap fitted with 3 receivers and 8 transmitters (11 
optodes in total) which were fully adjustable by the researcher, allowing for optode 
placement to be readjusted to fit more comfortably with the shape of each wearer’s head 
while making sufficient contact with the scalp. Transmitters and receivers were spaced at 
2.5 cm distance on the cap which was also padded and made from sponge to cushion the 
sensor placement and reduce pain or skin imprinting as optodes were metal. To reduce 
ambient light interference, an additional black headband was applied over the optodes 
which covered the entire forehead (see Figure 4.4). The OxyMon fNIRS system by Artinis 
Medical Systems was used and data was recorded and analysed using the accompanying 
Oxysoft software package. This hardware takes topographical readings of up to 6 cm deep 
(3-4 cm recommended with fNIRS), with a data sampling rate of 500 Hz. The standard 
nominal wavelengths are outlined in diagram 4.1, though they can be adjusted (default 
wavelengths were used in this study). Optodes also transmit data using high-speed fibre 
optic cables, and the software allows for up to 50 Hz frequency readings.      
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Figure 4.3 – The 12 channel (C) configuration mapped across the PFC, relative to the positioning of 
transmitters (T) and receivers (R). One channel equals the path between one transmitter and one 
receiver. Three regions of interest (ROI) are also depicted: the right PFC (orange) medial PFC (green) 
and left PFC (purple).  
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Figure 4.4 – The fNIRS cap as it appears on the wearer’s head with transmitters (blue) and receivers 
(yellow) spaced across the PFC.  
 
 
4.5.1.3 Signal Processing Technique 
 
Raw data was processed for analysis using the OxySoft accompanying software analysis 
package. A low-pass filter of 0.1 was applied to eradicate noise stemming from 
physiological artefacts, such as heartbeat frequency and blood pressure changes, and a 
high-pass filter of 4 was also used to minimise noise from muscle and eye movement. Data 
was acquired at a 50 Hz sampling rate, and average oxy-Hb and deoxy-Hb calculations were 
taken for the baseline period and for each cognitive performance measure. OxySoft 
produced oxy-HB and deoxy-Hb averages in Microsoft Excel format and then the 
correlational based signal improvement (CBSI) method was applied to the raw data which 
reduces signal noise interference by introducing a correction to average haemodynamic 
change calculations. Without such a correction, signal quality can be contaminated by 
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motion induced noise, which can cause oxy-Hb and deoxy-Hb signals to become more 
positively correlated when they should typically be strongly negatively correlated. Thus, 
fNIRS produces 3 separate components: (a) the true signal measuring haemodynamic 
response, (b) noise (motion induced and other kinds) which mimics haemodynamic 
changes, (c) and white noise. The CBSI aims to capture (a) only, and improve the overall 
quality and reliability of the signal (see Cui, Bray, and Reiss (2010) for a full review of the 
signal processing method and statistical formula). As such, after running the formula in an 
Excel document, a single oxy-Hb change value was then produced (deoxy-Hb values were 
not required as they were inverse values of oxy-Hb counterparts) and data was exported to 
SPSS Version 25 for statistical analysis.  
4.5.1.4 Strengths and Limitations 
fNIRS is a non-invasive, continuous wave (CW) neuroimaging technology that imposes less 
physical constraint than established methods like functional magnetic resonance imaging 
(fMRI) and computerised tomography (CT) scanning as the user is not confined within 
apparatus. This can allow for data collection under realistic conditions as subjects can 
complete tasks involving robust body movements, enabling participation in a wider range 
of tasks than fMRI would allow. The DLPFC is accessible to fNIRS, allowing measurements of 
higher cognitive function to be made in more true-to-life settings (Leff et al., 2011). 
Moreover, fNIRS has superior spatial resolution when compared to EEG, allowing for a 
deeper image of neuronal activity (Anwar et al., 2016). The affordability of the technology 
also increases its accessibility for research, making fNIRS increasingly popular in 
neuroimaging studies (Yang & Chen, 2013).  
Although fNIRS is a useful neuroimaging technology, various limitations can be ascribed to 
its use. Chiefly, as previously mentioned, CW devices cannot take absolute measurements 
of haemodynamic response, even when using the MBLL to account for scattering light in 
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divergent tissues, as findings are only compared against a baseline period. Furthermore, 
recordings suffer from a poor depth resolution when compared with fMRI, as optodes can 
only measure up to 3 mm depth underlying the skull (Anwar et al., 2016). Additionally, 
temporal resolution is poor with haemodynamic measurements, particularly when 
compared with EEG (Leff et al., 2011). Signals from fNIRS are also sensitive to the 
extracerebral layers, such as the hair and scalp. Tests of cognitive function, which are 
increasingly used with fNIRS, can increase ANS activity, which can produce non-neuronal 
driven haemodynamic changes in the extracerebral layers and thus contaminate NIR signals 
which can lead to the occurrence of false positives and negatives (Fairclough, Burns, & 
Kreplin, 2018; Hoshi & Michael, 2005) (see Figure 4.5). These changes can also occur due to 
the discomfort of optode attachment against the scalp, which can create participant stress 
leading to ANS activation (Tachtsidis & Scholkmann, 2016). Hair has also been found to 
influence fNIRS signals, as certain pigmentations readily absorb NIR light more than others. 
Head movement must also be accounted for as this can create movement artefacts and 
dislodge optodes which can lead to ambient light bleeding, a cause of signal interference 
(Hoshi & Michael, 2005). 
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Figure 4.5 – The assumption and the reality of the components which comprise an fNIRS signal. 
Extracerebral and systematic activity are potential confounders in all fNIRS research but are 
particularly problematic if the ANS is stimulated. As such, fNIRS can be highly susceptible to other 
physiological influences (Scholkmann et al., 2014).  
 
 
 
4.5.2 Electrocardiogram (ECG) 
 
ECG is a technology that records electrical activation of the heart by monitoring potential 
changes on the surface of the skin. These changes are created by a process of polarisation 
and depolarisation of the heart, initiated by specialised pacemaker cells which begin this 
process. Polarisation occurs when electrolytes infuse cells, charging the cell membrane 
with an electrical current. Depolarisation is therefore the process of cell membrane 
discharge, when electrolytes leave the cell and spread through the myocardium. ECG 
detects atrial and ventricular muscle excitation, which causes heart muscle contraction. 
Throughout the process of polarisation and depolarisation, the tissues surrounding the 
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heart conduct an electrical current, causing an echo of cardiac activity which is detected at 
the skin by electrodes and captures an image of the heart in motion (Pflanzer & McMullen, 
2016). 
4.5.2.1 The ECG Trace 
 
An ECG trace captures the electrical activity of the heart, specifically the process of 
polarisation and depolarisation. A single waveform (see Figure 4.6) illustrates the P wave, 
QRS complex and T wave. The P wave is the first event recorded and signals the 
depolarisation of the atrial muscle; usually lasting 80-100 milliseconds. The P-R interval, an 
isoelectric period (the short zero voltage period) immediately following the P wave and 
before the QRS complex begins, is the time between atrial depolarisation and the time the 
impulse needs to travel to the ventricle, this lasts between 120-200 milliseconds. The QRS 
complex begins immediately afterwards and shows ventricular depolarisation, a rapid 
process between 60-100 milliseconds. The ST segment is the isoelectric period following 
the QRS, when the ventricular muscle is completely depolarised. The T wave is the final 
event in a single waveform and represents ventricular repolarisation, which lasts longer 
than depolarisation but is not normally measured. Instead it is common practice to record 
the Q-T interval, the period of depolarisation and repolarisation of the ventricle, which lasts 
between 200-400 milliseconds, but varies based on heart rate (Klabunde, 2011). A single 
waveform is a cardiac action potential, and a rhythm strip is a measurement of repeating 
waveforms which is typically how ECG is recorded. Heart rate variability can be measured 
by recording the time variations between successive R peaks on a rhythm strip, called the 
R-R interval, or sometimes the inter-beat interval (IBI), which can be used to index changes 
in heart beat and the autonomic nervous system (ANS).  
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4.5.2.2 Introduction to Heart Rate Variability  
 
HRV is a measure of variability in the time period between successive heart beats which 
can be observed with ECG, and was first proposed as a reliable measure of distress and 
premature mortality in fetal research (Horn & Lee, 1965). The decades following have since 
increased focus on HRV as an indicator of the heart’s reaction to changing circumstances 
brought about by often unpredictable stimuli (Acharya, Joseph, Kannathal, Min, & Suri, 
2007) and as an effective index of attention and mental effort (Berntson et al., 1997). HRV 
can be measured at 3 distinct frequencies: very low frequency, low frequency and high 
frequency. Very low and low frequency contributions to HRV include: thermoregulatory 
processes, vascular auto-rhythmicity, haemodynamic response delays and the renin-
angiotensin system (blood pressure control) (Berntson et al., 1997). High frequency 
measurements are indexed by respiratory sinus arrhythmia (RSA), a respiratory pattern 
which increases the sinus rate during inspiration and decreases it with expiration. RSA is 
controlled by parasympathetic activity at the sinus node (SA node) in the heart, which can 
provide information on cardiac vagal control (also termed vagal tone) (Berntson, Cacioppo, 
& Grossman, 2007). Respiratory-frequency rhythms create changes in the discharge 
frequency of the SA node, which intrinsically relates RSA to breathing patterns. Vagal 
innvervation of the SA node therefore leads to respiratory inhibition, reducing PNS control 
of cardiac functioning, which can be assessed by observing variations in R-R intervals on a 
continuous ECG trace (Berntson et al., 1997). As such, HRV is a robust psychophysiological 
method for indexing changes in parasympathetic control.  
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Figure 4.6 – A typical ECG trace, and the individual components demarcated. A cardiac action 
potential is recorded in the depolarization and repolarization of the atrial and ventricular muscles. 
An ECG trace can also be used to measure HRV by observing spatial differences between R peaks  
(Pflanzer & McMullen, 2016). 
 
 
4.5.2.3 Current Configuration  
 
As this research focused on neurovascular indicators of increases in cognitive effort, a 3-
lead Biopac ECG was used to capture changes in heartrate variability. Three electrodes 
were placed across the torso: two below each collar bone and one above the hip. Pinch 
clips were attached to the electrodes: positive (right collar bone), negative (left collar bone) 
and earth (above the hip). This configuration conforms to Einthoven’s Triangle (see Figure 
4.7) which demonstrates appropriate electrode placements to capture echoes of the heart 
(for further details on the principles of ECG consult Doyle, 2011). Furthermore, an 
additional pinch clip at the base of the 3 leads was attached to clothing to prevent the clips 
from pulling on electrodes and distorting measurements. Data was collected and analysed 
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using the accompanying Biopac Student Lab Pro software package, and all recordings were 
taken in milliseconds and at 50 Hz. 
4.5.2.4 Signal processing technique 
 
Raw data was processed using BSL Pro, a HRV data analysis software package. Both time 
and frequency domain measurements were conducted on heart rate data to triangulate 
findings and increase reliability. Time domain measurements included RMSSD and NN50, 
and a single frequency measurement was used at high frequency (HF). Noise and 
movement artefacts were identified and removed using AcqKnowledge, an accompanying 
data analysis software package of BSL Pro, and HRV averages were collated into text files 
and analysed using SPSS version 25.  
 
 
 
 
 
 
 
 
 
70 | P a g e  
 
Figure 4.7 – A diagram of Einthoven’s Triangle, demonstrating the correct electrode placement on 
the body to capture a picture of heart activity. In the current study positive (white) is attached below 
the right collar bone, negative (black) below the left collar bone and earth (red) above the left hip.  
 
4.5.2.5 Strengths and limitations 
 
ECG is non-invasive and affordable with a wide range of research applications. Despite 
superficial readings of cardio activity, ECG reveals a wealth of information about the rate 
and rhythm of the heart, which can be used to assess a range of physiological changes in 
the body (Klabunde, 2011). For instance, despite only capturing echoes of atrial and 
ventricular muscle activity at the skin and excluding interior measurements, readings of 
HRV are still possible which index heart reactivity and can provide a picture of cardiac 
health (Doyle, 2011). Moreover, the physiological signal of ECG is robust to signal 
Lead I 
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interference such as movement noise, which allows use of the apparatus during exercise 
and other tasks which require physical activity (Giles, Draper, & Research, 2018), 
particularly with newer technology which is ambulatory (Jeon, Kim, Jeon, & Lee, 2014). Due 
to signal strength, movement artefacts and noise can also be identified and easily removed 
during analysis. 
Nevertheless, ECG has several limitations of note. For instance, HRV measurements can be 
interrupted by talking during the recording process, as speech interrupts the respiratory 
cycle and can alter the IBI on an ECG trace (Hampton, 2013). Short-term recordings may 
also be insufficient for determining irregular or differential HRV, and longer measurements 
may have to be employed to identify heart rate variances. Furthermore, HRV is very 
sensitive to ectopic beats, and if data is not inspected carefully, uncorrected artefacts may 
go undetected (Electrophysiology, 1996). Finally, measurements at high exercise intensities 
can create large amounts of variation on the ECG trace, which make HRV analysis difficult 
to conduct (Giles et al., 2018). 
4.5.3 Blood Pressure Meter 
 
A blood pressure meter (also called a sphygmomanometer), is a device used to record 
systolic and diastolic blood pressure. The technology works by attaching a cuff around the 
upper arm which then inflates and collapses, asserting pressure on the artery directly 
below and constricting blood flow. The pressure applied to the cuff is then slowly released, 
and blood flow returns to the artery. Depending on the device used (manual or digital) 
systolic and diastolic blood pressures are recorded differently. In the current research, a 
digital cuff was used which assesses oscillations in the artery with an in-built pressure 
sensor. The oscillometric waveform, an algorithm calculated by the device, calculates the 
mean systolic pressure by estimating when the artery is completely constricted, and 
72 | P a g e  
 
diastolic pressure when it is fully released. Blood pressure is recorded in millimetres of 
mercury (mmHg), and the meter provides average systolic and diastolic estimates during 
the period of time in which the artery deflates and refills, but does not provide continuous, 
real-time measurements (Klabunde, 2011; Kukita, Mitsunami, Aritome, Kato, & Onishi, 
2016).  
4.5.3.1 Introduction to systolic and diastolic blood pressure 
 
Systolic and diastolic blood pressure indicate the total pressure in blood vessels traveling to 
and from the heart. Systolic measurements are taken as the heart beats, recording the 
resulting pressure that carries blood to the arteries from the contracting heart muscles. 
Diastolic measurements record blood pressure during the interval between beats, when 
the heart fills with blood prior to muscle contraction. Systolic blood pressure increases 
when the heart muscles pump blood around the body with greater force, and systolic 
pressure rises as resistance to that blood flow increases. Optimal blood pressure is 
displayed in Figure 4.8. An increase in blood pressure is related to an increase in stressful 
stimuli, and can be used as a physiological indicator of an increase in effort and cognitive 
workload (Herring & Paterson, 2018). 
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Figure 4.8 – Chart displaying low to high systolic and diastolic blood pressure readings (mmHg). 
Higher blood pressure occurs when cardiovascular activity increases.  
 
 
4.5.3.2 Strengths and limitations  
 
There are various limitations of blood pressure measurements.  Primarily, as previously 
stated, using a standardized arm-cuff method, the meter cannot provide continuous, real-
time readings unlike ECG and fNIRS. As such, dynamic changes in blood pressure are 
difficult to record under laboratory conditions, because readings have to be taken at fixed 
time points, which may not fully reflect blood pressure fluctuations in all experimental 
tasks. A further limitation of the meter is the sensitivity in the cuff to arm movement, 
which can distort the measurement and create false readings. Moreover, digital meters, 
like the one used in this research, are less precise than manual readers, due to an algorithm 
that takes estimations, and not exact measurements, of systolic and diastolic blood 
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pressure. This makes the likelihood of measurement errors higher with digital meters 
(Shahbabu, Dasgupta, Sarkar, & Sahoo, 2016). Blood pressure readings do, however, have 
various advantages, particularly concerning the accessibility of the technology. Firstly, the 
digital meter does not require clinical expertise to use, making it user-friendly to 
researchers. Additionally, this technology is affordable, and is a popular tool in physiology 
research. Finally, like ECG, the blood pressure meter can also be used alongside other 
neurophysiological measures, and as such can be integrated into complex and multi-
disciplinary research designs.  
 
4.6 Chapter Summary  
 
This chapter discussed the aims and methodology implemented in the 3 studies which 
make up this thesis. These aims were derived from peer-reviewed literature and an 
evaluation of different research methods discussed in the previous chapters. Furthermore, 
several methods emerged to examine the various research aims, including: a cross-
sectional survey; cognitive performance measures; use of fNIRS neuroimaging apparatus; 
ECG and sphygmomanometer. Close examination of fNIRS by Artinis Medical Systems and 
use of the CBSI analysis technique revealed that it is an effective neuroimaging technique 
with strong spatial resolution which can access the DLPFC, a region of the brain strongly 
associated with cognition. Furthermore, 3-lead Biopac ECG with HF measurements of HRV 
is a strong means of measuring the heart’s reactivity to stress and cognitive workload. Use 
of a digital sphygmomanometer alongside these methods is another effective tool for 
indexing physiological reactivity and taken together a neurophysiological measurement of 
cognitive effort and workload can be obtained. Consequently, what follows are 3 research 
studies designed to comprehensively examine PCE use. The first study responds to the 
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previously discussed prevalence estimates which suggest that use of CE, specifically 
modafinil, is on the rise in UK universities. As such, a cross-university survey investigating 
the patterns and factors potentially predicting use of CE is discussed in the next chapter. 
Furthermore, Study 2 and 3 take a closer look at long-term modafinil use on cognition, 
neurophysiology and psychophysiology to establish what impact the drug has on these 
functions.  
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Chapter 5: Study 1 – Investigating Levels of CE use and Predictive Factors Across four UK 
Universities. 
 
5.1 Chapter Overview 
 
In Chapter 1, CE prevalence rates across Europe and the USA were reviewed and although 
PCE use was noticeably smaller in Europe than the USA, some data indicated that use of 
these drugs is on the rise. This chapter describes a study that examined PCE user rates in 
four UK universities to test the previous claims, and examined the relationship between use 
and predictive variables, including demographic, and educational factors. The implications 
of CE use in UK universities are discussed, and these findings also inform the rationale for 
studies 2 and 3 of the thesis.  
5.2 Introduction 
 
Evidence suggests that use of prescription and illegal drugs for the purpose of improved 
performance during work and while studying is on the rise. Such reports began in the 
media, where use of PCEs to facilitate academic performance has been estimated to be as 
high as 10% in some UK universities (Lennard, 2009; The Student Room, 2016). Even so, 
further examination of these claims reveals that, due to the lack of scientific rigour and 
robust methods when investigating use, such prevalence estimates may be sensationalised 
(Partridge, Bell, Lucke, Yeates, & Hall, 2011). Nevertheless, peer-reviewed studies indicate 
that, although prevalence is not found to be as consistently high as media speculation, it 
does appear to be on the rise both in the UK and internationally (Maier, Ferris & Winstock, 
2018). Still, it is difficult to provide comparable cross-cultural prevalence estimates because 
of differences in defining CE use and due to variations in how it is measured between 
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studies (Advokat & Scheithauer, 2013; Emanuel et al., 2013; Maier et al., 2016; Maier & 
Schaub, 2015; Mazanov, Dunn, Connor, & Fielding, 2013). However, it is clear that CE user 
rates are generally higher in the USA than Europe. For instance, estimates put non-medical 
stimulant use in American universities between 5 to 55% (McCabe, West, Teter, & Boyd, 
2014; Smith & Farah, 2011), whereas use in Germany appears to be as low as < 1% (Dietz, 
2013). Furthermore, in the UK, PCE use appears to be marginally higher than Germany but 
still below the USA (≤5%) (Holloway & Bennett, 2012; Singh et al., 2014a), though there are 
relatively few largescale studies.   
Notwithstanding limitations of prevalence estimates, available research clearly indicates 
that use of soft enhancers is considerably more prevalent than that of prescription 
stimulants and illegal drugs for PCE around the world (Maier et al., 2013; Singh, Bard, & 
Jackson, 2014b; Wolff, Brand, Baumgarten, Lösel, & Ziegler, 2017). Moreover, when soft 
enhancer use is disregarded, the next most popular substances are MPH, d-amphetamine 
and modafinil. In Europe, MPH is the most popular PCE drug used non-medically among 
university students (Mache, Eickenhorst, Vitzthum, Klapp, & Groneberg, 2012; Maier & 
Schaub, 2015), and in the USA d-amphetamine is most prevalent (Varga, 2012). Student use 
of both of these substances is notably low in the UK, although modafinil is shown to be the 
most commonly used PCE (Maier, Ferris & Winstock, 2018), despite use being limited 
elsewhere (Maier et al., 2016). Furthermore, respondents who report non-medical PCE use 
are also more likely to use illegal drugs both recreationally and to enhance study (Maier et 
al., 2006; McCabe, Boyd & Teter, 2009; McCabe, West, Teter, & Boyd, 2014). For instance, 
Maier et al. (2016) found that past use of cocaine, amphetamine, cannabis and MDMA 
were all significant predictors of PCE use and made respondents 6 to 20 times more likely 
to use prescription stimulants non-medically. Furthermore, a later study by the same group 
is the most comprehensive examination of international CE use to date, with 100,000 
people surveyed across 15 major countries (Maier, Ferris & Winstock, 2018). Respondents 
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completed the Global Drug Survey (GDS) in 2015 and 2017, and both illegal drug and PCE 
use was seen to increase in all countries. In the UK alone, illegal stimulant use increased 
from 1.9% to 13.3%, and PCE use went from 1.7% to 5.1%. Additionally, modafinil use in 
the UK was the highest among the other countries, and significantly increased from 2015 
(3.2%) to 2017 (10%) to be consistent with previous reports by the media. Of course, 
samples were self-selected meaning that accurate prevalence estimates in the UK and the 
other countries are not fully known. Nevertheless, rising figures between the two dates 
indicate growth in non-medical PCE use. 
Certain demographic and personality factors have also been found to influence CE use. 
Many studies reveal gender differences in PCE use, with men most likely to take illicit drugs 
and PCE both recreationally and for study (Maier et al., 2016; Maier et al., 2018). Age has 
similarly been linked to use, as over 25s, and more specifically people aged 35 to 44, are 
found to be more likely to take PCE (Maier et al., 2016; Maier at al., 2018). Furthermore, 
simply being in higher education is not associated with use but working alongside study on 
a part-time or full-time basis is (Maier et al., 2016). Additionally, more senior students, such 
as undergraduates in their final year and those in postgraduate study, have been shown to 
be more likely to use illicit drugs and PCE than junior undergraduates (Maier et al., 2013). 
An assessment of attitudes toward PCE use has also found that moral perceptions of use, 
examined through fictional vignettes, are linked to consumption, with respondents who 
believe that use is morally acceptable more likely to be users or consider use (Maier, 
Liakoni, et al., 2015). Finally, it has been demonstrated that higher levels of academic stress 
are related to PCE use (Maier et al., 2013), but studies have failed to assess whether 
consumption is similarly related to various factors which might contribute to this stress. 
Therefore, the aim of the current study was to fully explore CE use in 4 universities across 
the UK. A survey study has yet to be conducted in the UK which investigates levels of CE 
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use and factors which predict use concurrently. Consequently, this survey examines factors 
which previous studies have shown to be related to CE use (i.e., gender, age, moral 
perceptions, employment status and year of study) and those that have yet to be explored. 
Academic stress has been linked to PCE use, but factors which might underlie such pressure 
have not. For instance, semester-time accommodation (whether a student lives with 
parents or is self-supported) and gross annual income are variables which may add to 
university stress, as either of these factors could feasibly limit time or access to study 
resources. Furthermore, academic performance, learning styles (whether a student takes a 
surface or deep learning approach) and academic self-efficacy may also successfully predict 
PCE use. Prior research has already linked low academic performance and academic self-
efficacy to substance abuse (Meier, Hill, Small, & Luthar, 2015; Smorti, 2014; Welsh, 
Shentu, & Sarvey, 2019), and while the same is not true of learning styles, it is also feasible 
that less successful study strategies (i.e., a surface learning approach) could be linked to CE 
use as a method of compensation. As such, these variables were also explored in order to 
address several hypotheses. First, it was predicted that use of soft enhancers would be 
higher than PCE regardless of user intent (H1). Second, it was predicted that modafinil 
would be the most popular PCE drug for study purposes (H2). Third, reported use of illegal 
drugs for study would be smaller than soft enhancers and PCE, but recreational use would 
be higher than PCE (H3). Finally, sociodemographic and personality factors would predict 
use. Specifically: Gender (being male), age (being older), level of study (being 
postgraduate), learning styles (being a surface learner) and moral perceptions of PCE use 
(H4). 
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5.3 Method 
 
5.3.1 Participants 
 
Data was collected from January 2016 to September 2017. An opportunity sampling 
method was used with snowball sampling and 750 university students responded to the 
survey from across four UK universities: Northwest 1 (NW1), Northwest 2 (NW2), East 
Midlands 1 (EM1) and Northeast 1 (NE1). In total, 389 respondents completed all measures 
and were included in analysis. However, response rates varied substantially between 
academic institutions (NW1: N = 256, NW2: N = 71) making cross-university statistical 
analysis unviable. As such, samples were combined into a single set. On average, 
participants were 22 years old (SD = 4), and more females completed all sections of the 
survey than males (females = 70.31%). Age was also similar between CE user groups 
(nonusers = mean: 21, SD: 5; soft enhancer users = mean: 22, SD: 4; illicit drug users = 
mean: 23, SD: 6 PCE users = mean: 22, SD: 3), and groups were predominantly female 
(female users = nonusers: 80%, soft enhancers: 77%, illicit drugs 81%), except in the case of 
PCE users (male users = PCE: 57%).  
5.3.2 Design 
 
The current study was an exploratory between-groups cross-sectional survey with a mixed 
design used to measure respondent data. The first between-groups factor was CE user 
group which had 4 levels (nonusers; soft enhancer users; soft enhancer and illicit drug 
users; and soft enhancer, illicit drug and PCE users, hereafter entitled: nonusers, soft 
enhancer users, illicit drug users and PCE users). The second between-groups factor was 
type of use with 2 levels (recreational vs. study). Furthermore, there were 2 dependent 
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variables for analysis concerning levels of CE use (lifetime use and previous year use). 
Finally, several additional variables examined sociodemographic and educational status to 
assess their impact on CE use, including: age, gender, term-time accommodation, level of 
study, employment statuses, semester time address, mode of study, annual income, UCAS 
points, moral perception, academic self-efficacy and learning style (see Data Analysis 
Strategy for further details).   
5.3.3 Materials 
 
Participants completed the Cognitive Enhancement Use Survey along with the Academic 
Self-Efficacy Scale, the R-SPQ-2F and the CE-MJT. The survey was hosted on Qualtrics 
Software by Qualtrics Software Company (Seattle, Washington), an online survey platform. 
Participants completed the anonymous survey via a link which was compatible with their 
personal computer or mobile and tablet devices. Data was then downloaded in Microsoft 
Word document format and transferred to an SPSS spreadsheet for analysis.  
5.3.3.1 Cognitive Enhancement Use Survey 
 
To investigate patterns of CE use at UK universities, a comprehensive survey was created 
which examines use of a wide inventory of CE related drugs. The questionnaire was divided 
into sections which appeared in randomised order to reduce order effects and examined 
sample demographics and patterns of CE use.  
i) Demographics. 
Respondents were asked about their: age, gender (A. Male, B. Female, C. Transgender), 
maximum level of academic achievement (A. Foundation degree, B. First year 
undergraduate, C. Second year undergraduate, D. Third year undergraduate, E. Master’s 
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degree, PGCERT, PGDIP, F. PhD or professional doctorate), study status (A. Full-time 
student, B. Part-time student), employment status (A. Unemployed, B. Part-time employed, 
C. Full-time employed) and term time accommodation (A. Student accommodation, B. 
Privately rent, C. Live with parents/guardian, D. Other). Participants were also asked for 
estimates of gross annual income and UCAS points upon entry to university.  
ii) Levels of CE Use. 
Use of different psychoactive substances is also investigated, including: alcohol and illegal 
drugs (amphetamine, cocaine and cannabis); PCEs (d-amphetamine, MPH, modafinil and 
piracetam); caffeine based soft enhancers (coffee, caffeine pills, energy drinks and 
guarana); and herbal-based (nutraceutical) soft enhancers (ginseng, gingko biloba, 
citicoline, galantamine and bacopa monniera). Use is recorded for: lifetime (study aid or 
recreationally), previous year (study aid or recreationally), and number of occasions used in 
a month (typical month and month prior to an exam). Circumstances of use are also 
assessed, including: route of administration (A. swallowed, B. Smoked, C. Snorted, D. 
Injected); acquisition (A. Internet, B. Drug Dealer, C. Friend, D. Family member, E. Retailer, 
F. Prescription), and difficulty of acquisition (presented on a 5-point Likert scale: 1 = very 
easy, 5 = very difficult). 
5.3.3.2 The Academic Self-Efficacy Scale  
 
The Academic Self-Efficacy Scale is a 10-item scale investigating academic self-efficacy, 
which is characterised as a person’s belief in their academic performance (McIlroy, Poole, 
Ursavas & Moriarty, 2015). Each item is scored on a 7-point Likert scale (1 = very strongly 
disagree, 7 = very strongly agree). Questions 5, 6 and 9 are reverse scored and a total score 
is calculated by adding the sum of all answered questions together (range from 7 to 70) and 
higher scores indicate greater academic self-efficacy. Questions include items such as ‘If I 
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don’t understand an academic problem, I persevere until I do’ and ‘No matter how hard I 
try, I can’t seem to come to terms with many of the issues in my academic curriculum’ 
(reverse scored). Reliability analysis with data from this study shows strong internal 
consistency (α = .733).  
5.3.3.3 The Revised Study Process Questionnaire (R-SPQ-2F) 
 
The R-SPQ-2F is a 20-item questionnaire which assesses learning styles. Questions are 
presented on a 5-point Likert scale (A = always true of me, E = never true of me). Items are 
presented as statements, such as; ‘I find that at times studying gives me a feeling of deep 
personal satisfaction’ and (reverse scored) ‘My aim is to pass the course while doing as 
little work as possible’. Respondents are categorised across 4 dimensions (A. Deep motive, 
B. deep strategy, C. surface motive D. surface strategy). Five items are dedicated to each 
dimension and the questionnaire is scored by converting responses into numbers (A = 5, E = 
1 and inverted for reverse items), which provides an individual score for each dimension. 
Higher scores on the deep motive and deep strategy dimensions indicate a deep approach 
to learning, whereas similar scores on the surface motive and surface strategy dimensions 
signify a surface learning style. A score of 25 across any of the 4 facets suggests the highest 
possible preference toward that learning approach (Biggs, Kember & Leung, 2001).  
5.3.3.4 Cognitive Enhancement Moral Judgment Test (CE-MJT) 
 
The CE-MJT is a 22-item PCE moral judgement scale based on the Moral Judgement Test 
(MJT), which assesses moral judgement competence (Lind, 2013). This scale focuses on PCE 
use specifically and is similar in structure to the MJT. The CE-MJT is divided into three 
sections, examining moral attitudes towards: MPH, modafinil and d-amphetamine use. 
Each section opens with a short story detailing a moral conundrum which concerns the use 
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of a PCE drug at university. There are 7 items in each section presented on a 7-point Likert 
scale (1 = strongly disagree, 7 = strongly agree). Each section is tallied individually and total 
scores range from 7 to 49, though certain items are reverse scored (Sally: 3, 4, 7; Simon: 1, 
2, 4, 5, 7; John: 2, 4, 6, 7). A higher score indicates greater moral acceptability toward each 
PCE drug, and a composite score can be obtained by adding the scores from the 3 vignettes 
together. Questions are presented as statements, such as standard questions; ‘It doesn’t 
matter what techniques Sally uses to study only that she gets good grades’ and ‘Simon is 
wrong to have used Adderall for so long during his studies’ (reverse scored). A final 
question at the end of the test also asks participants ‘How difficult was it to answer these 
questions?’ Moreover, reliability tests with the data revealed that each subscale of the CE-
MJT was internally consistent (d-amphetamine vignette: α = .833, modafinil vignette: .844, 
α = MPH vignette: α = .897) (See Appendix for full test). 
5.3.4 Procedure 
 
The study was approved by Liverpool John Moores University Research Ethics Committee in 
January 2016 and received gatekeeper approval from the other three participating 
institutions.  Gatekeepers at each university promoted the study to their student cohort. 
Participants were contacted through institutional email lists and were sent a recruitment 
email detailing the aims and participant information for the study. A digital copy of the 
participant information sheet (PIS) was also included and the recruitment email had a URL 
to the online survey which was hosted on a secure Qualtrics server. After providing 
consent, participants began the cognitive enhancement use survey, a questionnaire 
comprised of 4 sections assessing: patterns of CE use, learning styles, academic self-
efficacy, and moral judgement. The presentation of each section of the survey was 
randomized, to reduce order effects and response bias. At the end of the survey, 
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participants were given the opportunity to provide an email address to be entered into a 
prize draw for a £50 retail voucher.  
5.3.6 Data Analysis Strategy 
 
Data was downloaded from the Qualtrics server and cleaned using IBM’s Statistical Package 
for the Social Sciences (SPSS) Version 25. A single period of use or more of drugs belonging 
to any of the user group categories (nonuser, soft enhancer user, illicit drug user and PCE 
user) was enough to be assigned to that CE group. Unfortunately, due to limitations 
imposed by total responses to the survey, it was not possible to create groups of 
respondents who exclusively used only one category of drug (e.g., only PCE and no other 
substances), as such, some respondents used substances from multiple categories. In 
addition to descriptive statistics used to investigate sample characteristics, Chi square 
analysis was used to examine differences in levels of use between user groups and 
between recreational and study use with the individual drugs belonging to each category 
(e.g., PCE: modafinil, MPH, d-amphetamine and piracetam). Furthermore, mixed ANOVA 
assessed user group differences in response to the moral vignettes (i.e., modafinil vignette, 
MPH vignette and d-amphetamine vignette), while between-groups ANOVA examined 
differences in users on the Academic Self-Efficacy Scale. Multivariate analysis of variance 
(MANOVA) was also used to analyse differences between user group categories on learning 
styles reported on the R-SPQ-2F (i.e, deep motive, surface motive, deep strategy and 
surface strategy learning styles). Finally, a multinomial logistic regression was conducted to 
identify predictors of CE use. Various categories for predictor variables were combined to 
strengthen regression analysis, including year of study (undergraduate or postgraduate), 
employment status (employed or unemployed) and term-time accommodation (living with 
or away from parents). Variables were entered or excluded from the model based on 
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whether they showed significance in several ANOVA with the different user groups as the 
IV. Previous research in the area did not indicate a consistent order of importance to CE use 
so a forced entry method was used. Furthermore, Mode of study, annual income, and 
UCAS points were excluded from regression analysis because of inadequate response rates 
to those questions in some CE user groups.   
5.4 Results 
 
5.4.1 Sample Demographics 
 
Demographic and educational information for each group is presented in Table 5.1. 
Multiple 2 x 4 chi-square cross-tabulations were used to compare user groups on the 
various demographic variables. Unfortunately, due to insufficient responses in the illicit 
drug users’ group (n = 0), gross annual income could not be assessed, but all other 
demographic variables were included in analysis. Overall, there were more females (X2 (2, N 
= 389) = 32.74, p < .001) in the non-user, soft enhancer, and illicit drug groups. However, 
there were more male PCE users than female (male users = PCE: 57%). There was no 
significant differences between full-time or part-time study (X2 (1, N = 389) = 3.03, p > .05), 
current year of study (X2 (1, N = 389) = 21.15, p > .05) employment status (X2 (1, N = 389) = 
3.85, p > .05) or semester-time accommodation (X2 (1, N = 389) = 7.47, p > .05) on lifetime 
CE use. A between-groups analysis showed that age (F(3, 376) = .62, p > .05, ƞp2 = .013) and 
UCAS points on entry to university (F(3, 219) = 1.55, p > .05, ƞp2 = .011), did not significantly 
differ between the user groups.  
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Table 5.1 –Demographic and educational information in respondents who completed all sections of 
the survey.  
     
 Nonusers 
 
Soft 
Enhancers 
Illicit Drugs PCE Total 
 N  
 
N  
 
N  
 
N  
 
N  
 
 Mean (SD) 
Age 21.73 
(2.08) 
120 22.04 
(4.73) 
215 23.44 
(6.12) 
18 22.27 
(3.18) 
26 22.02 
(4.81) 
379 
UCAS 324.99 
(89.97) 
72 315.80 
(96.64) 
122 251.63 
(80.89) 
10 315.47 
(55.00) 
17 316.46 
(91.82) 
219 
Gender %  
Female 80.00% 100 77.47% 172 81.25% 13 40.00% 10 76.03% 295 
Male 20.00% 25 22.52% 50 18.75% 3 60.00% 15 23.96% 93 
Study Year % 
Undergraduate 80.08% 101 76.57% 170 87.05% 14 69.23% 18 77.89% 303 
Postgraduate 19.02% 24 23.42% 52 12.05% 2 30.76% 8 22.10% 86 
Study Status % 
Full-time 96.74% 119 97.74% 217 100% 16 92.30% 24 97.15% 376 
Part-time 3.25% 4 2.25% 5 0% 0 7.69% 2 2.84% 11 
Employment 
Status 
% 
Unemployed 59.19% 74 55.40% 123 43.75% 7 69.23% 18 57.06% 222 
Employed 40.08% 51 44.59% 99 56.25% 9 30.76% 8 42.93% 167 
Semester 
Residence 
% 
Student/Private 
Residence 
77.41% 96 80.18% 178 81.25% 13 80.79% 21 79.38% 308 
Parental/Guardian 
Residence 
22.58 28 19.81% 44 18.75% 3 19.23% 5 20.61% 80 
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5.4.2 Patterns of Use 
 
Lifetime and previous year use of CE substances for study and recreation are presented in 
Table 5.2. Regardless of intent, use of soft enhancers was highest across lifetime, followed 
by illicit drugs then PCE. Additionally, use was greater recreationally than for study 
purposes with soft enhancer and illicit drugs, but not for PCEs which saw marginally higher 
use as a study aid. Levels of use fell in the previous year, but maintained a similar trend, 
except for recreational use of illicit drugs and PCE’s which were markedly smaller than 
general lifetime use.  
 
Table 5.2 – Lifetime and previous year use of soft enhancers, illicit drugs and PCE for recreational 
and study purposes.  Expected values for one-sample chi-square are recorded here.  
 N (%) 
Institution Study 
Soft 
Recreational 
Soft 
Study 
Illicit 
Recreational 
Illicit 
Study 
PCE 
Recreational 
PCE 
Lifetime 
Total 
261  
(67.09%) 
341  
(87.66%) 
24  
(6.16%) 
161  
(41.38%) 
26  
(6.68%) 
22 
 (5.65%) 
Expected 
Value (E) 
80.21 31.13 32.26 
Previous 
Year Total 
239 
(61.43%) 
333 
(85.60%) 
18 
(4.62%) 
110 
(28.27%) 
22 
(5.65%) 
11 
(2.82%) 
Note: Abbreviations: Soft, soft enhancer; Recreational, recreational use. 
One-sample chi-square analysis showed that significantly more respondents had used soft 
enhancers recreationally than for study in their lifetime (X2 (1, N = 389) = 73.92, p < .05) 
(See Table 5.3). Caffeinated products were those used most widely for study, while alcohol 
was the most popular drug recreationally. However, noticeably fewer people reported 
using alcohol as a study aid, although this was still more than reported levels of the 
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nutraceutical substances. Nonetheless, more people reported using nutraceuticals 
recreationally, but this was still comparatively lower than caffeinated products and alcohol. 
Moreover, levels of use in the previous year were marginally smaller but similar for most 
soft enhancers, except for nutraceuticals which were noticeably smaller both for study and 
recreational use, suggesting extremely limited use of these substances within the sample.  
Table 5.3 – Lifetime and previous year use of drugs categorised as soft enhancers for recreational 
or study purposes. 
 Lifetime 
N (%) 
Previous Year 
N (%) 
 Study Recreation Study Recreation 
Alcohol 31 
(7.96%) 
320 
(82.26%) 
22 
(5.65%) 
310 
(79.69%) 
Bacopa 
Monniera 
6 
(1.54%) 
13 
(3.34%) 
2 
(0.51%) 
5 
(1.28%) 
Caffeine Pills 70 
(17.99%) 
64 
(16.45%) 
47 
(12.08%) 
37 
(9.51%) 
Citicoline 5 
(1.28%) 
11 
(2.82%) 
3 
(0.77%) 
6 
(1.54%) 
Coffee 194 
(49.87%) 
218 
(56.04%) 
186 
(47.81%) 
213 
(54.75%) 
Energy Drinks 167 
(42.93%) 
189 
(48.58%) 
132 
(33.93%) 
166 
(42.67%) 
Ginseng 26 
(6.68%) 
42 
(10.79%) 
11 
(2.82%) 
23 
(5.91%) 
Ginkgo Biloba 14 
(3.59%) 
19 
(4.88%) 
6 
(1.54%) 
5 
(1.28%) 
Guarana 12 
(3.08%) 
27 
(6.94%) 
6 
(1.54%) 
12 
(3.08%) 
Tobacca 43 
(11.05%) 
150 
(38.56%) 
36 
(9.25%) 
118 
(30.33%) 
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Lifetime and previous year illicit drug use is presented in Table 5.4. One-sample chi-square 
analysis revealed that significantly more respondents used illicit drugs for recreational 
purposes than for study (X2 (1, N = 389) = 36.22, p < .001). Cannabis was the most used 
drug across the lifetime and in the last year, and this was predominantly for recreation. The 
same was true for cocaine and amphetamine, although reports of use were lower 
compared with the other drugs.  
Table 5.4 – Lifetime use of drugs categorised as illicit substances for recreational or study purposes.  
 Lifetime 
N (%) 
Previous Year 
N (%) 
 Study Recreation Study Recreation 
Amphetamine 7 
(1.79%) 
30 
(7.71%) 
3 
(0.77%) 
13 
(3.34%) 
Cannabis 18 
(4.62%) 
158 
(40.61%) 
11 
(2.82%) 
104 
(26.73) 
Cocaine 8 
(2.05%) 
65 
(16.70%) 
6 
(1.54%) 
42 
(10.79%) 
 
Lifetime and previous year use of PCE drugs is presented in Table 5.5. A one-sample chi-
square test revealed that lifetime PCE use was also significantly more likely to be for 
recreational than for study purposes (X2 (1, N = 389) = 56.20, p < .001). However, patterns 
of use were not as consistent as with the other categories. Lifetime estimates revealed 
that, recreationally, d-amphetamine was the most used substance, but for study, modafinil 
was most popular. Methylphenidate had similar levels of use for recreation and study, and 
piracetam was the most uncommonly used drug in both categories. In the previous year, d-
amphetamine and modafinil were the most used recreational substances, and their use 
was only marginally smaller for study. Modafinil remained the most popular study drug, 
despite being markedly less common for recreational use, and piracetam was again the 
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most unpopular across categories. As such, PCE use was generally rare when compared 
with soft enhancers and illicit drugs, and patterns of use were less consistent.  
Table 5.5 – Lifetime and previous year use of PCE drugs for recreational or study purposes.  
 Lifetime 
N (%) 
Previous Year 
N (%) 
 Study Recreation Study Recreation 
D-Amphetamine 8 
(1.28%) 
12 
(3.08%) 
6 
(1.54%) 
7 
(1.79%) 
MPH 10 
(2.57%) 
11 
(2.82%) 
6 
(1.54%) 
7 
(1.79%) 
Modafinil 19 
(4.88%) 
9 
(2.31%) 
15 
(3.85%) 
4 
(2.31%) 
Piracetam 3 
(0.77%) 
7 
(1.79%) 
1 
(0.25%) 
3 
(0.77%) 
 
 
5.3 CE User Group Comparisons  
 
Data on moral judgements, learning strategies and academic self-efficacy are presented in 
Table 5.6. Mixed ANOVA was conducted on user group responses to the 3 moral judgement 
vignettes (within group analysis: d-amphetamine vignette, MPH vignette, modafinil 
vignette). The assumption of sphericity was not met (p < .05), and therefore homogeneity 
could not be assumed. As such, the Greenhouse-Geisser correction was used to report 
effects. There was a highly significant main effect of vignette on moral judgement, (F(1.89, 
379) = 62.43, p < .001,  ƞp2 = .933). Contrasts revealed a linear trend, in that respondents 
believed John’s MPH use was less morally acceptable than Sally’s modafinil use, and her 
use less acceptable than Simon’s use of d-amphetamine, (F(1, 379) = 27.13 p < .05, ƞp2 = 
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.719). However, the interaction between vignettes and user groups was non-significant 
(F(5.69, 379) = 1.11, p > .05, ƞp2 = .027). Nevertheless, follow-up one-way ANOVA did reveal 
that there were significant differences between user groups on the MPH vignette (F(3, 385) 
= 8.53, p < .001, ƞp2 = .636), d-amphetamine vignette (F(3, 384) = 8.54, p < .001, ƞp2 = .670) 
and modafinil vignette (F(3, 384) = 10.64, p < .001, ƞp2 = .601). Further post-hoc Bonferroni 
analysis showed that PCE users found the use of all 3 substances significantly more morally 
justifiable than the other groups. Moreover, between groups analysis showed that there 
was no significant difference between user groups and how morally challenging 
participants found the questions (F(3, 388) = 1.29, p > .05, ƞp2 = .081). 
Multivariate analysis of variance was conducted to assess user group differences in learning 
strategies. Findings indicated that there were no significant user group differences across 
the four learning styles (F(3, 348) = .653, p > .05, ƞp2 = .004) suggesting that that regardless 
of CE use, respondents had similar approaches to learning. Between-groups ANOVA was 
also used to compare the groups on academic self-efficacy and perceptions of risks and 
benefits of CE use. This showed that CE user groups did not significantly differ on either 
academic self-efficacy (F(3, 361) = 1.43, p > .05, ƞp2 = .011) or risk perceptions (F( 3, 361) = 
.675, p > .05 ƞp2 = .001). 
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 Table 5.6 – Showing CE user group scores across the behavioural measures:  academic self-efficacy, 
learning styles and moral judgements.  
 Nonusers S. 
Enhancers 
Illicit Drugs PCE Total 
Mean (SD) 
N =  
Academic 
Self-Efficacy 
30.57 
(7.75) 
108 30.03 
(7.75) 
215 31.80 
(10.54) 
16 33.25 
(8.86) 
24  30.48 
(7.68) 
362 
Deep Motive 
Learning 
16.15 
(3.68) 
101 16.18 
(4.00) 
211 15.76 
(3.96) 
13 16.16 
(4.32) 
24 16.15 
(3.91) 
349 
Deep Strategy 
Learning 
15.76 
(3.56) 
101 15.82 
(3.93) 
211 15.07 
(4.07) 
13 15.54 
(3.48) 
24 15.76 
(3.79) 
349 
Surface 
Motive 
Learning 
19.10 
(3.94) 
101 19.03 
(4.08) 
211 17.76 
(3.46) 
13 17.20 
(4.10) 
24 18.88 
(4.04) 
349 
Surface 
Strategy 
Learning 
15.98 
(3.01) 
101 16.00 
(3.12) 
211 15.69 
(3.94) 
13 15.87 
(2.21) 
25 15.97 
(3.06) 
349 
MPH 
Vignette 
22.60 
(8.42) 
123 23.42 
(8.48) 
218 29.50 
(8.27) 
16 30.26 
(5.84) 
26 23.87 
(8.55) 
383 
D-
Amphetamine 
Vignette 
28.41 
(9.80) 
123 29.69 
(9.39) 
218 35.06 
(9.69) 
16 38.88 
(7.20) 
26 30.13 
(9.75) 
383 
Modafinil 
Vignette 
24.47 
(8.12) 
123 26.31 
(8.77) 
218 31.56 
(9.20) 
16 35.65 
(8.32) 
26 26.57 
(8.99) 
383 
Note: Abbreviations S. Enhancers, soft enhancers; SD, standard deviation.  
 
5.4.4 Multinomial Logistic Regression  
 
Univariate ANOVA and chi-square cross tabulations were used as screening analysis to 
assess the suitability of the different factors for predicting soft enhancer, illicit drug and 
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PCE use in the logistic model. With ANOVA, significant main effects were found for age (F(3, 
359) = 3.250, p < .05, ƞp2 = .127) the modafinil moral vignette (F(3, 387) = 14.245, p < .001, 
ƞp2 = .610), d-amphetamine moral vignette (F(3, 385) = 8.543, p < .001, ƞp2 = .263) and MPH 
moral vignette (F(3, 384) = 10.649, p < .001, ƞp2 = .277). No significant main effects were 
observed for academic self-efficacy (F(3, 361) = 1.437, p > .05, ƞp2 = .012), or any of the 
learning styles (surface strategy: F(3, 361) = .025, p > .05, ƞp2 = .000; deep strategy: F(3, 
360) = .038, p > .05, ƞp2 = .002; surface motive: F(3, 363) = 1.810, p > .05, ƞp2 = .015; deep 
motive: F(3, 362) = .009, p > .05, ƞp2 = .000). For chi-square analysis, there was a significant 
association of gender (X2(3) = 19.384, p < .001), but all other cross tabulations were non-
significant (study level: X2(3) = 2.827, p > .05; employment status: X2(3) = 3.211, p > .05; 
semester time residence: X2(3) = .443, p > .05). Consequently, the H4 could not be fully 
supported as not all variables posited significantly differed across user groups. As such, all 
remaining predictor variables with significant main effects were run in the regression 
model.  
Multinomial logistic regression was used to investigate the possible predictor variables 
associated with the different CE user groups. Each CE group (soft enhancer, illicit and PCE 
user) was compared against nonusers throughout analysis. The model was highly 
statistically significant (X2(15) = 63.745, p < .001). Beta values, odds ratios and upper and 
lower confidence intervals for the different CE user groups are presented in Table 5.7. Age 
significantly predicted soft enhancer use (b = .186, Wald X2(1) = 4.128, p < .05) in that being 
older was associated with greater use. Responses to the modafinil moral vignette also 
significantly predicted soft enhancer use (b = .061, Wald X2(1) = 4.605, p < .05.). 
Furthermore, odds ratios indicate that respondents were more likely to use soft enhancers 
for study the more they believed modafinil use to be morally justifiable. However, gender 
(b = -.162, Wald X2(1) = .265, p > .05.), perceptions of d-amphetamine (b = -.004, Wald X2(1) 
= .021, p > .05.) and MPH (b = -.016, Wald X2(1) = .623, p > .05.) use were not significant 
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predictors of soft enhancer use. With illicit drugs for study, age was found to be the only 
significant predictor variable (b = .186, Wald X2(1) = 4.433, p < .05), although responses to 
the modafinil moral judgement vignette showed a statistical trend (b = .2.987, Wald X2(1) = 
3.226, p = .090). Gender (b = .627, Wald X2(1) = .695, p > .05), perceptions of d-
amphetamine (b = .068, Wald X2(1) = 2.123, p > .05) and MPH (b = .015, Wald X2(1) = .076, p 
> .05) use did not significantly predict illicit substance use.  For PCE use, age was also a 
significant predictor (b = .152, Wald X2(1) = 3.622, p < .05.) again being associated with 
older users.  Gender was also a significant predictor, (b = -1.199, Wald X2(1) = 5.210, p < .05, 
with males more likely to use PCE than females. Responses to the modafinil moral vignette 
also significantly predicted PCE use (b = .099, Wald X2(1) = 4.610, p < .05.) with confidence 
intervals revealing that respondents were more likely to use PCE for study if they believed 
modafinil use was more morally justifiable.  Both perceptions of d-amphetamine (b = .023, 
Wald X2(1) = .355, p > .05.) and MPH (b = .045, Wald X2(1) = .866, p > .05.) did not 
significantly predict PCE use. 
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Table 5.7 – Beta values, odds ratios and confidence intervals of predictor variables as they relate to soft enhancer, illicit drug and PCE use.  
 B(SE) Lower Odds Ratio Upper N 
 Soft Enhancer Illicit Drugs PCE Soft 
Enhancers 
Illicit 
Drugs 
PCE Soft 
Enhance
rs 
Illicit 
Drugs 
PCE Soft 
Enhancers 
Illicit 
Drugs 
PCE  
Age .096(.047)* .186(.088)* .152(.080)* 1.003 1.013 .995 1.101 1.205 1.164 1.207 1.432 1.36
2 
360 
Gender -.162(.314) .627(.752)  -1.199(.525)* .460 .429 .108 .851 1.871 .301 1.574 8.170 .844 388 
(male: 93) 
Moral Vignette: 
modafinil 
.047(.025)* .083(.054) .099(.046)* .999 .978 1.00
9 
1.049 1.087 1.104 1.100 1.207 1.20
9 
388 
Moral Vignette: 
d-amphetamine 
-.004(.021) .068(.047) .023(.038) .957 .977 .949 .996 1.070 1.023 1.037 1.173 1.10
3 
386 
Moral Vignette: 
methylphenidate  
-.016(.021) .015(.053) .045(.048) .944 .915 .952 .984 1.015 1.046 1.025 1.125 1.15
0 
385 
N 222 16 26           
Note: R2 = .165 (Cox & Snell), .191 (Nagelkerke). Model X2 (15) = 63.745, significant at .05* 
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5.5 Discussion 
 
Findings from this survey support most hypotheses outlined for study 1. As expected, soft 
enhancers were used more than PCE and illegal drugs regardless of user intent. Soft 
enhancers were also the most frequently reported class of drugs used as a study aid, 
followed by PCE and illegal drugs. Additionally, modafinil was the most popular PCE drug 
for study purposes, with levels of use in the sample similar to those reported in previous 
research. Moreover, recreational past year PCE use was much lower than soft enhancers 
and illicit drugs, but for study, rates were similar to illicit drugs. Furthermore, the statistical 
model significantly predicted CE use, as did several individual predictor variables. 
Respondents were more likely to use all categories of CE if they were older. Greater belief 
in modafinil use being morally acceptable also significantly predicted soft enhancer and 
PCE use, and being male was associated with PCE use. Finally, all other factors failed to 
predict CE use individually. As a result, the H1, H2, H3 were accepted, but as not all 
sociodemographic factors predicted use, the H4 was not.  
Levels of CE use among the sample were similar to what has previously been reported in 
Europe and the UK. The proportion of respondents who used soft enhancers recreationally 
and for study was substantially higher than what is reported with PCE and illegal drugs, 
perhaps owing to the popularity and general availability of these substances over 
prohibited and more novel drugs. Moreover, as discussed in Chapter 1 and in the 
introduction to this chapter, levels of PCE use in the UK are generally low anyway, with 
many estimates of use equal to or below 5% (Holloway & Bennett, 2012; Singh et al., 
2014a). However, despite data being collected during the same time period, this is 
markedly lower than figures presented by Maier, Ferrins and Winstock (2018) which 
suggested that recent use, particularly for modafinil, was closer to media reports (Lennard, 
2009; The Student Room, 2016). Of course, as already observed, Maier and colleagues’ 
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sample was self-selected, and as a consequence it cannot be used as a true representation 
of prevalence. Furthermore, other studies have yet to report similar levels of PCE use in the 
UK, which suggests that level of use may be low.  
One of the most important findings to emerge from this survey was the popularity of 
modafinil above other PCE. Furthermore, moral perceptions of modafinil use significantly 
predicted soft enhancer and PCE use. Not only does this support evidence that modafinil is 
the most popular PCE in the UK as it was viewed as the most morally acceptable, but it 
raises the question of whether or not a pro-moral stance toward the drug leads to use. As 
such, future research should expand on the relationship between moral perceptions and 
modafinil use, possibly via moderation analysis. Furthermore, studies should also focus on 
factors which may predict use more specifically and give greater emphasis to personality 
measures which research has already linked to PCE use (Maier et al., 2015).  
5.6. Chapter Summary  
 
This chapter set out to investigate a sparsely researched area in the UK. Only a handful of 
studies have examined CE use in British universities, and this survey was the first UK-only 
study to investigate factors which could predict use. As expected, soft enhancers, 
particularly those containing caffeine, were by far the most reported for the purpose of 
study, with illegal drugs and PCE used considerably less for all purposes. Nonetheless, as 
anticipated, modafinil emerged as the most popular PCE substance among respondents, 
which is consistent with recent findings in previous research. Moreover, the statistical 
model successfully predicted CE use, as being older, male and having a favourable opinion 
of modafinil use were all significant predictors. Consequently, despite PCE use still being 
limited in the UK and elsewhere, there is sufficient evidence from this survey and previous 
studies to suggest that modafinil use is on the rise in UK universities, and as such, the drug 
warrants further investigation. Furthermore, little is understood about persistent use of 
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this substance in terms of its potential to adversely affect cognition and neurophysiology. 
As such, Chapters 6 and 7 explore cognitive, psychophysiological and neurophysiological 
functioning with long-term nonmedical use.  
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Chapter 6: Study 2 – Differences in Cognitive Performance between Modafinil Users and 
Non-using Controls.  
 
6.1 Chapter Overview 
 
The previous chapter looked broadly at levels of CE use and associated factors in UK 
universities, and identified the novel stimulant modafinil as the most popular PCE. 
Following on from this discovery, this chapter describes a study which examines executive 
functioning in long-term modafinil users and non-using controls, with the aim to assess 
whether or not continued use of this drug adversely effects various cognitive functions. 
Additionally, Chapter 2 demonstrated that response inhibition, working memory and 
sustained attention were improved with acute modafinil, as such a Go/No-go test, 2-back 
working memory task and continuous performance task were used to assess the impact of 
long-term use.  
6.2 Introduction 
 
Previous chapters have demonstrated that modafinil appears to be the most popular PCE 
among students in the UK, and Study 1 further supported these findings. Furthermore, 
modafinil has been shown to benefit cognitive processes in healthy and clinical populations 
(Minzenberg & Carter, 2008). Acute administration studies have highlighted the drug’s 
potential to improve functions in several cognitive domains, including working memory, 
attention and other processes associated with the prefrontal cortex (Battleday & Brem, 
2016). Furthermore, studies assessing dose-dependent effects have found that similar 
benefits can be conferred from low (100mg) and high doses (600mg), with the greatest 
advantages being given to healthy but sleep deprived adults (Minzenberg & Carter, 2008). 
101 | P a g e  
 
Additionally, in terms of cognitive benefits, research shows that even small doses are 
comparable to 600mg of caffeine and 20mg of d-amphetamine, suggesting that in clinically 
recommended quantities the drug is an effective stimulant (Wesensten et al., 2005). 
Moreover, modafinil has even been found to reverse working memory deficits and other 
cognitive functions in psychiatric and ADHD populations, bringing performance in-line with 
healthy controls (Turner et al., 2004). Nonetheless, studies examining modafinil use in 
healthy, non-sleep deprived adults have shown equivocal findings, although benefits have 
been found in various domains, including; attentional and working memory processes 
without a speed/accuracy trade-off (Müller et al., 2004; Müller et al., 2013), inhibitory 
control (Rycroft et al., 2007; Turner et al., 2003) and alertness and sustained attention 
(Baranski et al., 2004; Randall & Shneerson, 2005; Randall et al., 2005) (see Chapter 2 for 
full review).  
Despite these studies showing some benefits to cognition, research does not appear to 
have investigated the impact of the drug on cognitive performance with prolonged use (3 
months and above). Furthermore, at the time of writing, studies have not assessed 
whether using modafinil against medical guidelines (i.e., not for prescribed purposes) for 
this period of time could cause adverse effects in the brain and to cognitive function, even 
if previous studies show the drug is well tolerated with short-term use (see Chapter 2). 
While studies indicate that in healthy people, working memory, response inhibition and 
sustained attention are the executive functions most facilitated by use, it is unclear for how 
long these benefits are sustained, and if after the psychoactive effects of the drug expire 
cognitive deficits are apparent. It is feasible that, like illegal stimulants, continued 
nonmedical use of modafinil is neurotoxic (Gawin & Ellinwood, 1988), given the 
neurochemical similarities the drug has as a dopamine reuptake inhibitor to cocaine 
(Zolkowska et al., 2009). Therefore, like cocaine, this could lead to persistent cognitive 
deficits in certain domains, particularly those which show improvement during acute use. 
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As such, this study sought to investigate cognitive performance in long-term modafinil 
users who have been abstinent for at least 48 hours, a period of time sufficient to fully 
deplete the psychoactive effects of the drug based on an elimination half-life of 9 to 14 
hours (McClellan & Spencer, 1998). Participants completed a 2-back working memory task, 
a go/no-go task (response inhibition) and the continuous performance task (sustained 
attention) to ascertain whether or not long-term modafinil use leads to deficits in these 
areas, and to address various hypotheses. Modafinil users would perform significantly 
worse on cognitive performance measures than nonusers (H5). More frequent modafinil 
use would also predict poorer performance on the cognitive performance measures, as 
would greater poly-drug use and recent use of illicit stimulants and cannabis (H6). Lastly, it 
was also anticipated that modafinil use would be significantly correlated with greater levels 
of poly-drug use reported by participants in the modified Background Drug Use 
Questionnaire (H7). 
6.3 Method 
 
6.3.1 Participants 
 
Data collection occurred between January 2017 and February 2018. Fifteen modafinil users 
(mean age = 24.80, SD = 3.48, males = 83.33%) and 18 non-using controls (mean age = 
25.72, SD = 3.93 males = 47.77%) participated in the study, with opportunity and snowball 
sampling methods used for recruitment. Furthermore, participants were contacted through 
university mailing lists and on speciality online PCE user forums. To be considered a 
modafinil user, participants had to report using the drug for at least 12 months and on 
average at least once a month, while nonusers had to have no history of modafinil use, 
although ‘other’ drug use was permitted.  
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6.3.2 Design 
 
A mixed design was implemented to examine behavioural data. The between-groups factor 
was user group which had 2 levels (modafinil user vs. nonuser). There were various 
dependent variables of interest, including response inhibition (go/no-go: total errors, go 
errors, no-go errors, horizontal errors, vertical errors, total response rate, vertical response 
rate and horizontal response rate), sustained attention (continuous performance: hits, 
misses and response time) and working memory score (2-back: hits, misses, correct 
rejections, false alarms and no response).  
6.3.3 Materials 
 
Participants completed a total of 3 cognitive performance measures: the 2-back working 
memory task, a visual cued version of the Go/No-go task and the continuous performance 
task. They also filled in the Hospital Anxiety and Depression Scale (HADS) and a modified 
version of the Background Drug Use Questionnaire to investigate their substance use 
history. Each measure is fully described below: 
 
6.3.3.1 Hospital Anxiety and Depression Scale (HADS) 
 
The HADS is a clinical measure of state anxiety and depression (Zigmond & Snaith, 1983). 
Seven items assess anxiety and 7 assess depression. Questions are presented as statements 
on a 4-point Likert scale (e.g., 0 = Not at all, 3 = Most of the time) such as; ‘I feel tense or 
‘would up’ (anxiety) and ‘I can laugh and see the funny side of things’ (depression). Anxiety 
and depression score are tallied separately and reported at the bottom of the paper (0 – 7 
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= Normal, 8 – 10 = Borderline abnormal, 11 – 21 = Abnormal). Reliability analysis with data 
from this study revealed strong internal consistency for anxiety (α = .812) and depression 
scores (α = .898).  
6.3.3.2 Modified Background Drug Use Questionnaire 
 
The modified Background Drug Use Questionnaire is a measure of substance use patterns 
derived from the Background Drug Use Questionnaire (see Montgomery et al., 2005 for 
original survey). This version emphasises modafinil use but also investigates an inventory of 
other drugs and other background variables. 
i) Substance Use.  
At the onset of the survey participants are asked if they have ever used modafinil (yes/no) 
and if so for how long (months/years). Use of a comprehensive list of other psychoactive 
drugs is then assessed, including: alcohol, amphetamine, cannabis, cocaine, crack, DMT, 
GHB, herbal E, heroin, ketamine, LSD, LCB, mushrooms, poppers, Prozac, salvia divindrum, 
tranquillisers, tobacco, Viagra, steroids, mephedrone and naphyrone. Past use is explored 
including when respondents first began using (month and year) and when they last used 
(hours, days, weeks, months or years previous). Frequency of use in the previous 12 
months is also investigated (e.g., tablets/grams/mg taken in one session and over the 
course of a week/month/year).  
ii) Other Variables.  
Respondents are asked about their: age, gender, qualifications (CSE, GCE, GCSE, A-level, 
NVG, Government employment training scheme, craft/trade, HND, degree, ‘other’ and 
none), previous convictions (drug related or not), living circumstances (live alone, with 
parents, with partner, marriage partner, single parent family, live with friends, no fixed 
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abode or ‘other’) their current employment status (full-time, part-time, unemployed, self-
employed, student or ‘other’). and units of alcohol normally consumed (daily, weekly, 
fortnightly, monthly or ‘other’). They are also asked general health related questions for 
participant screening, including; whether they have been hospitalised with a specific 
condition (neurological, heart or respiratory) whether they have a diagnosis of a clinical 
disorder (diabetes, anxiety, depression, flashbacks, panic attacks, paranoia, phobias or 
schizophrenia), and whether they consider themselves in good health (very good, good, 
average, poor or very poor) . 
 
6.3.3.3 2-Back Working Memory Task 
 
The n-back task presents participants with a sequence of letters/numbers that appear one 
at a time on a computer screen (Owen, McMillan, Laird, & Bullmore, 2005). Depending on 
the difficulty of the condition used, participants have to identify whether the letter 
currently presented on screen matches a letter presented ‘X’ number of items previously. 
The higher the value of n, the greater the working memory demand. This study used a 2-
back paradigm, requiring participants to identify letter matches two stimuli apart. In both 
conditions, black letters appeared one at a time in bold Times New Roman font overlaid 
against a white screen. Items were presented for 1500 ms and responses were recorded in 
a further 500 ms window following the presentation of the letter. For the 2-back, the task 
was presented in a single block with a total duration of 5 minutes. Participants were 
required to press ‘5’ on the number pad when they recognised a hit, and ‘1’ for non-hit. In 
both conditions, participants completed a short practice trial before the experiment and 
received a percentage of accuracy based on total hits. At the conclusion of the test 
participants received a breakdown of their total hits, misses, correct rejections and no 
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responses. This version of the 2-back was created using E-Prime software by Psychology 
Software Tools (Kirchner, 1958). 
6.3.3.4 Cued Go/No-Go Task 
 
A test of response inhibition, participants are exposed to a transparent rectangle that 
appears in the centre of a white computer screen in either a vertical or horizontal 
configuration (Nosek & Banaji, 2001). After a small delay, the rectangle is changed to either 
blue or green and presented for 500 ms. Participants are instructed to press the space bar 
as fast as possible on a keyboard provided if the rectangle turns green, but not if it turns 
blue. Responses are recorded within the 500 ms timeframe. The task is presented in three 
blocks and has a total duration of ten minutes. This version of the Go/No-Go Task was 
downloaded and run using Inquisit.  
6.3.3.5 Continuous Performance Task 
 
A task assessing prolonged attention which has previously been used to investigate the 
cognitive effects of stimulant medications (Riccio, Waldrop, Reynolds, Lowe, & 
neurosciences, 2001; Verbaten et al., 1994). Participants are presented with a random 
sequence of numbers which appear on a computer screen one at a time and range from 0 – 
9. They are instructed to identify even numbers and press the space bar when they are 
encountered, but they must ignore odd numbers (zero is considered non-even). The task is 
presented in a single block of 10 minutes, and scores are stored as a text file after 
completion. This task was also downloaded and run using Inquisit.  
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6.3.4 Procedure 
 
The current study was approved by Liverpool John Moores University Research Ethics 
Committee in October 2016. Participants were contacted and recruited from the local 
student cohort through mailing lists and a student research participation scheme, and via 
advertisements on speciality PCE user forums. In all emails and advertisements, recipients 
were provided with a digital copy of the PIS which outlined the study aims and exclusion 
criteria and what would be expected of them at the lab. Potential participants were 
excluded if they had a recent history of cardiac or clinical psychiatric conditions. On arrival, 
participants were also provided with a paper copy of the PIS and a consent form. After 
giving consent, they completed the modified Background Drug Use Questionnaire to 
provide information on modafinil use, other drug use patterns and demographic 
information, and they completed the Hospital Anxiety and Depression Scale. Following this, 
participants sat at a computer and completed the 3 computerised tasks. Order of task 
presentation was randomised.  Participants completed: the 2-back working memory task, 
the continuous performance task and the go/no-go task, each of which lasted 
approximately 10 minutes. After completing the tasks, participants received a paper 
debrief which explained the aims of the research and were provided with contact details 
for counselling and drug use information services.  
6.3.5 Data Analysis Strategy 
 
Data analysis was carried out using SPSS version 25, and ANOVA was used to analyse 
between-groups differences on all behavioural measures. Descriptive analysis was 
conducted on health screening questions to identify those participants who were ineligible 
to continue with the study although none were reported (i.e., had a neurological condition 
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or history of a clinical disorder). On the continuous performance task, data was first 
extrapolated using E-Data Aid from E-Prime software, and average hits, misses and 
response times were calculated and then transferred into an SPSS datasheet and analysed 
using univariate ANOVA. Additionally, where repeated ANOVA were run on the same data 
set (i.e., on a single cognitive performance measure), Bonferroni adjustments were made 
to alpha levels to minimise the occurrence of type-1 errors. Furthermore, to assess other 
factors which might influence performance on the tasks (i.e., use of other substances) 
hierarchical multiple regression was used. Regression analysis was conducted across 2 
stages. In total, 6 regression models were carried out which assessed: 2-back hits, 2-back 
misses, Go/No-go total response rate, CPT hits, CPT misses and CPT response rate as 
dependent variables. Certain variables were excluded from analysis due to near 
indistinguishable performance between participants, such as hits and misses on the Go/No-
go task. Additionally, average monthly modafinil use, total number of substances used in 
the previous 3 months, use of illegal stimulants, (i.e., cocaine and amphetamine use), 
cannabis and alcohol in the previous year were predictor variables. At stage 1 of the 
regression, average monthly modafinil use was the only predictor, and at stage 2 drug use 
variables found to at least approach significance with behavioural variables in bivariate 
correlations were included. This order was chosen because investigating long-term 
modafinil use is central to the aims of this study, and because, as previously discussed, the 
drug is shown to affect cognitive processes which are implicated in the cognitive tasks. A 
correlation matrix was also created between predictor variables to assess collinear 
relationships and investigate patterns of polydrug use in the sample.  
6.4 Results 
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6.4.1 Demographics  
 
Analysis of drug use demographics revealed recent use of multiple substances throughout 
the sample. For instance, the modafinil user group reported a mean average use of 5.74 
(SD = 4.43) tablets a month over the past year, with average tablet intake ranging from 2 to 
16 in the sample. Moreover, in the previous 3 months participants reported use of multiple 
substances listed in the modified Background Drug use Questionnaire (mean = 3.03, SD = 
2.49). However, when prevalence was investigated between the user groups, a t-test 
revealed that the modafinil group used significantly more substances than nonusers (t(33) 
= 4.160, p < .05, d = .32) (users: Mean = 4.67, SD = 2.84; nonusers: Mean = 1.47, SD = 1.04). 
Alcohol, illegal stimulant and cannabis use was also assessed, but due to low response rates 
across the sample on these measures, frequency of use could not be investigated and 
instead analysis focused on whether or not these substances had been used in the past 
year. For alcohol, 74% reported use and there were no apparent differences between user 
groups (t(33) = .303, p > .05, d = .00). With illegal stimulants, use was markedly lower at 
44%, and again there were no statistically significant differences between groups (t(33) = 
1.677, p > .05, d = .11). Finally, cannabis use was higher than stimulant use, with 55% 
reported prevalence, but like the other substances, groups did not significantly differ in use 
(t(33) = .809, p > .05, d = .10). 
Furthermore, 79% (N = 27) of the sample recorded some degree of educational attainment. 
All respondents indicated that they had achieved level 2 (GCSE or equivalent) and level 3 
(A-level, NVQ or equivalent) qualifications prior, which was unsurprising as many were 
students currently study at university. Additionally, all participants reported that they were 
in the process of completing a higher education qualification (degree/diploma equivalent 
or higher), but few stated having level 6 qualifications or higher (users: N = 1; nonusers: N = 
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3). Consequently, meaningful analysis between groups could not be conducted as they 
appeared to be matched.  
6.4.2 Behavioural Measures 
Anxiety and depression score on the HADS are recorded in Table 6.1. Univariate ANOVA 
found no significant between-groups differences in self-reported anxiety or depression 
between modafinil users and nonusers.  
Table 6.1 – Average modafinil user and nonuser scores on the HADS.  
HADS Long-term 
Modafinil Users 
Nonusers ANOVA 
 Mean (SD) Mean (SD) F(1,33) Sig 
Anxiety 5.67 
(3.39) 
5.29 
(3.73) 
.074, p >.05, ƞp2 = .003 
Depression 3.83 
(2.98) 
2.93 
(2.92) 
.443, p >.05, ƞp2 = .025 
 
Results from the 2-back are displayed in Table 6.2. Despite users on average appearing to 
have marginally more hits and fewer misses than nonusers, findings from univariate 
ANOVA were not statistically significant. Furthermore, the groups did not significantly differ 
on total correct rejections, false alarms or in failed responses, suggesting that working 
memory performance overall was not impacted by modafinil user status.  
Table 6.2 – Performance on the 2-back working memory task between modafinil users and 
nonusers.  
2-back Long-term 
Modafinil Users 
Nonusers ANOVA 
 Mean (SD) F(1,33) Sig Effect 
Hits 22.87 
(4.67) 
20.16 
(6.65) 
1.786 >.05 ƞp2 = .051 
Misses 5.33 
(4.35) 
7.26 
(4.25) 
.203 >.05 ƞp2 = .050 
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Correct 
Rejections 
50.87 
(15.65) 
47.58 
(16.78) 
.563  >.05 ƞp2 = .011 
False Alarms 1.40 
(2.37) 
1.84 
(3.28) 
1.039 >.05 ƞp2 = .031 
No Response 9.53 
(20.14) 
12.21 
(22.51) 
.130 >.05 ƞp2 = .004 
 
Performance scores on the Go/No-go task are displayed in Table 6.3. Regardless of user 
group, errors were minimal. Moreover, univariate ANOVA revealed no between-groups 
differences in total errors, ‘go’ target errors and ‘no-go’ target errors. Interestingly, ANOVA 
revealed a significant difference in response time between user groups, and inspection of 
descriptive statistics revealed that modafinil users had quicker response times overall, and 
when cues were presented both vertically and horizontally. This finding suggests that while 
user status might not impact response, it may influence attentional speed without a trade-
off in accuracy.  
Table 6.3 – Performance scores for total errors and response rates in milliseconds to the different 
stimuli on the Go/No-go task.  
Go/No-go Long-term 
Modafinil Users 
Nonusers ANOVA 
 Mean (SD) F(1,33) Sig Effect 
Total Errors .004 
(.006) 
.003 
(.004) 
.135 >.05 ƞp2 = .004 
Go Target 
Errors 
.001 
(.003) 
.000 
(.000) 
1.740 >.05 ƞp2 = .052 
No-go Target 
Errors 
.007 
(.011) 
.006 
(.006) 
.042  >.05 ƞp2 = .001 
Response Rate 
Total  
322 
(37.40) 
357 
(48.71) 
*5.130 <.05 ƞp2 = .158 
*Significant at .05 
Results from the CPT are displayed in Table 6.5. Although users appeared to have 
marginally more hits than nonusers, univariate ANOVA revealed that there were no 
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significant between-groups differences in total hits or misses. Moreover, the response time 
advantage seen in the Go/No-go task was not evident in the CPT.    
Table 6.4 – Performance scores for total hits, misses and response rate in milliseconds to number 
pairs on the CPT.  
CPT Long-term 
Modafinil Users 
Nonusers ANOVA 
 Mean (SD) F(1,33) Sig Effect 
Hits 759.27 
(37.33) 
725.63 
(177.48) 
.517 >.05 ƞp2 = .016 
Misses 80.73 
(37.33) 
70.16 
(30.19) 
.835 >.05 ƞp2 = .025 
Response Rate 456.52 
(37.99) 
442.07 
(111.87) 
.228  >.05 ƞp2 = .007 
Response time recorded in milliseconds. 
 
6.4.3 Hierarchical Regression  
 
Standardised beta coefficients, and significance values for substance use variables and their 
impact on task performance are presented in Table 6.6. Prior to carrying out multiple 
regression analysis, the required assumptions were tested and met. To examine 
multicollinearity, a Pearson’s r correlation matix was run and is presented in Table 6.5. 
Furthermore, analysis was conducted in 2 stages, first assessing the impact of average 
monthly modafinil use over the past year, then by including the use of other substances in 
a second model. The second stage of the model was determined by examining bivariate  
correlations between substance use variables and the respective task performance 
variables. This was done instead of entering all variables into the model because the 
sample size lacked the appropriate statistical power for a more ambitious design. As such, 
those substance use variables which approached significance were included in stage 2. In 
total, 6 analyses were conducted, revealing mixed fingings.  
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Table 6.5 –Pearson’s r coefficients for drug use variables derived from self-reported use on the 
Background Drug Use Questionnaire.  
 
Pearson’s r Correlations Total No. of 
Substances 
Used: 3 
months 
Total 
Stimulant 
Use: Previous 
year 
Total Cannabis 
Use: Previous 
year 
Total Alcohol 
Use: Previous 
year 
Average Monthly 
Modafinil Use 
*.322 .253 .329 .096 
Total No. of Substances 
Used: 3 months 
 *.375 .302 .165 
Total Stimulant Use: 
Previous year 
  *.382 .184 
Total Cannabis Use: 
Previous year 
   *.378 
Total Alcohol Use: 
Previous year 
    
N:34 (15 modafinil users). *Significant at .05 
 
Pearson’s correlational analysis found several moderate significant relationships between 
drug use variables. Predictably, total number of substances used in the previous 3 months 
was significantly correlated with the number of participants who reported illegal stimulant 
use in the last year (r = .375, p < .05). Moreover, stimulant use was also moderately 
correlated with cannabis use (r = .382, p < .05), and cannabis use was in turn correlated 
with previous year alcohol use (r = .378, p < .05). This implies that people who used one 
illegal drug were more likely to use another, suggesting that polydrug use was prevalent in 
the sample. Nonetheless, average monthly modafinil use over the past year was not 
significantly correlated with any other substance use variable, suggesting that modafinil 
users tended not to have recent experiences of polydrug use. Furthermore, despite some 
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moderate correlations, coefficients were of acceptable collinearity (Field, 2013), meaning 
that multiple regression could be conducted 
 
When drug use variables were correlated against the respective behavioural measures, 
findings were mixed. As the study was primarily concerned with investigating modafinil 
use, average monthly modafinil use was included based on theoretical assumptions rather 
than assessing the strength of bivariate correlations first. Nevertheless, for total number of 
substances used in the previous 3 months, Go/No-go response rate was moderately 
significantly correlated (r = -.314, p < .05), and CPT misses approached significance (r = .251, 
p =  .07). Previous year stimulant use was significantly negatively associated with CPT hits (r 
= -.296, p < .05) but no other variable, and previous year cannabis use was only negatively 
associated with CPT response rate (r =  -.335, p < .05). Finally, previous year alcohol use was 
moderately negatively correlated with 2-back hits (r = -.301, p < .05) and highly positively 
correlated with 2-back misses (r = .479, p < .01). All other associations between drug use 
and behavioural variables were non-significant and thus not included in the second stages 
of the regression analyses
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Table 6.6 – Standardised Beta coefficients for substance use variables and performance on different 
aspects of the behavioural measures. Substance use variables were subject to bivariate correlation 
analysis prior to performing multiple regression to predict model strength and to screen for which 
factors were unsuitable in the analyses.  
 
Hierarchical 
Regression 
2-back: 
Hits 
2-back: 
Misses 
 
G/NG R. 
Rate: 
Total 
CPT: Hits 
 
CPT: 
Misses 
 
CPT: R. 
Rate 
 
Stage 1 Standardised Beta Coefficients 
Average Monthly 
Modafinil Use 
.258 -.160 *-.423 .066 .208 -.013 
Stage 2  
Average Monthly 
Modafinil Use 
.284 -.204 **-.450 .137 .191 .088 
Total No. of 
Substances Used: 3 
months 
- - .084 - .055 - 
Total Stimulant Use: 
Previous year 
- - - -.282 - - 
Total Cannabis Use: 
Previous year 
- - - - - -.308 
Total Alcohol Use: 
Previous year 
-.275 *.459 - - - - 
N: 33 (15 modafinil users). t-test df = 32. *Significant at .05. **Significant at .01. Abbreviation: G/NG, 
Go/No-go. R. Rate, Response Rate. 
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Hierarchical regression revealed that 2-back hits was not predicted at stage 1 (F(1,32) = 
.005, p > .05; F change: F(1,32) = 2.275, p > .05) or 2 (F(1,32) = 1.436, p > .05) of the 
analysis. For 2-back misses, findings diverged, as stage 1 was non-significant (F(1,32) = .842, 
p > .05; F change: F(1,32) = .336, p < .05) but stage 2 was successful (F(1,32) = 4.746, p < 
.05). At stage one, R2 only explained 2.6% of variation in misses, but at stage 2 this 
increased to 23.4%. This is no doubt because use of alcohol in the previous year was a 
significant predictive factor, with alcohol users demonstrating more misses than nonusers. 
On Go/no-go total response rate, stage 1 (F(1,33) = 6.976, p < .05; F change: F(1,32) = 
6.976, p < .05) of analysis was statistically significant, and so was stage 2 (F(1,33) = 3.527, p 
< .05). At stage 1, R2 explained 17.9% of variance in response rate, which rose to 20.1% at 
stage 2. However, only average monthly modafinil use was a notable predictor at both 
stages of analysis, proving significant at stage 1 and highly significant at stage 2. As such, 
findings indicate that increased frequency of modafinil use alone predicted faster response 
times on the Go/No-Go task. Finally, regression showed null findings on the CPT, as the 
model was non-significant at accounting for variance in hits at stage 1 (F(1,33) = .138, p > 
.05; F change: F(1,32) = .138, p > .05) and 2 (F(1,33) = 1.325, p > .05), misses at stage 1 
(F(1,33) = 1.452, p > .05; F change: F(1,32) = 1.452, p > .05) and 2 (F(5,33) = .749, p > .05) 
and response time at stage 1 (F(1,33) = .005, p > .05; F change: F(1,32) = .005, p > .05) and 2 
(F(5,33) = 1.436, p > .05). As such, recent use of modafinil and other substances did not 
appear to predict variability in prolonged attention on the CPT.  
 
6.5 Discussion 
 
The findings from this study did not support most hypotheses outlined earlier in the 
Chapter. In fact, in some incidences, results suggest the opposite of what was predicted. 
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For instance, examination of studies with illegal stimulants suggested that, given the similar 
mechanism of action in the dopamine system with modafinil, users would exhibit deficits in 
cognitive performance, which would be expressed by poorer performance on the cognitive 
tasks. This was not found to be the case. In fact, modafinil users demonstrated decreased 
response time compared with controls on the Cued Go/No-go task and a similiar amount of 
hits and misses, inferring that they had increased attentional speed without a trade-off to 
accuracy. Furthermore, greater frequency of modafinil use did not predict performance on 
the cognitive measures. However, more frequent use was a significant predictor of a 
quicker response rate on the Go/No-go, and taken together with total number of substance 
used in the previous 3 months, both stages of the model significantly predicted response 
time. Together with greater alcohol use in the previous year, reduced frequency of 
modafinl use also predicted 2-back misses but not hits. For CPT hits, misses and response 
rate, all substance use variables were non-significant. Finally, there was a significant 
moderate positive correlation between modafinil use and polydrug use over the previous 3 
months. Therefore, as modafinil users showed no behavioural differences in some tasks 
and improved performance in attentional speed, the H5 and H6 could not be accepted. 
However, modafinil users did use more substances than nonusers, and as such the H7 was 
accepted.  
 
Despite research with illegal stimulants showing cognitive deficits in long-term stimulant 
users, the current study revealed that modafinil users perform better in some measures of 
cognitive performance. This suggests that, contrary to expectations and despite the 
neurochemical similarities with illegal stimulants, that long-term modafinil use may not 
lead to the same deficits. In fact, findings show similarity to Müller and colleagues’ acute 
administration research which demonstrated increased attentional speed without an 
accuracy trade-off, and research by Marchant et al. (2009) which showed a general 
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increase in speed of attention. Of course, in the current study, users had been abstinent 
from modafinil for at least 48 hours, a period of time shown earlier in this Chapter to fully 
deplete the psychoactive effect of the drug, suggesting that benefits conferred from this 
substance may continue to exist after the acute effects have expired. Given that there were 
no improvements in the CPT or 2-back hits, it is possible that either this is an artefact in the 
data, or that attentional speed may only be improved under specific circumstances. It is 
also possible that the lack of pronounced differences in working memory performance may 
be attributable to the fact that the 2-back was too easy, and an increase in difficulty may 
demonstrate behavioural differences between user groups. However, in spite of this 
apparent limitation, no other study has yet demonstrated benefits to cognitive 
performance in long-term modafinil users. As such, future research should aim to further 
investigate modafinil use and cognition, and focus on harder working memory paradigms 
and tasks that assess response inhibition.  
 
6.6 Chapter Summary 
 
This chapter explored cognitive performance on various behavioural measures in long-term 
modafinil users vs. nonusing controls. Findings indicated that, while users showed no 
advantages over nonusers on working memory performance or sustained attention, they 
did perform significantly faster on a response inhibition task without sacrificing accuracy, 
which is consistent with previous acute administration studies. As a result, findings did not 
support most hypotheses previously outlined, suggesting that although modafinil may have 
a similar mechanism of action to illict stimulants like cocaine, the drug’s effects on the 
brain and cognition appear such that it might improve performance in certain cognitive 
domains even after acute psychoactive effects have expired. As such, the results appear to 
contradict expectations, implying that modafinil acts in a unique capacity on the brain to 
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illegal stimulants. In order to further explore these unexpected findings, the final study of 
this thesis uses the neuroimaging technology fNIRS to explore prefrontal brain activation in 
modafinil users when they complete cognitive performance measures which induce greater 
cognitive workload, including a harder 3-back working memory test and different difficulty 
conditions of the MTF. Moreover, measures of HRV and blood pressure are also included to 
make a wider assessment of long-term modafinil use on cardiovascular functioning, to see 
whether the drug also has a physiological impact.  
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Chapter 7: Study 3 – Long-Term Modafinil use, Psychophysiological and 
Neurophysiological Indicators of Effort: Findings from functional near-infrared 
spectroscopy and electrocardiogram.  
 
7.1 Chapter Overview 
 
In the previous chapter, cognitive performance was assessed across several cognitive 
performance measures, comparing modafinil users and nonusers. However, various 
findings which defied expectations led to the need for further inquiry. This chapter 
describes a study which examines the neurophysiological correlates of cognitive effort, 
using fNIRS, ECG and blood pressure measurements to investigate haemodynamic response 
and autonomic activity between user groups during completion of a more challenging 3-
back working memory task and a multitasking paradigm.  
7.2 Introduction 
 
Cognitive deficits from chronic illegal stimulant use are well documented (Gouzoulis-
Mayfrank & Daumann, 2009). These deficits are thought to stem from dopaminergic 
deregulation and destruction of dopamine transporters, with long-term use shown to lead 
to adverse psychological and physical health outcomes (McCann & Ricaurte, 2004; Pereira, 
Andrade, & Valentão, 2015). Moreover, studies have highlighted persistent deficits in 
working memory and executive function in chronic stimulant users (Reske, Eidt, Delis, & 
Paulus, 2010; Vonmoos et al., 2014), as well as higher than average blood pressure and 
irregular HRV (Koenig, Menke, Hillecke, Thayer, & Jarczok, 2015). However, despite some 
similarities in method of action with illegal stimulants, little is known about the long-term 
impact of PCEs on cognitive, neurological and cardiovascular functioning. 
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Neuroimaging technologies are robust instruments for capturing neuronal activity, and a 
wealth of research has already shown that they can provide neurological correlates of 
cognitive deficits (Ranchet et al., 2017; Unni et al., 2015). Additionally, the emergence of 
fNIRS has provided a means of observing haemodynamic response to neuronal activation, 
which studies reveal is sensitive when localising cognitive impairments in working memory 
and executive function (Ehlis et al., 2008; Izzetoglu et al., 2004). The DLPFC is particularly 
accessible with fNIRS, which several recent studies have illustrated with ecstasy polydrug 
users. For instance, in one study, increased activation in the left DLPFC but a lack of 
behavioural differences on the Chicago World Fluency Test showed that ecstasy users 
experienced increased cognitive workload relative to controls, suggesting underlying 
cognitive deficits (Roberts & Montgomery, 2015a). Furthermore, on a letter generation 
inhibitory control task, the same authors found that ecstasy users experienced increased 
oxy-Hb change in the left and right DLPFC again with no differences in behavioural output 
(Roberts & Montgomery, 2015b). Additionally, with working memory performance, ecstasy 
users demonstrate increased activation in the left and right DLPFC without performance 
differences on a verbal and spatial updating task, with recent use and greater levels of use 
both linked to working memory deficits (Montgomery et al., 2017). Still, a study by the 
same group showed that on the MTF, ecstasy users exhibited decreased oxy-Hb change 
relative to nonusers despite similar performance on all subtasks, suggesting that while 
some cognitive domains may be negatively impacted by use, others may improve (Roberts 
et al., 2015). Research using fNIRS in prescription stimulant users is extremely limited and 
focuses on adolescent with ADHD. For example, it has been demonstrated that adolescents 
prescribed MPH show greater right DLPFC activation relative to controls without 
behavioural differences in response inhibition (Moser et al., 2009). Furthermore, on an n-
back task, adolescents with ADHD showed reduced oxy-Hb change compared with controls 
in the VLPFC and a significantly worse working memory performance, suggesting that 
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cognitive deficits may also be linked to reductions in VLPFC activity (Ehlis et al., 2008). 
Finally, on a go/no-go task, ADHD adolescents exhibited increased right PFC activation and 
better task performance after MPH administration than before it, implying that greater 
activity in the region is associated with improved response inhibition (Monden et al., 2012). 
Therefore, fNIRS appears to be a suitable tool for capturing the neurological link between 
cognitive deficits and increases in cognitive workload. 
Studies with the cardiovascular system have also assessed stimulant use. For instance, 
long-term use of cocaine and amphetamine is associated with cardiovascular toxicity and in 
extreme cases can lead to myocardial infarction and even death (Richards et al., 2016). 
Such drugs stimulate the SNS via various neurotransmitter networks, which in turn 
increases oxygen demand on the heart and heightens blood pressure (Stankowski et al., 
2015). However, there is little research assessing adult stimulant use and the impact on 
HRV.  A recent systematic review found that in studies with adult users of cocaine, high-
frequency HRV was reduced in resting state (Koenig et al., 2015), although no studies have 
been identified which investigate the effects of long-term PCE use on HRV, despite recent 
evidence that shows acute use of both MPH and modafinil increase heart rate and SBP (Li 
et al., 2017; Taneja et al., 2005).  
As such, despite some compelling findings using neurophysiological methods to investigate 
substance use during completion of cognitive performance measures, studies have failed to 
investigate long-term nonmedical modafinil use, despite the pharmacological similarities 
shared with illegal stimulants. The current research aims to assess changes in prefrontal 
haemodynamic response, blood pressure and HRV in response to a working memory and a 
multitasking stressor in modafinil users and non-using controls. Following on from the 
previous study which focused solely on behavioural performance, oxy-Hb change, high 
frequency HRV and systolic and diastolic blood pressure are also recorded to address 
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psychophysiological and neurophysiological indicators of effort and to address several 
hypotheses. It was anticipated that long-term modafinil users would exhibit differences in 
haemodynamic response which would occur bilaterally in the left and right DLPFC 
indicating increased cognitive effort when compared with controls during the cognitive 
performance measures (H8). Differences were also expected to be observed in heart rate 
variability and blood pressure, with users anticipated to show atypical heart rate variability 
and elevated blood pressure (H9). All participants would exhibit increased haemodynamic 
activity and blood pressure as well as a significant reduction in R-R interval relative to 
baseline during the cognitive tasks. This was expected to be more pronounced in the hard 
condition than the easy condition (H10). Long-term modafinil users would report a 
significantly greater mental effort on the NASA-TLX than nonusers, and this would escalate 
with increasing task difficulty. Furthermore, they would also perform significantly worse on 
the cognitive performance measures (H11). 
7.3 Method 
 
7.3.1 Participants 
 
Data was collected from February 2018 to December 2018. Thirteen modafinil users (mean 
age = 24.72, SD = 4.37, males = 100%) and 21 non-using controls (mean age = 26.62, SD = 
3.65, males = 62%) were recruited with an opportunity sampling and snowball sampling 
method via university mailing lists and online CE user forums. However, as the modafinil 
user sample was entirely male, females were excluded from the control group so that the 
groups were gender-matched, bringing the final number for analysis to 13 modafinil users 
and 10 nonusers (mean age = 26.25, SD = 2.43). To be considered a modafinil user, 
participants had to have used modafinil for a minimum of 12 months and at least once a 
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month, and nonusers had to have no history of modafinil use, although a history with use 
of other substances was permitted. Furthermore, participants were only eligible if they 
abstained from psychoactive substances other than caffeine for 48 hours before the study.  
7.3.2 Design 
 
A mixed design was used to analyse neurophysiological and behavioural data. The 
between-groups variable was user group which had 2 levels (modafinil users vs. nonusers). 
There were several within-groups factors across all measures. On the MTF difficulty 
conditions (low and high), within-group comparisons were made across each subtask and 
score totals. Differences in perceived workload recorded on the NASA-TLX were also 
analysed between MTF difficulty conditions and the 3-back. For neurophysiological data, 
differences in oxy-Hb change, blood pressure and HRV were made between the tasks. 
There were several dependent variables of interest, including: task scores, haemodynamic 
response, HRV and blood pressure. 
7.3.3 Materials 
 
Participants completed the 3-back and low and high difficulty variants of the MTF while 
fastened into the fNIRS cap and wearing ECG electrodes and a blood pressure monitor (All 
neurophysiological apparatus is fully described in Chapter 4). All questionnaire and 
cognitive performance measures are detailed below: 
7.3.3.1 Hospital Anxiety and Depression Scale (HADS) 
 
The HADS is a clinical measure of state anxiety and depression and is fully described in 
Chapter 6 (Zigmond & Snaith, 1983). Reliability analysis with data from this study 
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demonstrated good internal consistency for anxiety (α = .755) and depression scores (α = 
.796).  
7.3.3.2 Modified Background Drug Use Questionnaire 
 
The modified Background Drug Use Questionnaire is a measure of substance use patterns 
derived from the Background Drug Use Questionnaire which emphasises modafinil use (see 
Montgomery et al., 2005 for original survey). This version is fully described in Chapter 6.  
 
7.3.3.3 NASA Task Load Index (NASA-TLX) 
 
The NASA-TLX is a measure of subjective workload completed at the conclusion of a task 
(Hart & Staveland, 1988). There are 6 subscales (mental demand, physical demand, 
temporal demand, personal performance estimation, total effort and frustration) each 
presented on a 100mm visual analogue scale. Participants are required to mark somewhere 
across each line in pencil to indicate their perceived workload. Responses toward the right 
side indicate high workload, and those toward the left suggest low. Subscales are 
calculated using a ruler and scores can be obtained for each individual type of workload or 
averaged together into a singular measure of perceived workload.   
7.3.3.4 3-Back 
 
The n-back task presents participants with a sequence of letters/numbers that appear one 
at a time on a computer screen (Owen et al., 2005). Depending on the difficulty of the 
condition used, participants have to identify whether the letter currently presented on 
screen matches a letter presented ‘X’ number of items previously. The higher the value of 
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n, the greater the working memory demand. This study used a 3-back paradigm, requiring 
participants to identify letter matches 3 stimuli apart. In both conditions, black letters 
appeared one at a time in bold Times New Roman font overlaid against a white screen. 
Items were presented for 1500 ms and responses were recorded in a further 500 ms 
window following the presentation of the letter. For the 3-back, the task was presented in 
3 blocks for a total duration of 10 minutes. Participants were required to press ‘5’ on the 
number pad when they recognised a hit, and ‘1’ for non-hit. In both conditions, participants 
completed a short practice trial before the experiment and received a percentage of 
accuracy based on total hits. At the conclusion of the test participants received a 
breakdown of their total hits, misses, correct rejections and no responses. This version of 
the 3-back was created using E-Prime software by Psychology Software Tools (Kirchner, 
1958). 
7.3.3.5 The Multitasking Framework 
 
The Multitasking Framework (created by Purple Research Solutions UK) is a paradigm for 
assessing cognitive demand using a montage of performance-driven tasks that can be 
completed alone or simultaneously to examine different aspects of executive function 
(Wetherell, Sidgreaves, & Stress, 2005). The more tasks participants are required to 
complete, the greater the cognitive load. Difficulty can also be manipulated by altering the 
speed or workload of the different tasks. There is a total of eight tasks which can be 
selected, each examining different cognitive functions. Participants can complete up to four 
tasks at once which appear in an onscreen window divided into quadrants. A numerical 
score is presented at the centre of the window which increases in value as participants 
succeed in the tasks but decreases if they respond incorrectly or fail to adequately split 
their attention between quadrants. This test has previously been used in similar studies 
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which measure stress and cognitive demand in long-term substance users (Parrott et al., 
2014; Roberts et al., 2015; Wetherell, Atherton, Grainger, Brosnan, Scholey, et al., 2012). In 
this study, this framework was divided into two difficulty conditions: low and high. In both 
conditions, participants were exposed to four tasks: visual monitoring, psychomotor, 
mental arithmetic and a Stroop test.  
Visual monitoring task. A task examining attention monitoring, participants encounter a 
dot in the centre of a series of concentric circles which steadily moves toward the outer 
ring. A higher score is awarded if the dot is reset when it is closer to the outermost circle. 
However, if the dot passes the final circle then a score penalty is applied for each second 
that it is not reset. 
Visual warning task. A test examining psychomotor functions, six stunted red bars appear 
alongside each other and build to different heights continuously throughout the test. Once 
the bars have reached maximum height a flashing red warming message appears. Each bar 
is assigned a number from 1 – 6 with the tallest being assigned 6 and the smallest 1. 
Participants are required to select each bar from tallest to smallest and turn the display 
from red to green so that the bars can reset and be reduced to equal size. If the bars are 
reset immediately after the warning then points are awarded, but if they are selected in 
the wrong order or after a delay then a penalty is incurred. 
Mental arithmetic. A test of working memory, participants complete a series of sums 
consisting of two or three digits depending on difficulty, and are required to add, subtract 
or divide. Correct answers award points, but incorrect answers or response delays incur a 
penalty.  
Stroop test. A test of inhibitory control, participants are exposed to the following group of 
four colour names which appear one at a time on the screen: ‘Red’, ‘Blue’, ‘Yellow’ and 
‘Green’. However, each name is presented in a different colour font to what the name 
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suggests (i.e., ‘Blue’ is presented in red font), and participants are required to identify the 
colour of the word and not what it reads. Four colour pallets are presented alongside the 
word and participants must select the right colour. The right selection awards points, but 
incorrect inputs incur penalties.  
Figure 7.1 – The Multitasking Framework in progress. Tasks are divided into 4 quadrants and a 
numeral score is displayed at the centre of the window.  
 
7.3.4 Procedure 
 
This study was approved by Liverpool John Moores University Research Ethics Committee 
in December 2017. Participants were recruited from the university and the surrounding 
area through LJMU email lists and online PCE discussion groups. A digital copy of the 
participant information sheet was provided in all correspondences which detailed the aims 
of the study and what would happen to participants in the lab. On arrival, participants also 
received a paper copy of the PIS and a consent form. After giving consent, participants 
completed the Modified Background Drug Use Questionnaire, to collect demographic 
information and assess modafinil and other substance use history, and the Hospital Anxiety 
and Depression Scale. Functional near-infrared spectroscopy and ECG electrodes were then 
fastened to the participant and their left arm was placed in a blood pressure cuff. A 3-
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minute montage of relaxing images and music was then played on a computer while 
baseline recordings from fNIRS, ECG and the blood pressure cuff were taken. Following 
baseline measures, participants were randomly allocated to complete either the easy or 
hard condition of the Multitasking framework (MTF) which lasted approximately 10 
minutes. After a short break, they were administered the 3-back which lasted another 10 
minutes. Finally, participants completed the remaining difficulty condition of the MTF and 
after completion were provided with a paper debrief. During all cognitive tasks, recordings 
from fNIRS, ECG and blood pressure were taken, and at the conclusion of each task 
participants filled out the NASA-TLX to assess perceived workload.  
7.3.5 Data analysis strategy 
 
Neurophysiological data was cleaned using various software packages. For fNIRS, the 
OxyMon integrated software Oxysoft by Artinis Medical Systems was used to clean signal 
noise and remove movement artefacts. This was achieved by applying low and high pass 
filtering to eradicate interference caused by ambient light sources and the cardiovascular 
system, and by eyeballing the data graph for sharp spikes (movement artefacts) and 
manually removing them. Raw data was also subject to CBSI analysis, which removes 
positive correlations between oxy and deoxy-Hb, thus improving signal quality and only 
requiring analysis of oxy-Hb data (see Chapter 4 for full details). AcqKnowledge, the 
accompanying analysis package of BSL PRO, was used on ECG raw signal data. Data analysis 
was conducted with SPSS version 25. For the behavioural data, several mixed MANOVA 
compared user groups and general differences in performance between the MTF difficulty 
conditions and the subtasks as well as differences on the 6 subscales of the NASA-TLX. 
Moreover, between-groups one-way ANOVA compared user groups on 3-back hits and 
misses. For neurophysiological data, a series of mixed MANOVAs compared user groups 
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across tasks on haemodynamic changes between the right, medial and left prefrontal 
cortices and also looked at regional differences on the left and right DLPFC. Partial 
correlations were also run on each fNIRS channel while controlling for the remaining 
channels to compare regional connectivity during the tasks between the groups. User 
groups were also compared on high frequency HRV and SBP and DBP scores, and general 
differences between tasks were also assessed.  
 7.4 Results 
 
7.4.1 Educational Attainment  
 
All participants indicated some kind of prior educational attainment (N = 23). As in the 
previous study, every respondent recorded a level 2 (GCSE or equivalent) and level 3 (A-
level, NVQ or equivalent) qualification. Furthermore, most participants were currently 
enrolled in higher education (N = 21), except for two nonusers who failed to provide a 
response. Therefore, educational attainment appeared to be matched between user 
groups.   
7.4.2 Behavioural Measures 
 
Anxiety and depression scores on the HADS are presented in Table 7.1. Between-groups 
ANOVA found that there were no significant differences between user groups on anxiety or 
depression score (see Table 7.1). 
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Table 7.1 – Average modafinil user and nonuser scores on the HADS.  
 
HADS Long-term 
Modafinil Users 
Nonusers ANOVA 
 Mean (SD) Mean (SD) F(1,19) Sig Effect 
Anxiety 5.38 
(3.59) 
7.13 
(6.01) 
.699  p >.05 ƞp2 = .035 
Depression 3.00 
(2.27) 
4.75 
(4.95) 
1.234  p >.05 ƞp2 = .022 
 
Average performance on the MTF and 3-back are presented in Table 7.2 and Table 7.3. A 
mixed MANOVA analysing differences on the MTF difficulty conditions found a non-
significant within-groups effect on overall score (F(1,21) = 1.868, p > .05, ƞp2 = .099) with 
participants unexpectedly exhibiting a similar performance on the MTF easy condition and 
the hard condition. There was also a non-significant between-groups effect of users vs. 
nonusers (F(1,21) = .072, p > 05, ƞp2 = .009), however a follow-up ANOVA revealed that 
users did significantly better on the MTF high difficulty condition than nonusers (F(1,21) = 
3.570, p < .05, ƞp2 = .198). Moreover, MANOVA on the subtasks of the MTF revealed several 
mixed findings. There was a significant within-groups difference between the MTF difficulty 
conditions (F(1,21) = 28.629, p < .001, ƞp2 = .799) but a non-significant between-groups 
effect of user group (F(1,21) = 2,300, p > .05, ƞp2 = .088). Moreover, post hoc t-tests 
revealed that, on average, participants scored higher on the low difficulty mental 
arithmetic task than the high difficulty, but unexpectedly did better on the high difficulty 
versions of the visual warning and tracking tasks while there was no significant difference 
on the Stroop (see Table 7.2). Furthermore, there was a significant condition x group 
interaction (F(1,21) = 3.684, p < .05, ƞp2 = .130), suggesting that users differed in 
performance to nonusers on the MTF difficult conditions. Follow-up post hoc t-tests 
revealed that on the high difficulty Stroop test, modafinil users scored significantly higher 
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than nonusers (t(20) = 2.723, p < .05, d = .11 ), but did not score differently on any other 
subtask. Finally, a one-way ANOVA found that on the 3-back, there were no significant 
between-groups differences between long-term users and nonusers on total hits and 
misses. 
Table 7.2 – Average scores on the low and high difficulty conditions of the MTF.  
 
MTF Long-term Modafinil 
Users 
Nonusers t-test 
 Mean (SD) t(1,20) = 
 Low 
Difficulty 
High 
Difficulty 
Low 
Difficulty 
High 
Difficulty 
Within-groups results 
MTF Score 2675.38 
(1244.03) 
2832.31 
(1503.00) 
2480.50 
(1615.89) 
1503 
(1432.49) 
*2.127, <.05, d = .18 
Arithmetic 193.85 
(199.10) 
42.31 
(169.56) 
185.00 
(221.68) 
41.25 
(65.77) 
***4.211, <.001, d = .54 
Stroop 2157.69 
(1215.01) 
2165.38 
(986.26) 
1966.25 
(1519.99) 
790.13 
(1327.43) 
1.509, >.05, d = .08 
Tracking 102.31 
(37.57) 
300.77 
(205.04) 
93.00 
(39.06) 
308.00 
(293.44) 
***-4.105, <.001, d = .52 
Warning 223.08 
(25.29) 
352.50 
(53.65) 
226.25 
(10.60)  
352.50 
(53.65) 
***-8.133, <.001, d = .77 
                     Note:* Significant at .05, **significant at .01, ***significant at .001 
                      Abbreviation: MTF, multitasking framework.  
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Table 7.3 – Mean scores on the 3-back task between modafinil users and nonusers.   
 
3-back Long-term 
Modafinil Users 
Nonusers ANOVA 
 Mean (SD) F(1,21) Sig Effect 
Hits 11.69 
(4.42) 
9.25 
(6.86) 
.995 >.05 ƞp2 = .023 
Misses 29.23 
(9.94) 
27.88 
(9.74) 
.093 >.05 ƞp2 = .002 
 
Results on the NASA-TLX are displayed in Table 7.4. Mixed MANOVA revealed a highly 
significant within-groups effect of task on self-reported workload (F(2,21) = 17.925, p < 
.001, ƞp2 = .666). Additionally, a significant condition x subscale interaction was apparent 
(F(5,21) = 38.554, p < .05, ƞp2 = .975) suggesting that task-load across individual scales 
differed in relation to cognitive task.  Moreover, repeated measures ANOVA on each 
subscale supported this finding as each was highly significant (see Table 7.4), and contrasts 
revealed a linear increase in self-reported task-load with the MTF easy condition requiring 
the least demand, followed by the MTF hard condition and then the 3-back on all subscales 
of the NASA-TLX.  However, MANOVA revealed that there were no significant between-
group differences observed among user groups (F(1,21) = .635, p > .05, ƞp2 = .032) and no 
significant condition x user group interactions (F(1,21) = 1.920, p > .05, ƞp2 = .176), 
indicating that long-term users did not differ to controls in any of the cognitive tests on 
self-reported task-load.
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Table 7.4 – Mean scores on the subscales of the NASA-TLX for the cognitive tasks. Bonferroni adjustments were also made to alpha levels for the within-group ANOVA.  
   
NASA-TLX Modafinil Users Nonusers ANOVA 
 Mean (SD) F(2,21) = 
MTF 
Conditions 
Low 
Difficulty 
High 
Difficulty 
3-Back Low 
Difficulty  
High 
Difficulty 
3-Back Within-groups results 
Mental 48.46 
(23.20)  
72.77 
(17.48) 
73.38 
(14.06) 
51.63 
(18.60)  
79.00 
(23.58) 
83.63 
(16.65) 
**28.337, p<.01, ƞp2 = .795 
Physical 12.31 
(11.63) 
31.23 
(27.26) 
19.69 
(20.15) 
 19.75 
(15.13) 
43.00 
(38.78) 
25.50 
(23.43) 
*6.126, p<.05, ƞp2 = .404 
Temporal 51.31 
(22.34)  
70.77 
(20.19) 
65.85 
(25.73) 
 51.63 
(23.60) 
78.38 
(21.51) 
70.13 
(25.73) 
**12.114, p<.01, ƞp2 = .539 
Effort 57.23 
(15.80)  
74.08 
(16.33) 
75.38 
(14.32) 
 49.50 
(20.07) 
75.00 
(26.81) 
79.38 
(9.30) 
**22.059, p<.01, ƞp2 = .726 
Performance 64.23 
(18.82)  
48.08 
(20.34) 
26.15 
(19.94) 
 62.38 
(32.96) 
50.63 
(30.11) 
31.00 
(33.43) 
**22.094, p<.01, ƞp2 = 719 
Frustration 47.23 
(25.60) 
62.15 
(18.37) 
58.15 
(28.30) 
33.50 
(29.60) 
61.38 
(23.57) 
76.25 
(17.86) 
**9.849, p<.01, ƞp2 = .635 
Note: * Significant at .05, **significant at .01. Abbreviation: MTF, multitasking framework.
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7.4.3 fNIRS Analysis 
 
Averages for oxy-Hb change from baseline among modafinil users and nonusers for the 
MTF low and high difficulty are shown in Table 7.5, and averages on the 3-back are 
presented in Table 7.6. Optodes were divided into regions of the PFC based on their 
position on the forehead (see Table 7.5 and table 7.6 for further details). Furthermore, the 
right PFC, medial PFC and left PFC were tested in separate MANOVA. Before multivariate 
analysis, bivariate correlations were carried out with optodes comprising each ROI. 
Optodes 8, 10 and 12 correlated significant with other channels in their respective regions 
and across multiple conditions, thus they were excluded from MANOVA due to 
multicollinearity.  
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Table 7.5 – Mean average oxy-Hb change on the MTF easy and hard conditions across the 12 
optodes. The right PFC (optodes 1, 2, 7 and 8), medial PFC (optodes 3, 4, 9 and 10) and left PFC 
(optodes 5, 6, 11 and 12) are presented in different blocks.   
 Modafinil users Nonusers MANOVA 
 MTF Easy MTF Hard MTF Easy MTF Hard Results 
Mean (SD) Oxy-Hb 
Right PFC  
Op 1 .12 
(5.25) 
-.33 
(3.35) 
-.01 
(7.38) 
-1.85 
(4.63) 
Group: F(1,21) = 1.443, 
p > .05, ƞp2 = .071 
Op 2 -.94 
(3.62) 
-.47 
(2.78) 
3.20 
(9.14) 
2.98 
(8.84) 
Condition: F(1,21) = 
1.923, p > .05, ƞp2 = .092 
Op 7 2.67 
(7.33) 
.85 
(6.10) 
3.27 
(3.79) 
3.88 
(4.48) 
Region: F(3,21) = 1.931, 
p > .05, ƞp2 = .092 
Op 8 -.85 
(4.08) 
.26 
(5.56) 
.81 
(10.68) 
.71 
(10.80) 
Group x condition = 
F(1,21) = .026, p > .05, 
ƞp2 = .001 
Medial PFC 
Op 3 -1.89 
(5.26)  
-.29 
(2.51) 
-3.10 
(6.04) 
-1.55 
(6.39) 
Group: F(1,21) = 2.555, 
p > .05, ƞp2 =.142 
Op 4 1.67 
(3.25) 
2.63 
(7.51) 
-2.32 
(6.27) 
-2.06 
(6.13) 
Condition: F(1,21) = 
4.006, p = .06, ƞp2 = .174 
Op 9 -1.65 
(1.62) 
-1.57 
(1.47) 
-4.03 
(2.37) 
-2.60 
(1.92) 
Region: F(3,21) = 2.008, 
p = .07, ƞp2 = .182 
Op 10 .52 
(5.40) 
1.44 
(8.50) 
-2.80 
(8.43) 
-2.81 
(7.30) 
Group x condition = 
F(1,21) = .042, p > .05, 
ƞp2 = .002 
Left PFC 
Op 5 3.52 
(6.20) 
2.26 
(8.04) 
2.75 
(8.38) 
-1.87 
(3.43) 
Group: F(1,21) = 2.165, 
p > .05, ƞp2 = .100 
Op 6 .59 
(1.20) 
.49 
(1.87) 
-.49 
(3.38) 
-.49 
(3.38) 
Condition: F(1,21) = 
.058, p > .05, ƞp2 = .003 
Op 11   3.94 
(6.67) 
5.13 
(6.67) 
-.33 
(10.46) 
.95 
(10.11) 
Region: F(3,32) = 1.744, 
p > .05, ƞp2 = .084 
Op 12 -.32 
(5.07) 
-.53 
(5.61) 
-2.19 
(10.41) 
-.82 
(10.59) 
Group x condition = 
F(1,21) = .011, p > .05, 
ƞp2 = .001 
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Note: Abbreviations: MTF, multitasking framework; oxy, oxygenated; deoxy, deoxygenated; op, 
optode.  
Various mixed MANOVA analyzing potential differences in haemodynamic response across 
the right PFC, medial PFC and left PFC revealed null results. On the right PFC, there were no 
significant within-group differences with the low and high difficulty conditions of the MTF 
for oxy-Hb change.  Furthermore, no differences were observed among the optodes in the 
right PFC, suggesting that oxy-Hb levels in the region remained similar across the difficulty 
conditions. On the medial PFC, there was no effect of the MTF difficulty conditions on oxy-
Hb change, but a statistical trend was apparent between the regional optodes, which 
contrasts show is because optode 3, located on the top-right side of the region, showed 
greater oxy-Hb decreases than the other channels. Moreover, there were no significant 
within-groups effects for oxy-Hb change in the left PFC on the MTF difficulty conditions or 
the optodes in the region. For between-groups analysis, there were no significant 
differences apparent in the right PFC, medial PFC or left PFC in oxy-Hb change (see Table 
7.4 for MANOVA results), suggesting that modafinil users and nonusers experienced the 
same amount of cognitive workload on the MTF. Finally, there were no significant within or 
between-group interactions observable across any of the three PFC regions.  
On the 3-back, several mixed MANOVA revealed varied results. There were no significant 
within-group differences for optodes covering the right PFC, medial PFC or left PFC. 
However, between-groups analysis revealed mixed findings, as there were no significant 
differences apparent between user groups and oxy-Hb change in the right and medial PFC. 
Nonetheless, there was a significant effect of user group on oxy-Hb change in the left PFC, 
which contrasts revealed was because users generally experienced an increase in oxy-Hb 
while nonusers had a decrease, a finding which suggests that users exerted more cognitive 
effort than nonusers. Lastly, there were no significant interactions apparent across the PFC 
regions (see Table 7.6 for MANOVA results).  
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Table 7.6 – Mean oxy-Hb change on the 3-back across the 12 optodes. Optodes are divided into the 
right PFC, medial PFC and right PFC as described in the previous table. 
 Modafinil users Nonusers MANOVA 
3-Back Oxy-Hb  
Mean (SD)  
Right PFC Results 
Op 1 .08 
(3.48) 
-1.01 
(5.01) 
Group: F(1,21) = 3.246 p 
= .06, ƞp2 = .176 
Op 2 -1.01 
(5.01) 
4.23 
(10.62) 
 
Op 7 .43 
(4.57) 
4.97 
(3.54) 
 Region: F(3,21) = 3.073, 
p > .05, ƞp2 = .166 
Op 8 .22 
(4.20) 
2.52 
(11.90) 
 
Medial PFC  
Op 3 -.49 
(4.87) 
-2.50 
(6.71) 
Group: F(1,21) = 2.701, p 
> .05, ƞp2 = .124 
Op 4 1.97 
(6.50) 
-2.87 
(6.13) 
 
Op 9 -1.96 
(1.53) 
-2.81 
(2.38) 
Region: F(3,21) = .944, p 
< .05), ƞp2 = .095 
Op 10 1.73 
(7.88) 
-3.98 
(7.93) 
 
Left PFC  
Op 5 2.33 
(6.09) 
-1.28 
(3.63) 
*Group: F(1,21) = 7.268, 
p < .05, ƞp2 = .277 
Op 6 .12 
(1.27) 
-1.45 
(4.30) 
 
Op 11 4.78 
(6.99) 
.04 
(8.70) 
Region: F(3,21) = .284, p 
> .05, ƞp2 = .031 
Op 12 -.98 
(5.27) 
-3.39 
(9.58) 
 
           Note:  * Significant at .05, **significant at .01, ***significant at .001. Abbreviations: MTF, 
multitasking framework; oxy, oxygenated; op, optode. 
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7.4.4 Blood Pressure and HRV Analysis 
 
Table 7.7 shows average SBP, DBP and high and low frequency HRV for long-term modafinil 
users and nonusers across the cognitive tasks. For blood pressure analysis, mixed MANOVA 
revealed that there was a highly significant within-groups effect of MTF difficulty condition 
on SBP (see table 7.7 for within-groups results). Moreover, contrasts showed that both 
tasks significantly raised SBP when compared with baseline, and that the MTF hard 
condition significantly raised SBP higher than the MTF easy condition. Furthermore, there 
was a significant between-groups effect (F(1,21) = 4.356, p < .05, ƞp2 = .295) which contrasts 
revealed was apparent during completion of the MTF low and high conditions, as nonusers 
had significantly higher blood pressure than users. Findings for DBP were similar, within-
groups analysis revealed a significant effect of the cognitive tasks, although contrast 
analysis showed that while the MTF easy and hard conditions had significant increases from 
baseline, they did not differ from each other. However, unlike SBP, there was no significant 
between-groups effect (F(1,21) = 1.367, p > .05, ƞp2 = .098) or condition x user group 
interaction (F(1,21) = .943, p > .05, ƞp2 = .057), suggesting that DBP was not influenced by 
user status. On the 3-back, MANOVA also revealed a highly significant within-groups effect 
of the task on SBP, with contrasts showing that SBP was higher during the 3-back than 
baseline. Again, there was no between-groups effect (F(1,21) = 1.319, p > .05, ƞp2 = .101) or 
interaction (F(1,21) = .522, p > .05, ƞp2 = .016) suggesting that user status did not impact 
SBP. Finally, there was no significant within-groups effect on DBP, nor was there a 
between-groups effect of user group (F(1,21) = .229, p > .05, ƞp2 = .016) or a significant 
interaction (F(1,21) = .803, p > .05, ƞp2 = .024). 
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Table 7.7 – Average SBP, DBP and high frequency HRV for long-term users and nonusers at baseline 
and during the cognitive tasks. 
 Modafinil Users Nonusers MANOVA 
F 
Systolic blood 
pressure 
Mean (SD) Within-Groups 
Results 
Systolic Blood Pressure 
Baseline 110.69 
(9.35) 
116.50 
(10.26) 
 
MTF Low 114.69 
(10.29) 
122.88 
(10.97) 
***MTF = F(2,21) = 
10.495, p < .001, ƞp2 = .295 
MTF High 118.77 
(7.46) 
130.00 
(14.57) 
 
3-back 116.08 
(9.47) 
120.63 
(15.79) 
**3-back = F(1,21) = 
5.413, p < .01, ƞp2 = .191 
Diastolic Blood Pressure 
Baseline 71.00 
(9.60) 
73.63 
(11.52) 
 
MTF Low 75.77 
(5.93) 
79.00 
(12.15) 
*MTF = F(2,21) = 3.541, p 
< .05, ƞp2 = .097 
MTF High 73.77 
(8.23) 
80.25 
(8.94) 
 
3-back 73.23 
(9.61) 
75.63 
(11.46) 
3-back = (F(1,21) = .1.480, 
p > .05) , ƞp2 = .015 
High Frequency Heart Rate Variability 
Baseline .155 
(.19) 
.30 
(.37) 
 
MTF Low 3.99 
(7.59) 
1.61 
(3.17) 
MTF = F(2,21) = 2.962, p > 
.05, ƞp2 = .044 
MTF High 2.83 
(9.34) 
5.80 
(15.48) 
 
3-back 15.99 
(33.13) 
16.98 
(28.30) 
*3-back = (F(1,21) = 5.314, 
p < .05) , ƞp2 = .170 
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Note:  * Significant at .05, **significant at .01, ***significant at .001. Abbreviations: MTF; 
Multitasking framework; low, low difficulty; high, high difficulty. 
 
Heart rate variability analysis was conducted with high frequency data, which increased 
sensitivity to detect parasympathetic changes. A mixed MANOVA comparing HRV across 
MTF difficulty conditions found no significant within-groups effect. Contrasts revealed that 
participants had greater HRV on the MTF difficulty conditions than baseline, but, 
unexpectedly, there were no differences between the difficulty conditions themselves. 
Furthermore, there was no between-groups effect between users and nonusers apparent 
(F(1,21) = .015, p > .05, ƞp2 = .007), nor was there a significant condition x user group 
interaction (F(1,21) = .949, p > .05, ƞp2 = .058), indicating that HRV was not impacted by 
long-term modafinil use. Lastly, MANOVA comparing HRV on the 3-back from baseline 
found a significant effect, and contrasts showed that HRV was greater during the task than 
at baseline. Again, there was no significant between-groups effect of user group on HRV 
(F(1,21) = .007) = p > .05, ƞp2 = .002) and no apparent interaction (F(1,21) = 1.049) = p > .05, 
ƞp2 = .032), indicating that the 3-back task was the only variable which influenced HRV.  
7.4.5 fNIRS Connectivity Analysis 
 
Partial correlations comparing each channel on the MTF low difficulty condition between 
user groups are presented in Table 7.8, while partial correlations on the MTF high difficulty 
are shown in Table 7.9, and partial correlations on the 3-back are presented in Table 7.10. 
Correlation coefficients represent the relationship between two channels while controlling 
for any potential second order effects of the 10 other channels. Heat maps illustrate the 
connectivity between channels, with coefficients in red shades showing positive 
relationships and those in blue showing negative.
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Table 7.8 – Partial correlation matrices depicting connectivity across the 12 channels in users and nonusers on the MTF low difficulty condition. Coefficients are presented 
in a heat map for greater visual illustration. 
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Channel connectivity between users and nonusers on the MTF low difficulty condition was 
similar, though some differences were apparent (See Table 7.8). In general, with both 
groups, positive correlations were highest in adjacent channels, or channels located in the 
same region (i.e., channels within the medial PFC), while negative correlations tended to be 
strongest in optodes further apart and in different regions (i.e., between the left and right 
PFC), although there were some exceptions. In both groups, there was visible connectivity 
in the right PFC, with channels 1 and 2 and channels 1 and 7 being moderately positively 
correlated. Interestingly, there were group differences visible with left PFC connectivity, as 
nonusers exhibited moderate positively correlated connectivity in channels 11 and 12, 
while users showed a minor negative correlation. Nonetheless, with both groups, channels 
11 and 5, located in the left PFC, were moderately positively correlated. However, the 
biggest group difference was apparent between channels 7 and 12 which are in the right 
and left PFC, respectively. While users showed no connectivity between the channels, 
nonusers exhibited a strong negative correlation, which suggests that there was a 
significant difference in how the left and right PFC interacted during the task between user 
groups.
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Table 7.9 – Partial correlation matrices depicting connectivity across the 12 channels in users and nonusers on the MTF high difficulty condition. Coefficients are presented 
in a heat map for greater visual illustration. 
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On the MTF high difficulty condition, channel connectivity appeared to diverge between 
user groups (see Table 7.9). Overall, users experienced moderate and high positively 
correlated connectivity between optodes, whereas nonusers showed greater negatively 
correlated activity. In nonusers this suggests a haemodynamic trade-off, in that as oxy-Hb 
increased in some regions it was met by a decrease in others. With users, greater oxy-Hb 
increases across channels suggests greater cognitive workload during the task. However, 
groups were similar in some regards, particularly with adjacent channels, where several 
notable positive correlations were apparent (e.g., channels 2 and 3, channels 4 and 5 and 
channels 10 and 11). Optodes in specific regions also showed less connectivity in general. In 
the left PFC, channels 11 and 12 were uncorrelated in nonusers and negatively correlated 
in users; however, channels 5 and 6 in the same region were moderately negatively 
correlated in nonusers and appeared to lack correlation in users. Most notable was the 
medial PFC, where channels 9 and 10 were moderately negatively correlated in nonusers 
and strongly negatively correlated in users. There was also cross regional connectivity 
apparent in users, where channels 8 and 10, located in the right PFC and left PFC 
respectively, had a strong positive correlation. 
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Table 7.10. – Partial correlation matrices depicting connectivity across the 12 channels in users and nonusers on the 3-back. Coefficients are presented in a heat map for 
greater visual illustration. 
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On the 3-back, connectivity also seemed to diverge between user groups (see Table 7.10). 
Channels tended to be more negatively correlated within nonusers, though to a lesser 
extent than seen on the MTF high difficulty condition. In nonusers, channels 9 and 3, both 
located in the medial PFC, were negatively correlated with more channels than users, 
although in both groups, channels 9 and 10 were highly negatively correlated, suggesting 
decreased activation of the medial PFC during the task. The left PFC showed greater 
activation in users than nonusers, as channels 11 and 5 were highly correlated among users 
but not with nonusers. Cross regional connectivity was also visible between the left and 
medial PFC in nonusers, as channels 9 and 10 were moderately correlated with channel 1. 
In users these channels showed weak and moderately negative correlations, suggesting 
that increases to right PFC activation was met with a trade-off in decreased medial PFC 
activity. Overall, users appeared to exhibit greater activation during the task than nonusers, 
particularly in the left PFC.  
 
7.5. Discussion 
 
Findings from this study do not support the hypotheses outlined earlier in the Chapter. 
Contrary to expectations, modafinil users did not exhibit differences in bilateral activation 
to the left and right DLPFC during any of the MTF difficulty conditions. However, 
connectivity analysis did show that during the MTF high difficulty condition, users 
experienced a general increase in oxy-Hb across multiple regions of the prefrontal cortex 
which was not apparent in nonusers. Furthermore, on the 3-back, users showed increased 
activation of the left PFC compared with nonusers, but this finding was not specific to the 
DLPFC as predicted. Connectivity analysis also revealed that users experienced strong 
connectivity between channels 11 and 5 which are situated in the left PFC, which supports 
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findings from the main fNIRS analysis. There were also no observable group differences in 
high-frequency HRV or DBP, although, unexpectedly, nonusers had significantly higher SBP 
pressure during the tasks than users. Moreover, regardless of user group, fNIRS failed to 
detect general oxy-Hb change between participants in the MTF difficulty conditions. 
Furthermore, high-frequency HRV showed that R-R interval significantly increased from 
baseline on the cognitive tasks, but there were no differences during the MTF difficulty 
conditions. The same was found with DBP, which showed a modest increase from baseline 
and no task differences. Nonetheless, SBP revealed a linear increase, as all cognitive tasks 
significantly raised blood pressure from baseline with the MTF high difficulty raising it more 
than the low difficulty. Additionally, while it was predicted that modafinil users would 
perform worse on the cognitive tasks than nonusers, on the MTF high difficulty the 
opposite was found to be true, as users outperformed nonusers, which analysis showed 
was due to a better performance on the Stroop task. Finally, against expectations, user 
groups did not differ in response to the subscales of the NASA-TLX, suggesting that there 
were no self-reported differences in perceived workload. As such, none of the hypotheses 
in this study could be accepted.  
Despite findings opposing predictions, differences in haemodynamic response between 
user groups reveal some neurophysiological differences which are in line with previously 
discussed research. Similar to findings from Montgomery et al. (2017) with ecstasy poly-
drug users, modafinil users showed greater oxy-Hb change during the 3-back despite 
showing a similar performance to nonusers. While, ostensibly, it may appear that a 
comparable performance on the 3-back suggests that modafinil users did not exhibit 
cognitive deficits in working memory, increased oxy-Hb in the left PFC, a region previously 
shown to govern working memory functions, suggests that users invested greater cognitive 
effort to achieve similar behavioural output to nonusers. This finding does appear to 
support the notion that, like illicit stimulants, long-term modafinil use may result in working 
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memory deficits. However, the same was not found during the MTF, as haemodynamic 
response was similar across the PFC between user groups, yet modafinil users exhibited 
improved performance compared with nonusers on the high difficulty Stroop. This is like 
findings from Study 2 which revealed quicker response rates on the cued go/no-go task for 
modafinil users which further suggests that they show improved response inhibition when 
compared with non-using controls.  It may then be that while the drug might be 
detrimental to certain cognitive functions, improvements to inhibitory control and reaction 
time suggest that it might ameliorate others. It should be noted, of course, that users did 
not perform better on the visual warning task, itself a test of attention and reaction time. 
As such, this finding could instead indicate that modafinil users make use of their cognitive 
resources more effectively, by focusing on tasks they find more manageable to meet the 
demands of the test. This may also explain why SBP was significantly lower in users than 
nonusers, particularly since blood pressure differences were most apparent during the MTF 
high difficulty condition. As modafinil users appeared to make better use of their resources, 
it stands to reason that they became less stressed than nonusers which reduced SBP.  
7.6 Chapter Summary 
 
In this chapter, haemodynamic response, HRV and blood pressure changes during 
completion of the 3-back working memory task and a multitasking stressor have been 
explored in modafinil users vs. healthy controls. Furthermore, this study is the first to 
address long-term modafinil use by examining the potential neurophysiological and 
psychophysiological impact of use. Use of fNIRS revealed potential working memory 
deficits in modafinil users who completed the 3-back, and blood pressure measurements 
showed users had lower SPB on all tasks. Furthermore, users also outperformed nonusers 
on the high difficulty Stroop, showing that, as was also demonstrated in Study 2, users 
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appear to have better inhibitory control. As such, this study revealed that while modafinil 
users appeared to demonstrate better performance in some areas, deficits may be 
apparent in others. Taken together with the previous study, modafinil appears to impact 
cognitive performance in ways which were not anticipated. Overall, CE strategies have 
been comprehensively explored, and long-term use of the most popular PCE drug, 
modafinil, has been found to have some effect on cognitive performance and 
haemodynamic response. The final chapter attempts to fully extrapolate the implications of 
the 3 studies which make up this thesis and places them in context with pre-existing 
literature.  
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Chapter 8: General Discussion. 
 
8.1 Thesis Summary 
The principal aim of this thesis was to investigate the use of cognitive enhancement drugs. 
It also aimed to: (1) investigate the aetiology of CE use in select UK universities, (2) assess 
the effects of long-term modafinil use on executive functioning, (3) explore the effects of 
long-term modafinil use on neurophysiological processes, and (4) examine the relationship 
between changes in cognitive performance and neurophysiological reactivity, to determine 
if neurovascular activation could be used as a proxy for cognitive workload. The first 
Chapter examined which substances are purported to enhance cognitive functioning, and 
these were defined as either ‘soft enhancers’ or ‘PCE’ based on product type and 
pharmacology. An examination of prevalence estimates found that the stimulant modafinil 
appeared to be the most popular PCE for study at university. Consequently, Chapter 2 
explored modafinil use in healthy and clinical populations, to determine what impact the 
substance has on cognitive performance, if it is an effective PCE, and its side effects and 
potential harms. It was concluded that although short-term use (< 3 months) was deemed 
to be relatively safe when administered as part of clinical studies, there was no available 
data on the safety and cognitive impact of non-clinical and longer periods of use (> 3 
months). Chapter 3 examined the most appropriate methods of detecting changes in 
cognitive workload, an umbrella term for measuring different aspects of cognitive 
performance in response to task difficulty, in long-term users of modafinil. This review 
showed that the most appropriate way was a mixture of subjective, cognitive and 
neurophysiological methods. Chapter 4 described the methods chosen in the later 
empirical studies, and outlined the theoretical frameworks which underpinned them, 
including why a survey methodology is best for collecting demographic and drug use data 
with substance using populations, and how fNIRS, ECG and blood pressure measurements 
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can be used as indicators of neurophysiological changes associated with increased cognitive 
workload.  
The three empirical studies which followed used various methods to explore CE use in the 
UK. Study 1 (Chapter 5) described a survey of CE use in university students, including the 
substances used, and the predictors of use. Use of substances for CE was predicted by age 
(being older), gender (being male), and believing use of modafinil for CE to be more morally 
acceptable predicted soft enhancer and PCE use. In keeping with previous research, 
modafinil was the most popular PCE drug among respondents, and so subsequent studies 
examined this drug. Study 2 (Chapter 6) examined cognitive performance across a range of 
executive functions which have been shown to improve with acute modafinil (as reviewed 
in Chapter 2), including working memory, sustained attention and inhibitory control. Due to 
the neurochemical similarities between modafinil and other psychostimulants like cocaine, 
it was hypothesised that long-term users would show poorer performance in these 
cognitive functions compared with non-using controls. This hypothesis was not supported, 
and modafinil users showed faster response times to all cues on the cued go/no-go task 
without demonstrating an accuracy trade-off, and there were no other performance 
differences between groups on the remaining tasks. Therefore, Study 3 (Chapter 7) built on 
these findings by adding neurophysiological measures to examine underlying mechanisms, 
and to see if long-term modafinil use, like other psychostimulants such as cocaine, was also 
associated with negative neurological and physiological effects during high-demand 
cognitive performance. The tests undertaken by participants were more cognitively 
challenging than the previous study and working memory and multitasking capacity was 
assessed. Like Study 2, modafinil users demonstrated better inhibitory control which was 
expressed on the high difficulty Stroop when compared with non-users, but they showed 
greater oxy-Hb change on the 3-back, despite no differences in performance on the task. 
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Heart rate variability was not statistically different between groups across the tasks, but 
SBP was consistently lower in modafinil users.  
8.2 Discussion of Findings 
 
Study 1 made numerous predictions regarding patterns of CE use, including: (H1) use of soft 
enhancers would generally be higher than PCE, (H2) modafinil would be the most popular 
PCE drug for study purposes, (H3) reported use of illegal drugs for study would be smaller 
than soft enhancers and PCE, but recreational use would be higher than PCE, and (H4) 
sociodemographic and personality factors would predict use, specifically: Gender (being 
male), age (being older) level of study (being a postgraduate), learning style (being a 
surface learner) and moral perceptions of PCE use (H4). Consequently, all hypotheses, 
beside the H4, were supported by the data, and observed levels of CE use generally 
supported previous research (Maier et al., 2013; Singh, Bard, & Jackson, 2014a; Wolff, 
Brand, Baumgarten, Lösel, & Ziegler, 2017). Perhaps the most unsurprising finding was the 
general popularity of soft enhancers containing caffeine. Coffee and energy drinks had the 
highest levels of lifetime use regardless of user intent, followed by caffeine pills. The 
greater popularity of soft enhancers over PCE seems to be due to these caffeinated 
products. Nutraceutical use was modest, and use of bacopa, ginkgo and guarana for study 
was lower than PCEs, especially modafinil use. In this study, Modafinil use was comparable 
to levels previously reported in the UK (Holloway & Bennett, 2012; Singh et al., 2014a), 
excluding the recent study by Maier and colleagues which suggested a recent and 
significant rise in use of the drug in the UK from 2015 to 2017 (Maier, Ferris & Winstock, 
2018). The popularity of modafinil was important for several reasons. As discussed in 
Chapter 2, the pharmacological similarity of modafinil with other psychostimulants 
highlights a public health concern if UK students are using stimulants as a study aid. 
Furthermore, without robust data on long-term effects of use of modafinil, public health 
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education cannot be provided. The popularity of modafinil is also important for universities 
to consider, as the use of substances to cope with study demands may reflect poor student 
support or issues with student working practices or workload. It may be that this finding 
highlights a need for universities to address PCE use as part of university policy, to make it 
clear that alternative coping methods are available and provide balanced health education 
on these substances. Nevertheless, level of modafinil use was still below what was 
previously suggested in the media (Lennard, 2009; The Student Room 2016) and in Maier 
and colleagues’ (2018) recent study. One reason might be that region of the country played 
a role in the results, as the study described in this thesis looked at use in four Northern 
universities only, and did not take account of user rates in the South of England or other 
parts of the UK as other studies did. Use might also be higher at specific universities, 
particularly those “elite” universities which form the Golden Triangle. This would explain 
reports by Varsity, a University of Cambridge newspaper which reported that 10% of 
students were using modafinil. It is possible that demands on students are higher at these 
institutions because of academic expectations, and students might be more likely to use 
techniques like PCE to aid them in study to achieve a good grade. Of course, the opposite 
could also be true and students at these universities might be more academically capable 
and could rely less on external aids such as PCE for study. However, it should be noted that 
study 1 included a Russell Group university, where there could arguably be a similar 
demand on students. Nonetheless, differences in use seen between studies may come as a 
combination of these factors.  
Previous research has also suggested that a number of variables were associated with 
greater CE use, including; being male and over 25 (Maier et al., 2016; Maier et al., 2018), 
working alongside study (Maier et al., 2016), being a final year undergraduate or in 
postgraduate study (Maier et al., 2013) and perceiving CE use to be more morally 
acceptable (Maier, Liakoni, et al., 2015). As a consequence, it was hypothesised that several 
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factors could form a predictive model, although screening analyses examining correlational 
relationships excluded some of the variables described from further exploration to avoid 
impairing the predictive ability of the final regression solution. This is contrary to previous 
studies, which clearly indicated that many of these factors were linked to CE use. The lack 
of predictive capability might therefore come as a result of the study being exploratory, as 
some variables were thought suitable for analysis without direct evidence of their impact 
on CE use. This was because it was determined that they could add to student stress, such 
as semester-time accommodation, or whether a student has a deep or surface approach to 
learning (see Chapter 5). Perhaps these exploratory variables are not perceived to 
contribute to student stress as much as anticipated, or perhaps stress is not a driving factor 
in use of these substances in the first place. Nevertheless, the variables remaining in the 
logistic model successfully predicted CE use. The most powerful predictor of PCE use was 
gender, as being male made use significantly more likely. This is also a common finding in 
prior research across Europe (Maier et al., 2016; Maier et al., 2018), so it is unsurprising 
that the same was found here. Being older also predicted greater use of all CE categories, 
perhaps due to the increased academic rigour/workload older people can expect as they 
progress through study. It was also unsurprising that moral perception of modafinil use 
predicted PCE and soft enhancer use. This might also reflect the popularity of modafinil in 
the UK, with users of the drug likely to have a more positive attitude to its use and a better 
attitude to the use of other strategies like soft enhancers. Nevertheless, it is interesting 
that moral perceptions of d-amphetamine and MPH did not predict use, although this is 
likely because, so few respondents reported using these substances in general. A higher 
response rate to the survey might have revealed a link between moral perception of these 
substances and CE use, as was demonstrated by Maier et al. (2015) in Swiss university 
students’ attitudes towards PCE use.  
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Several predictions were made for Study 2: including (H5) that modafinil users would 
perform worse on cognitive performance measures than nonusers, (H6) more frequent 
modafinil use would also predict poorer performance on the cognitive performance 
measures, as would greater poly-drug use and recent use of illicit stimulants and cannabis, 
and (H7) modafinil use would be significantly correlated with greater levels of poly-drug use 
reported by participants in the modified Background Drug Use Questionnaire. However, 
findings indicate that long-term modafinil use does not appear to have the same impact on 
cognitive performance, which was predicted due to its similar neurochemical properties to 
illegal stimulants. In fact, decreased response time to all cues on the cued go/no-go task 
implies that the drug may have extended benefits beyond initial periods of use, as it 
suggests that users were able to process stimuli and respond quicker. Chapter 2 already 
highlighted the cognitive benefits conferred from acute modafinil use, and studies indicate 
that in healthy people inhibitory control performance is enhanced (Marchant et al., 2009; 
Rycroft et al., 2007; Turner et al., 2003). However, the question remains as to why such 
improvements are observable after at least 48 hours of abstinence from the drug. This 
could be explained by methodological issues pertaining to the use of a cross-sectional 
survey. For instance, due to the scarcity of modafinil users in Study 2 and 3, drug use 
frequency and average dose could not be accurately assessed. It is possible that use was 
too infrequent for a true behavioural impact of long-term use of the drug to be recorded. 
Therefore, it might be that findings are less attributable to modafinil use and more aligned 
with personality type or another factor which can be linked to long-term users. 
Additionally, as statistical modelling in Study 1 successfully identified factors associated 
with PCE use, it appears intuitive to think along these lines. It has been reported that PCEs 
are commonly used to gain a competitive edge (Maier et al., 2015), as such, users of this 
drug might simply be more competitive than nonusers, and they could be more 
accustomed to competitive tasks like cognitive performance measures. Nevertheless, 
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performance was not significantly different in working memory or sustained attention, 
which discredits the notion that they are better across all performance measures. It is also 
possible that continued modafinil use leads to long-term changes in neurology and 
cognitive function in a similar way to how SSRIs alter certain forebrain structures over time 
(Haddjeri, Blier, & de Montigny, 1998). Even after cessation, antidepressants show some 
positive outcomes to behaviour and cognition (Amado-Boccara et al., 1995). The same 
could be true with modafinil, although a lack of robust data showing consistent use of the 
drug with the sample makes this a strenuous comparison, particularly since SSRI’s are often 
taken daily.  
In Study 3, modafinil use was examined using fNIRS to assess neurovascular coupling in the 
prefrontal cortex as a proxy of cognitive workload. It was predicted that: (H8), modafinil 
users would exhibit differences in haemodynamic response which would occur bilaterally in 
the left and right DLPFC indicating increased cognitive effort compared with controls during 
the cognitive performance measures, (H9) differences would also be observed in HRV and 
BP with users showing reduced HRV and elevated BP compared to nonusers, (H10) all 
participants would exhibit increased oxy-Hb change and blood pressure as well as a 
significant reduction in HRV relative to baseline during the cognitive tasks, (H11) and 
modafinil users would perform significantly worse on the cognitive performance measures 
than nonusers and also report greater mental workload on the NASA-TLX. In this study, 
findings were less consistent than Study 2, and although inhibitory control was better in 
users on the high difficulty Stroop, increased oxy-Hb change in users on the 3-back despite 
no behavioural differences implies an underlying deficit in working memory. 
Haemodynamic findings therefore contradict the notion that modafinil provides only long-
term improvements to cognitive functioning, and it may be that while inhibitory control is 
better, it comes at a cognitive trade-off to working memory performance. Moreover, 
working memory deficits are typical with repeat cocaine administration (Jovanovski, Erb, & 
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Zakzanis, 2005), as such the previous comparisons made between modafinil and other 
psychostimulants are pertinent. Furthermore, Study 3 also took account of blood pressure 
and HRV measurements, and although HRV was not significantly different between user 
groups, modafinil users generally had lower SPB than nonusers during all cognitive 
performance measures, suggesting that, physiologically, they coped better with the 
demands of the tasks. This could relate to the earlier suggestion that users are more 
accustomed to acting competitively than nonusers, and as a consequence they become less 
physiologically stressed during the cognitive performance measures. Furthermore, another 
interesting finding is that although users performed better on the high difficulty Stroop, 
when results are scrutinised it appears that users simply sustained strong performance 
between the low and high difficulty conditions, whereas nonusers demonstrated a 
significant decline at the harder difficulty. This may suggest that users are better at 
sustaining cognitive performance under challenging tasks than nonusers in general, and not 
simply in inhibitory control. Furthermore, there were no within-group differences between 
the different MTF difficulty conditions, which is surprising as previous research using the 
same task configuration has shown difficulty related performance differences (Wetherell & 
Carter, 2014). However, on closer inspection of performance on the visual warning and 
visual tracking tasks, users and nonusers improved their scores on the harder difficulty 
variants. One explanation could be that because in both instances the time required to 
respond to each task was far shorter during the harder difficulty, participants attended 
more closely to these tasks, which improved their scores. This could also explain why 
nonusers scored significantly lower on the high difficulty Stroop, as they were less effective 
at distributing their cognitive resources than modafinil users. Finally, it should be noted 
that there were no group differences on responses to the NASA-TLX, and despite the 
behavioural and neurophysiological differences, users did not differ to nonusers in 
perceived workload. This suggests that although some performance differences were 
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visible, participants did not indicate this during self-reporting. As such, this reflects that 
users did not acknowledge the increase in cognitive effort displayed on the 3-back which 
was visible due to the observed oxy-Hb increase, which indicates a lack of awareness.   
8.3 Methodological Strengths and Limitations 
 
The research described in this thesis makes several unique contributions. First, Study 1 
explored level of CE use and also looked at associated factors of use, including 
sociodemographic and educational variables. At the time of writing, this is the first study to 
attempt to form a predictive model of use which successfully highlighted gender, age and 
moral perception as variables significantly correlated with soft enhancer and PCE use, and 
also illustrated those factors which appear to be unrelated to use. Both Study 2 and 3 were 
also unique in that long-term modafinil users have not been cognitively tested previously. 
Chapter 2 demonstrated that prior research had explored acute modafinil use in different 
populations quite comprehensively, but until now no data existed with use exceeding 3 
months. Consequently, cognitive performance measures and use of multiple 
neurophysiological measures made a comprehensive psychophysiological assessment of 
modafinil use which had not been done previously. The strengths of this research 
programme are therefore linked to the novelty of the studies conducted.  
 
Throughout this thesis, several methodological decisions were made which have inherent 
limitations. Primarily, in Study 1, it should be highlighted that national university 
prevalence could not be estimated because the sample was self-selected and thus cannot 
be taken as true representation of PCE use at UK universities. Furthermore, estimates were 
not necessarily fully representative of the participating universities, particularly since 
response rates for two institutions were quite limited (EM1: N = 18, NE1: N = 44), making it 
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possible that users, or indeed nonusers, were disproportionately represented. Due to 
potential sampling biases, the study could over-represent CE users, as these respondents 
may have felt more compelled to participate in a survey investigating substance use 
behaviour at university than nonusers. Indeed, the opposite could also be true, and due to 
the novel nature of using PCE for study, and because of possible stigmas associated with 
use, respondents may also have been dishonest about use. However, to reduce false 
responses, participants were explicitly informed that responses were fully anonymous. 
Moreover, participants could have completed the survey more than once, particularly to 
increase chances of winning in the prize draw. Nonetheless, data was checked for response 
duplicates and matching IP addresses to minimise the chances of this occurring before 
analysis was conducted. Lastly, memory biases must be considered with an extensive self-
report measure like this one, as the survey requested quite specific information about past 
substance use, which may have been difficult to recall leading to inaccuracies in 
responding.  
Studies 2 and 3 also share a number of limitations because of a similar methodology with 
sampling and investigating drug use behaviour. First of all, substance use was self-reported 
with the modified Drug Use Questionnaire as researchers did not have access to a clinical 
sample of people prescribed modafinil daily, which could have assured consistent use of 
the drug. As such, like in Study 1, the research was vulnerable to participants inaccurately 
reporting, or deliberately misrepresenting, their drug use behaviour. This could be a result 
of memory problems, as the questionnaire relied on quite specific drug taking information, 
including exact time periods and quanities, which may have been difficult to recall. 
Furthermore, the threshold for inclusion in the long-term modafinil user group was limited 
to only once per month use for at least a year. This is mainly due to the overall novelty of 
the substance, and that modafinil is less popular than other stimulants such as caffeine (as 
shown in Study 1), making people who use more frequently difficult to obtain as 
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participants. For instance, in Study 2, the average user reported using 5.74 pills a month, 
which is considerably less than a daily dosing schedule. It could therefore be the case that 
use was not frequent enough in the sample to observe any further cognitive deficits, 
changes to HRV and blood pressure which are typically found with chronic stimulant use, or 
indeed potential benefits. In Study 2, modafinil users also reported using significantly more 
of other types of substances over the previous 3 months than nonusers, although there 
were no significant correlations between modafinil use in the previous year and other 
substance use variables. Therefore, it must be acknowledged that modafinil users were 
more likely to be general polydrug users, making it difficult to determine how the current 
findings were attributed just to modafinil use and not polysubstance use more generally. 
Despite this, correlational analysis did also reveal that modafinil users did not report 
greater use of alcohol, illegal stimulants or cannabis use than controls, suggesting that 
these drugs did not impact performance on the behavioural measures. In Study 3, due to 
the relatively limited availability of modafinil users during the time of data collection, the 
sample was not robust enough to perform regression analysis and look at the impact that 
frequency of use, and other potentially important factors such as poly-drug use, might have 
on neurophysiology. Limitations withstanding, this study is the first of its kind to assess the 
long-term impact of modafinil use on psychophysiology and neurophysiology. Furthermore, 
despite some drawbacks with the sample, this research is the first to demonstrate 
increased cognitive effort in modafinil users as a compensatory mechanism for what 
appears to be a working memory deficit.  
8.4 Future Research Implications 
 
The studies presented here include findings which could be further examined in future 
research. The survey study did show that, as predicted, modafinil was the most popular 
PCE drug, but it did not confirm Maier and colleagues (2018) recent findings of 10% user 
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rates in the sample. Of course, both studies used self-selected sampling which does not 
represent true user prevalence, it is therefore necessary to establish which figures more 
accurately represent use, and this could be achieved with a largescale survey study which 
takes account of prevalence in universities across different regions of the UK. Instead of 
relying on a self-selection, future studies should obtain a representative sample of UK 
students, which is randomly selected and takes account of different sociodemographics 
(i.e., age, ethnicity). Furthermore, future research should continue to establish a predictive 
model of use, looking at factors which are already known to be associated with use, such as 
gender and morality, and which also investigate unexplored variables. As educational and 
sociodemographic variables in Study 1 which were thought to contribute to stress did not 
predict CE use, perhaps personality measures might have greater predictive capability. 
Personality traits have been intricately linked to substance use behaviour. Perhaps one of 
the most highly regarded measures of personality traits is the Five-Factor Model (McCrae & 
John, 1992), which describes five personality dimensions: openness to experience, 
conscientiousness, extraversion, agreeableness and neuroticism. Furthermore, extraversion 
and openness have strong links to alcoholism (Martsh & Miller, 1997) and substance 
misuse (Terracciano, Löckenhoff, Crum, Bienvenu, & Costa, 2008), but neither of these 
scales have yet to be used to examine CE use. A model examining these factors might 
successfully predict CE use, and thus identify characteristics which could make students 
more inclined toward CE strategies.  
Future lab-based research with modafinil users should also make some considerations. As 
average monthly frequency of modafinil use varied within the cohort of users for both 
Study 2 and 3, there was no doubt a certain degree of unexplained variance attributed to 
this. As such, access to a clinical sample could minimise this variance and might provide a 
more accurate picture of the drug’s impact on behavioural and neurophysiological 
functioning by implementing a longitudinal design which follows participants across a 
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course of treatment. In Study 2, modafinil use was also found to be associated with poly-
drug use. It is unknown what impact the use of other substances had on cognitive 
performance, therefore any future study should try to recruit a sample with no recent 
history of other substance use, so that any potential effects can be more confidently 
attributed to modafinil use. Challenges may come as a result of recruiting such a specific 
sample of users, although a research programme which does not suffer the same time and 
resource constraints as a PhD may find this more attainable. Furthermore, research should 
attempt to replicate some of the findings from the studies described here, including the 
demonstrated improvements in inhibitory control without a speed/accuracy trade off, and 
the apparent underlying deficits to working memory processes. A different multitasking 
set-up might also improve on findings, as the inclusion of the visual warming and visual 
tracking tasks, and how participants attended more closely to these windows in the higher 
difficulty conditions, made differences in over-all scores between conditions non-
significant. The MTF allows for a change in the tasks which occupy the 4 windows, as such it 
could be useful to replace the current set-up with more tasks assessing working memory 
and inhibitory control. Finally, future research should attempt to find a gender balance in 
the sample, as it was a challenge in these studies to find an equal proportion of female 
modafinil users. It is unclear how much of an impact gender had on the results of Study 2, 
but a more equally distributed sample might reveal gender differences as a factor effecting 
performance.  
8.4.1 Implications for Policy and Practice  
 
Beyond academic research, the persistent nonmedical use of PCE substances, particularly 
among students at university, leaves several considerations for policy and practice. 
Principally, university and government bodies must first work together to consider a 
collective strategy when tackling PCE use, taking into consideration not just potential for 
164 | P a g e  
 
harm and abuse, but also prospective neuroethical implications. Several countries already 
prohibit possession of pharmaceutical substances without prescription (including the UK 
and USA), with possession often punishable under the law (Petersen & Petersen, 2019). 
Nevertheless, little is done to consider, or indeed understand, possession of these 
substances as study drugs. The findings from the studies described in this thesis outline the 
intricacies of this topic. Regardless of legality, the findings from Study 1, and literature 
discussed in Chapter 1, reveal that although use is not widespread, it is still prevalent. If 
legal status is therefore not sufficient to deter use, then a new approach must be sought. 
Study 3 indicated an underlying working memory deficit among modafinil users, although 
further research is required to fully establish this effect. Thus, if later findings corroborate 
this and other potential drawbacks, then policy and practice must respond accordingly. 
Increased access to health information regarding such drugs should be a primary objective, 
no less since PCE’s are poorly understood even among academics. As such, a drug 
information campaign targeting universities is essential if students are to make informed 
decisions about PCE use. Of course, difficulties arise when attempting to monitor use as 
universities are not sufficiently equipped to police students in this way, nor should this be 
the sought approach. Instead, institutions should set their gaze on what is driving students 
to these substances and should take steps to accommodate personal study needs. Chapter 
1, and the introductory section of Chapter 5, outlined that stress and perceived workload 
are common reasons provided by students for their PCE use. Consequently, effort should 
be taken to address these concerns at an administrative level, perhaps by increasing 
student outreach and making university-based counselling services widely available.  
From an ethical point of view, study benefits, and indeed grades, conferred by PCE raises 
issues of deservingness. Arguably, academic achievements born of these methods are less 
deserving of recognition than those without. If growing evidence suggests that PCE use 
continues to increase, then universities must thoroughly explore the accompanying ethical 
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implications, particularly if academic performance differences (i.e., better grades) become 
noticeable between users and nonusers. It is beyond the remit of this thesis to make moral 
claims regarding PCE use, thus no attempt has been made to do so. Nevertheless, 
universities should be prepared to ask these questions, to fully explore whether these 
methods are compatible with an academic ethos, and whether integrity is lost due to PCE 
use.  
8.5 Conclusions 
 
This thesis aimed to explore PCE use in UK university students and made several 
unexpected but important findings. Results indicate that long-term modafinil use is similar 
to effects seen with illegal stimulants in some ways, but markedly dissimilar in others. 
Furthermore, this study programme has taken a novel approach to PCE research, and 
findings with modafinil users reveal complexities which must be examined with future 
research to be better understood. It also appears that it is too reductionist to simply 
predict that modafinil exerts a similar long-term impact to other pharmaceutical or illegal 
stimulants without considering the drug’s unique neurochemical properties. Furthermore, 
in terms of how these findings translate to a real-world context, this thesis has revealed 
that although PCE use was shown to be modest, it does exist within UK universities. Thus, 
questions are raised for institutions on how to tackle the use of pharmaceuticals and 
whether to make additional provisions for students so that these techniques do not rise in 
prevalence and become a study norm. Furthermore, long-term nonmedical modafinil use 
must also be closely monitored, both in and outside university. Findings reveal mixed 
effects on cognitive performance and haemodynamic change, and this thesis shows that 
research with long-term use of this substance is still too premature to fully determine if 
modafinil is harmful or safe. Therefore, a lack of knowledge does not equate to the absence 
of harm, and the mixed findings from these studies show that public health information 
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should be provided to stem growing use until it is better understood. Consequently, 
findings from this thesis are encouraging, and reveal that there is still more to understand 
about the broad topic of PCE use if student use is to be properly addressed.  
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Appendix 
Moral judgement:  
Sally 
Sally’s exams are quickly approaching, and she is struggling to find the time to study. Sally 
has a part-time job to help pay her rent and works four evenings a week. This only leaves 
her with three available study days, but by Sally’s own admission, she is often too tired to 
revise on these days off. Sally’s friend, Sarah, understands that she is short of study time 
and suggests that Sally try modafinil, a prescription drug that will help her to stay awake 
and focused long enough to study. Sarah recommends the drug because she has used it in 
the past to help her revise for her own exams, and she says it has even helped her to 
achieve top marks. Sarah has some modafinil left over, and even offers to give it to Sally.    
 
1. Sally should use the modafinil offered to her by Sarah.       
Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
 
2. It is right for Sarah to offer Sally modafinil as a study aid.  
Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
 
3. Taking modafinil will give Sally an unfair academic advantage.  
Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
 
4. Sally is cheating if she takes modafinil to help her study.  
Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
 
5. It doesn’t matter what techniques Sally uses to study only that she gets good 
grades.  
Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
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6. The ends justify the means.  
Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
 
7. It doesn’t matter how beneficial they are as a study aid, taking drugs is wrong.  
Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
 
Simon  
Simon is in the final year of his undergraduate studies. Throughout his time at university, 
he has consistently used the drug Adderall, a substance that increases focus and alertness, 
to help him complete his assignments and study for exams. Simon kept his Adderall use a 
secret, as he feared that it would be viewed as cheating by his peers and by the university. 
But, when his classmate Claire recently asked for his advice on how to achieve higher 
grades, he told her all about his Ritalin use, and recommended it to her as a study aid. 
Unexpectedly, however, Claire was unhappy with Simon, and called him a cheater, and 
even reported him to the faculty for academic misconduct.  
1. Simon is wrong to have used Adderall for so long during his studies.  
Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
 
2. Claire did the right thing to report Simon for academic misconduct.  
Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
 
3. Simon should have continued to keep his Adderall use a secret.  
Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
 
4. Claire is right, Simon is a cheater.  
Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
 
5. It’s right that Simon is charged with academic misconduct.  
Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
 
199 | P a g e  
 
6. Simon should be allowed to use Adderall as a study aid if he wants.   
Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
 
7. It is immoral to use Adderall or any other substances as a study aid.  
Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
 
John 
John doesn’t believe in using brain enhancing drugs to get ahead a university and has 
repeatedly told his peers that he thinks it is cheating. He has never struggled with his 
studies, despite having multiple commitments, such as a part time job and a family. 
However, his son has recently been diagnosed with ADHD, which has proved to be a 
difficult time for John and his family. As a result, John’s studies have begun to get on top of 
him, and he has found it more and more difficult to keep up with the academic rigour. 
Tomorrow is a deadline for an important assignment, and John has barely even looked at 
the course material. If he doesn’t submit something, he will surely fail the module, and this 
could jeopardise his entire degree. However, if he takes his son’s ADHD medication, Ritalin, 
on just this one occasion, then he will have the focus to complete the assignment.  
 
1. John should bend the rules this once and take Ritalin to help him complete his 
assignment.  
Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
 
2. John is betraying his own values if he takes Ritalin.  
Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
 
3. There’s nothing wrong with using Ritalin as a study aid just once.  
Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
 
4. John should maintain his values even if he failures his assignment 
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Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
 
5. John’s difficult family situation justifies the use of drugs as a study aid.  
Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
 
6. John is cheating if he takes Ritalin.  
Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
 
7. Taking Ritalin is a hypocritical thing for John to do.  
Strongly 
disagree 
Disagree Moderately 
disagree 
Agree nor 
disagree 
Moderately 
agree 
Agree Strongly 
agree 
 
 
How difficult was it to answer these questions? 
Very easy Easy Moderately 
easy 
Neither 
easy nor 
difficult 
Moderately 
difficult 
difficult Very 
difficult 
 
